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SUMMARY 
 
 
Ovarian cancer (OC) is the most aggressive gynecological cancer with in excess of 22000 new cases 
diagnosed annually in the United States alone. OC is predominantly diagnosed at advanced stages due to the 
presentation of non-specific symptoms and the absence of adequate clinical markers for routine screening. 
The consequent prognosis associated with OC is appalling, with an extremely low 5-year survival rate, high 
incidence of recurrence and drug resistance. The current Gold Standard for the treatment of OC involves a 
combination of surgical resection and aggressive chemotherapy. However, many factors compromise the 
safety and efficacy of antineoplastic drugs, not least of all being systemic toxicity of the drugs which affect the 
quality of life of the patient during and after treatment, and may sometimes prove fatal. Camptothecin (CPT) is 
a highly efficacious, broad-spectrum antineoplastic drug, the clinical use of which has been hindered by a 
deleterious side-effect profile, poor aqueous solubility and instability under physiological conditions. This study 
aimed to address the shortfalls associated with the delivery and in vivo activity of CPT by applying nano-
technological engineering to produce a novel nano-enabled drug delivery system (DDS) that will be passively 
targeted to the tumour site following intravenous administration. Tumour tissue displays unique characteristics 
that collectively have been termed the Enhanced Permeability and Retention (EPR) phenomenon. Passive 
targeting of the formulated antineoplastic nano-lipobubbles (NLB) through this phenomenon will enable 
preferential accumulation of the DDS within tumour tissue, thereby reducing systemic side-effects and 
enhancing therapeutic activity. In addition, formulation as NLB improved the solubility of CPT thereby 
facilitating administration and enhancing the pharmacokinetic profile of the drug. Nano-sizing was the central 
consideration in this study and a size threshold of 200 nm was delineated for effective passive targeting. Pre-
formulation studies highlighted 2 feasible lipid combinations and the concentration ranges thereof, as well as 
an appropriate solvent system, emulsifier and CPT concentration for the formulation of nano-liposomes (NLS). 
The merits of two methods of NLS formulation were investigated as well as various formulation parameters. 
The Reverse-Phase Solvent Evaporation (RPSE) method was deemed the most suitable method of NLS 
preparation for this study. The delineation of independent variables and measured outcomes was central to 
the generation of a Face-centered Central Composite experimental design for each of the two lipid 
combinations. Systematic analysis of the fifteen formulations of each of these experimental designs produced 
experimental data that was mathematically modeled employing regression models to predict the effect of 
formulation variables on measured outcomes and hence, statistically optimize the formulations based on the 
desired average size, zeta potential, drug incorporation and mean dissolution time of formulated NLS. Each of 
the 2 statistically optimized formulations demonstrated a composite desirability >0.9. The effect of gaseous 
incorporation and sonication parameters involved in the conversion of NLS to NLB on the measured outcomes 
were assessed and optimized. Optimized NLB formulations were further modified to incorporate silibinin (SB), 
for the achievement of synergistic antineoplastic activity with CPT. The application of sequential polymeric 
coating proved substantially beneficial to the stability characteristics and drug release profiles of both NLB 
formulations, whilst the average size of NLB was maintained below 200 nm (141-190 nm). Substantial 
inversion of zeta potential following the application of CHT and PAA, as well as chemical structural changes 
determined by FTIR spectroscopy confirmed successful polymeric coating and highlighted the resultant 
favorable effect on formulation stability. Assessment of the physical stability of optimized formulations further 
substantiated the positive impact of polymeric coating and suggested excellent feasibility with regards to 
storage stability and clinical use. In vitro drug release studies readily highlighted the positive influence of 
polymeric coating on the drug release characteristics of CPT and SB. The results of cytotoxicity evaluation on 
A2780 epithelial ovarian cancer cells, by flow cytometry and real-time cell analysis, further corroborated the 
benefits of the altered drug release characteristics achieved following polymeric coating. Cumulative 
cytotoxicity demonstrated by optimized NLB 72 hours post-treatment ranged between 85%-95%. Cellular 
internalization of formulated NLB was swiftly achieved, with the extent of internalization exhibiting time-
dependent and size-dependent characteristics. The slower release of CPT and SB from coated NLB 
formulations resulted in enhanced and sustained cytotoxicity relative to uncoated NLB formulations and native 
drug compounds. Quantitation of the hemolytic potential of formulated NLB-DDS was significantly below the 
safety threshold for intravenous formulations. The optimized NLB-DDS displayed favorable characteristics for 
the achievement of passive targeting, satisfactory drug incorporation, substantial physical stability, favorable 
haemocompatibility, as well as enhanced cytotoxicity against A2780 cells relative to the native drugs.       
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CHAPTER 1 
AN OVERVIEW OF OVARIAN CANCER, RATIONALE AND  
MOTIVATION FOR THIS STUDY 
      
“However far modern science and technics have fallen short of their inherent possibilities, they 
have taught mankind at least one lesson: Nothing is impossible!” – Lewis Mumford (1895-1990) 
 
1.1 Introduction 
Cancer has, for centuries, been the bane of the medical fraternity and the last century has 
seen an alarming rise in incidence of cancer globally, with over 12 million new cases of 
cancer being diagnosed annually (World Health Organization (WHO), 2013). Large 
financial aid has been dedicated to research in the field of cancer etiology, detection and 
treatment, but up to date, we remain at the losing end of the battle against cancer. Cancer 
is the second leading cause of death worldwide and accounted for 7.6 million deaths in 
2008 (Jemal et al., 2011; WHO, 2013). The burden of cancer in the African setting paints 
an increasingly dismal picture, with approximately 715 000 new cases of cancer 
diagnosed and 542 000 mortalities reported on the continent in 2008, against the 
backdrop of the financial burdens of this disease on the health systems of a developing 
continent (McCormack and Schüz, 2012). Figure 1.1 presents the global distribution of 
cancer incidence, highlighting the magnitude of cancer burden across different regions 
(GLOBOCAN, 2008). The WHO has projected cancer-related mortalities to rise to over 11 
million by 2030 (WHO, 2013; Bray et al., 2012; Cancer Research UK, 2013). 
 
Cancer, as defined by the National Cancer Institute (NCI) in the United States, is an 
uncontrollable division and proliferation of abnormal cells and the invasion of these cells 
into surrounding tissue (NCI, 2012). This is a generic term and encompasses a multitude 
of malignancies that can affect numerous bodily systems (NCI, 2012). Carcinogenesis is a 
multistep process, involving a distorted expression of the transcriptional factors involved in 
cell replication (Ramasamy and Agarwal, 2008). The accumulation of sufficient alterations 
leads to mutations in the genes regulating cellular growth and differentiation and inhibit 
programmed cell death. Genetic alteration may also lead to the activation of oncogenes 
and deactivation of tumour suppressor genes (Macklin and Lowengrub, 2007). The 
cumulative effect is malignant transformation of cells, rapid growth and proliferation of 
these malignant cells, amplified angiogenesis, invasion into organs and body cavities and 
subsequent metastasis (Vogelstein and Kinzler, 2004).  
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Figure 1.1 A comprehensive view of the estimated number of new cancer cases diagnosed 
worldwide in 2008 (Source: GLOBOCAN, 2008). *Region estimates do not do not add up to the 
world estimate due to calculation method. 
 
Ovarian cancer is the most aggressive of, and the foremost cause of death from, all 
gynecological cancers (Chien et al., 2007; Cirstoiu-Hapca et al., 2010; Kim et al., 2011). 
The primary factors contributing to the poor prognosis and high mortality rate associated 
with ovarian cancer is a combination of non-specific symptoms and a lack of early 
detection modalities, leading to advanced disease, and often significant metastasis, at 
time of diagnosis (Ferrandina et al., 2006; Chien et al., 2007; Cirstoiu-Hapca et al., 2010; 
Kim et al., 2011). In addition, ovarian cancer has also displayed a high degree of 
recurrence, leading to a deplorable overall 5-year survival rate of between 30%-45% 
(Spentzos et al., 2004; Ferrandina et al., 2006). Table 1.1 highlights the disparity between 
5-year survival rates for ovarian cancer relative to that of other gynecological cancers and 
breast cancer. 
 
Table 1.1 Comparison of approximate 5-year survival rates for breast and gynecological cancers, 
highlighting the poor outcome, and critical need, for improvement in the treatment of ovarian cancer 
(American Cancer Society, 2012; Cancer Research UK, 2013). 
Cancer Type 5-year survival rate* 
Breast >80% 
Uterine 69% 
Cervical 67% 
Ovarian 30-45% 
         *Age standardized, overall statistics (not tumour stage-specific) 
 
Ovarian cancer can be classified as epithelial tumours, germ cell tumours, sex cord 
stromal tumours and tumours not otherwise specified, with over 90% of cases being of 
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epithelial origin (John Hopkins Pathology, 2001). A system of classification of epithelial 
ovarian carcinoma’s (EOC’s) as endorsed by the WHO, the International Federation of 
Gynecology and Obstetrics (FIGO) and the Society of Gynecologic Oncologists denotes 
the following subtypes based on histological presentations: (i) serous, (ii) mucinous, (iii) 
endometroid, (iv) clear cell and (v) poorly differentiated tumours, as illustrated in Figure 
1.2 (Modugno et al., 2001; Cloven et al., 2004; Nagle et al., 2008, Köbel et al., 2010; Su et 
al., 2013). Furthermore, ovarian cancer is classified as either invasive or of low malignant 
potential (Modugno et al., 2001).  
 
Elucidating the subtype of ovarian cancer may have significance in determining 
appropriate chemotherapeutic regimens, since different subtypes have shown differing 
sensitivity to specific antineoplastic drugs. Clear cell carcinoma of the ovary has been 
found to have poor prognosis, in terms of initial response and overall 5-year survival rate, 
despite its earlier detection due to chemoresistance to platinum-based therapies, which 
are used as first-line agents (Fujiwara et al., 2003; Itamochi et al., 2008). Clear cell EOC 
did however display lower extreme drug resistance to the antineoplastic drug paclitaxel 
compared to the serous subtype (Cloven et al., 2004). Hess and co-workers (2003) found 
a difference in response to first-line platinum based chemotherapy in patients with the 
mucinous subtype of ovarian cancer (Hess et al., 2003). Investigations conducted by 
Cloven and team (2004) highlighted a significant resistance to the antineoplastic agent 
cisplatin by mucinous EOC’s while the resistance to doxorubicin was lower for the 
mucinous subtype compared to serous EOC (Cloven et al., 2004). However, these 
findings have not transcended into the clinical domain, where adjuvant chemotherapy 
selection is usually based on stage and grade of tumours as well as standardized drug-
formulary based treatment regimens (Cloven et al., 2004). Nevertheless, it facilitates our 
understanding of factors affecting treatment outcomes and may shape the direction of 
future therapy towards increasingly individualized therapy with greater effectiveness.  
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Figure 1.2 Brief histological classification of EOC and primary features of each subtype (Adapted 
from Cloven et al., 2004). 
 
Clinical observations have shown ovarian cancer to be particularly chemosensitive with 
80% of patients responding to initial treatment (Chien et al., 2007). However, the high 
incidence of recurrence also results in chemoresistant malignancies (Chien et al., 2007). 
Despite a 70-80% response rate to initial therapy, ovarian cancer has exhibited a relapse 
rate of up to 75% in 18 to 28 months (Stuart, 2003). A case-controlled study conducted by 
Modugno and co-workers (2001) confirmed the role of nulliparity and a familial history of 
defects in the BRCA1 and BRCA2 genes in increasing the risk of developing ovarian 
cancer, while risk is lowered with each additional pregnancy, as well as with the use of 
oral contraceptives and tubal ligation (Modugno et al., 2001; Sellers et al., 2005). These 
findings were consistent with the results of other studies (Kurian et al., 2005; Nagle et al., 
2008).  
 
There is a strong trend of increasing risk of developing ovarian cancer as age progresses, 
with the median age of diagnosis approximating 60 years of age as indicated in Figure 
1.3. Diagnosis in older women also occurs at a later stage of the disease, since these 
women are usually postmenopausal and hence, the symptoms of dysfunctional ovaries 
may be less distinct (Tew and Lichtman, 2008; O’Cearbhaill et al., 2012).  Equi-staged 
tumours are also associated with a poorer prognosis in older women compared to a 
younger population (Koroukian et al., 2012). The aging global population indicates that the 
problem could become progressively distressing over time if a solution is not developed 
soon (O’Cearbhaill et al., 2012).  
Epithelial Ovarian 
Cancer (EOC)
Resemble epithelium of 
fallopian tube. Most 
common. 
Resemble endocervix 
epithelium. Typically 
diagnosed earlier  -> 
better prognosis.
Resembles endometrial 
epithelium. Typically 
diagnosed earlier -> better 
prognosis.
Glycogen-rich cells, 
resemble endometrial 
glands during pregnancy. 
Uncommon, earlier 
diagnosis.
Poor prognosis
Serous EOC
Mucinous EOC
Endometroid 
EOC
Clear cell EOC
Poorly 
differentiated 
EOC
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Figure 1.3 Age-specific incidence rates per 100 000 population in the UK, diagnosed annually 
between 2002 and 2006. Whilst the absolute values are specific to the UK region for a specified 
time period, the trend is globally representative. (Adapted from Cancer Research UK, 2013) 
 
1.2 Detection and diagnosis of ovarian cancer: The initial problem  
The lack of early detection mechanisms for ovarian cancer is perhaps the primary 
determinant of the poor therapeutic outcomes and overall 5-year survival rate associated 
with this condition. The intimate correlation between the stage of ovarian cancer at the 
time of diagnosis and the corresponding 5-year survival rates is widely documented and 
clearly illustrated in Figure 1.4 (Jacobs and Menon, 2004; Chu and Rubin, 2006; Köbel et 
al., 2010; Bamias et al., 2011; Rauh-Hain et al., 2011; Maringe et al., 2012).  
 
 
Figure 1.4 General trend in correlation of tumour stage at the time of diagnosis and the 
corresponding 5-year survival rate adapted from the latest statistics available from SEER for the 
USA (Howlader et al., 2012). This trend is significant and representative of current global trends. 1) 
localized tumour; 2) Spread to regional lymph nodes; 3) Distant metastasis; 4) Unknown stage. The 
proportion of ovarian cancer diagnoses made after metastasis outside the peritoneal region is in 
stark contrast to the portion of early diagnoses. The radical decline in 5-year survival rate 
(expressed as a percentage) as tumour stage progresses, is distinct and accounts for the poor 
prognosis associated with this condition.   
 
The obstacles in the development of screening tests for the early detection of ovarian 
cancer present feasibility challenges as well as economic challenges, complicated further 
by the experience of non-specific symptoms. Ovarian cancer lacks detectable histological 
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lesions which could be considered a precursor to tumour development and, as such, 
monitored regularly for early tumour detection (Jacobs and Menon, 2004; Chu and Rubin, 
2006). Cancer biomarkers that have been identified are predominantly from patients with 
advanced disease, providing a questionable reference for early stage disease (Jacobs 
and Menon, 2004; Rauh-Hain et al., 2011). The underlying molecular biology of ovarian 
cancer appears to differ between tumours that are detected early and have good 
treatment outcomes, and the more common late-stage tumours. Data highlighting these 
differences intimate that development of a screening test for early detection may not be 
successful in the detection of tumours with the later biological make-up, which is in fact 
the predominant form (Rauh-Hain et al., 2011). There exists no conclusive evidence 
related to the time required for tumour development and progression. Hence, a suitable 
interval between screening tests will be difficult to ascertain. Moreover, prevalence of 
ovarian cancer in the general population is low (Rauh-Hain et al., 2011). Determining the 
efficacy and applicability of developed screening tests will thus require a very large test 
population in order to obtain significant quantities of positive screening results, to be 
defined adequately sensitive and specific (Chu and Rubin, 2006).   
 
1.3 Micro-environmental tumour physiology: Barrier and potential in drug 
delivery 
The micro-environmental physiology of solid tumours has exhibited distinctions from 
normal healthy tissue which has complicated and compromised successful treatment, as 
illustrated in Figure 1.5. The significance of dissecting these differences became implicit in 
the 19th century when Steven Paget explicated his ‘seed and soil’ theory, which 
acknowledges the importance of tumour cells as well as the surrounding environment in 
the initiation and progression of cancer (Witz, 2009; Weber and Kuo, 2012). The foremost 
distinction exists between the vasculature of tumour tissue and the vasculature present in 
normal tissue. Tumoural blood vessels exhibit a higher proliferation rate with the resultant 
vasculature being convoluted with disorganized branching and structure, which creates 
inconsistency and unpredictability with regards to drug delivery and absorption through 
the tumour (Fukumura and Jain, 2007). Basement membrane formation is compromised, 
enlarged inter-endothelial junctions and an increase in vesicles, fenestrations and vesico-
vacuolar channels collectively result in hyperpermeability of tumoural vasculature. 
Transport of macromolecules via these inter-endothelial spaces has been widely exploited 
as a passive targeting mechanism. Diffusion is considered the primary mechanism by 
which molecules extravasate into tumour tissue. The size, shape, surface charge and 
structural integrity of a molecule determines the diffusivity of the molecule, and hence the 
extent and efficiency of extravasation into tumour tissue. Tumoural interstitial pressure is 
significantly higher. This combined with the absence of a fully functional lymphatic system, 
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alters transport of molecules through tumour tissue and has consequently been widely 
cited to result in the accumulation of macromolecules within tumour tissue. Expansion of 
tumour mass with spatial confinement creates mechanical stress, which compresses the 
lymphatic vessels rendering them non-functional. Moreover, tumoural pH is inclined to a 
more acidic nature. Tissue hypoxia due to the rapid tumour growth and the insufficiency of 
tumour vasculature to sustain the oxygen requirements has been attributed to the lower 
pH of tumour tissue (Fukumura and Jain, 2007; Weber and Kuo, 2012). Tumour tissue 
also displays altered metabolic patterns, with glycolysis being the predominant 
mechanism of energy production.  The ultimate production of hydrogen cations (H+) in the 
glycolytic process contributes significantly to the lower tumoural pH (Ward et al., 2013). 
This change in pH can alter the ionization characteristic of drug molecules, thereby 
affecting their solubility within tumour cells and absorption across membranes. The uptake 
of weak basic drugs such as doxorubicin is diminished by lower extracellular pH, hindering 
the efficacy thereof (Fukumura and Jian, 2007). The hypoxic and acidic environment 
impedes immunologic function and perpetuates metastasis and invasion (Macklin and 
Lowengrub, 2007).   
    
 
Figure 1.5 Visual illustration of the tumour micro-environmental factors influencing therapeutic       
efficacy. 
 
1.4 Current treatment protocol for ovarian cancer 
The current Gold Standard of treatment for ovarian cancer is surgical debridement 
followed by intravenously administered chemotherapy of a combination of paclitaxel and 
cisplatin or carboplatin (taxane/platinum compound combination) (Stuart, 2003; Spentzos 
et al., 2004; Cirstoiu-Hapca et al., 2010; Kim et al., 2011; Chang et al., 2012). However, 
many factors compromise the efficacy of available treatment for ovarian cancer. The 
strongly lipophilic nature of antineoplastic drugs complicates the formulation, 
administration and delivery of these drugs to target sites, which enhances the appeal of 
drug delivery vehicles. Paclitaxel, one of the first line drugs in the treatment of ovarian 
cancer requires solubilization by Cremophor EL, a vehicle that has displayed intense side-
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effects such as acute hypersensitivity reactions, hyperlipidaemia and peripheral 
neuropathy at the high doses required for antineoplastic therapy, which compromises its 
clinical usefulness (Gelderblom et al., 2001; Cirstoiu-Hapca et al., 2010).  
 
Antineoplastic drugs also exhibit limited specificity for tumour tissue, and a tendency to act 
indiscriminately, particularly on rapidly dividing tissue. This indiscriminate activity results in 
deleterious, dose-limiting and often life-threatening side-effects, such as cardiovascular 
complications, severe myelosuppression, compromised immunity, altered gastric function, 
myalgia and neurotoxicity, among others (Vauthier et al., 2003; Cho et al., 2007; Cirstoiu-
Hapca et al., 2010; Mohanty and Sahoo, 2010; Guo et al., 2011; Shapira et al., 2011). 
Cisplatin, the other first line agent used in the treatment of ovarian cancer, is associated 
with severe dose-limiting side-effects, the foremost being nephrotoxicity which has limited 
the use of cisplatin in 25-30% of patients (Chirino and Pedraza-Chaverri, 2009; Rjiba-
Touati et al., 2013). Approaches to alleviate or limit nephrotoxicity commonly involve the 
administration of rehydration fluids and diuretics in order to decrease renal accumulation 
of cisplatin. The concomitant administration of compounds with various functionalities, 
such as antioxidants, nitric oxide modulators and anti-apoptotic drugs have been 
investigated to reduce cisplatin-induced nephrotoxicity (Rjiba-Touati et al., 2013). Cisplatin 
demonstrates significant (<90%) protein binding with an initial plasma half-life shorter than 
1 hour (Chirino and Pedraza-Chaverri, 2009).  
 
Antineoplastic drugs are known to have a substantially narrow therapeutic window (Cai et 
al., 2011). Maintaining drug concentrations within the therapeutic window is particularly 
challenging. Specificity for cancer cells will therefore be a principal criterion in determining 
the success of new cancer therapies. 
 
1.5 Statement of the problem 
The poor aqueous solubility of antineoplastic drugs poses an initial formulation challenge. 
The intravenous route of administration remains the most feasible route of administration 
of antineoplastic chemotherapy due the patient acceptance, limited patient involvement 
such as that requiring the consumption of oral medication regimens, ease of 
administration and reduced risk of infection (as associated with the insertion of 
administration ports). Formulation of strongly lipophilic antineoplastic drugs as an 
intravenous preparation is significantly challenging, necessitating the use of a delivery 
vehicles, the shortfalls of which are explicated in Section 1.6. Various attempts to develop 
more hydrophilic derivatives usually resulted in a decrease in cytotoxic efficacy.  
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The unfavorable biodistribution of antineoplastic agents remains one of the most 
significant drawbacks of chemotherapy. Firstly, the critical side-effects resulting from 
activity at inappropriate target sites are dose-limiting and hence, can compromise 
successful therapeutic outcomes. Myelosuppression in particular can result in 
prolongation of intervals between cyclical drug administration’s allowing cancer cells to 
replicate and perhaps develop mechanisms of resistance. Other severe toxicities such as 
cardiotoxicity, neurotoxicity and nephrotoxicity may be fatal. The significance of severe 
gastrointestinal maladies should not be underestimated, as the patients’ nutritional status 
and electrolyte balance may be severely compromised. Secondly, unfavorable 
biodistribution of antineoplastic drugs reduces the concentration of drug available at the 
site of action to exert the desirable antineoplastic effect.  
 
The antineoplastic drug camptothecin (CPT) has exhibited tremendous cytotoxic activity 
against a wide range of tumours. However, pharmaceutical development and clinical 
application of this potent drug has been severely hampered due to the poor aqueous 
solubility and deleterious side-effect profile of CPT, as well as conversion to a significantly 
less biologically active carboxylate form under physiological conditions. Furthermore, the 
high affinity of the carboxylate form of CPT for human serum albumin (HSA) unfavorably 
drives the equilibrium from the active lactone form to the inactive carboxylate form.  
 
1.6 Approach to the problem 
This study proposes the development of a novel intravenously administered nano-
lipobubble drug delivery system (NLB-DDS) containing the antineoplastic drug CPT, with 
a size range below 200 nm. The shell of the NLB will be comprised of lipids, enabling the 
solubilization of the lipophilic model drug. A gaseous core will be introduced to impart 
bubble characteristics to the DDS. Polymeric coating of the NLB’s will further be employed 
to prolong drug release. 
 
Formulation as a nano-DDS allows for enhanced solubilization of the strongly lipophilic 
drug. This is further augmented by the presence of a lipoidal NLB shell. The use of 
phospholipids for the NLB shell, which are characterized by a polar head region as well as 
a non-polar tail region, facilitates incorporation of the lipophilic drug, whilst conferring 
aqueous compatibility characteristics on the formulation. This enables intravenous 
administration, barring the use of a delivery vehicle. The nano-scale size range (<200 nm) 
also has applicability to passive targeting in tumour tissue by the Enhanced Permeability 
and Retention (EPR) phenomenon, which favorably alters the biodistribution of 
antineoplastic drugs. The circulation half-life of nano-DDS is superior to micro-DDS due to 
evasion of the reticulo-endothelial system (RES). 
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The incorporation of CPT within the NLB has a dual function. Firstly, the physiologically 
labile drug, CPT, is protected from the unfavorable physiological environment prior to 
reaching the target tissue. Conversion to the inactive carboxylate form and subsequent 
association with HSA is thus prevented. Secondly, retardation of drug release from the 
NLB allows for adequate accumulation of the DDS within the target tumour tissue before 
significant drug is released in the systemic circulation. Combined with the passive 
targeting characteristics, prolonged drug release has the potential to tremendously 
improve the side-effect profile associated with CPT and other antineoplastic drugs. The 
favorably revised CPT biodistribution further results in higher concentration of drug within 
tumour tissue and significantly enhanced therapeutic effect. 
 
1.7 Rationale and Motivation for the study  
Angiogenesis occurs at a considerably elevated rate in tumour tissue compared to normal 
tissue (Rapoport, 2007). The tight junctions that are present in normal endothelial cells are 
in the region of 7 nm, while the tight junctions present in tumour tissue can manifest as 
large as 400 nm. Formulation of the proposed nano-DDS with a size range below 200 nm 
will allow passive targeting of the DDS to the tumour site and extravasation through the 
leaky vasculature (Gao et al., 2007; Rapoport, 2007; Abu-Lila et al., 2009). Figure 1.6 
demonstrates the preferential accumulation of the intended NLB-DDS at the tumour site. 
NLB behave as macromolecules in vivo and their uptake by the lymphatic system in 
tumour tissue is impaired. Following intravenous infusion of NLB, distribution throughout 
the systemic circulation will be minimized due to the passively targeted nature of the NLB 
on account of the EPR phenomenon, as discussed in greater detail in Chapter 2. Diffusion 
of the gaseous core out of the NLB over time will result in drug release through NLB 
cavitation.  
 
The advantages of passive tumour targeting are several-fold. Tumour targeting will enable 
the attainment of augmented levels of CPT at the tumour site by favorably altering 
biodistribution of the drug following intravenous administration, whilst preserving the state 
of healthy tissue. Hence, anti-tumour efficacy will be substantially increased while the 
side-effects associated with conventional chemotherapy will be dramatically reduced. 
Furthermore, the existence and concurrent treatment of co-morbidities will pose less of a 
challenge in the realm of cancer treatment due to site-specific release of 
chemotherapeutic drugs, which will minimize drug-disease and drug-drug interactions with 
co-existing morbidities and their treatment. 
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Poor aqueous solubility is an inherent characteristic of most antineoplastic drugs. The 
utilization of solubilizing agents has proven useful to a certain degree however these 
reagents demonstrate their own shortfalls such as side-effects and toxicity (Rapoport, 
2007). Formulation as nanosystems has resulted in improved solubilization, and 
subsequently enhanced absorption, of these drugs due to the high surface area:volume 
ratio afforded by the size and architecture of the nano-DDS’s as well as the presence of 
the lipid component in the proposed NLB formulation, which facilitates incorporation and 
solubilization of lipophilic drugs (Tirelli, 2006). NLB thus have the potential to enhance the 
bioavailability of antineoplastic drugs. 
 
Studies undertaken by Abu-Lila and co-workers (2009) highlighted the functionality of 
liposomes to deliver low molecular weight chemotherapeutic drugs to solid tumour sites by 
alteration of the biodistribution of these antineoplastic drugs (Abu-Lila et al., 2009). 
However, liposomes do not display significant stability and their size range often includes 
a large proportion of micron-sized particles. In addition, preparation steps have to be 
carefully controlled in order to achieve reproducibility in terms of size and entrapment 
efficiency (Koo et al., 2005). Since these factors could compromise the use of liposomes 
in intravenous drug delivery due to risks such as embolism and treatment failure due to 
instability, approaches will be instituted for stability enhancement, size control and 
improvement of drug loading. The employment of polymeric materials in combination with 
the liposomal structure for the NLB formulation will be instituted. 
 
The high cost of antineoplastic drugs and the rising incidence of malignancies will 
undoubtedly place a burden on the healthcare system, which most developing countries 
cannot afford. Enhanced drug efficacy will significantly reduce the quantity of 
antineoplastic drug required to eliminate tumour cells, thus allowing for a reduction in cost. 
Targeted therapy that displays increased mean residence time (MRT) in tumour tissue, 
will allow for reduced frequency and duration of therapy, which will provide psychological 
and physiological benefits for the patient. 
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Figure 1.6 Schematic illustration of the components of the NLB-DDS, the passive targeting, 
extravasation and resultant accumulation of the NLB-DDS within tumour tissue and the mechanism 
of antineoplastic drug release from the NLB.  
 
1.8 Aim and Objectives of this study 
The aim of this study was to design, optimize and characterize a camptothecin-loaded 
NLB-DDS exhibiting passive targeting to tumour tissue following intravenous 
administration. The passively targeted nature of the DDS will result from capitalization, by 
the nano-scale dimensions of the DDS, on the EPR phenomenon displayed by tumour 
tissue, thereby leading to concentrated release of drug at, and accumulation within, 
tumour tissue, enhancing antineoplastic efficacy and significantly reducing side-effects. 
Polymeric coating was instituted to retard drug release in the systemic circulation prior to 
reaching the tumour site, thereby altering the unfavorable biodistribution responsible for 
the devastating side-effects which have compromised the clinical use of CPT. The 
proposed DDS is intended to drastically improve the therapeutic outcome of ovarian 
cancer therapy, shorten duration of therapy, improve the health-related quality of life of the 
patient during therapy and increase the overall 5-year survival rate.   
 
In order to achieve these aims the following objectives were identified: 
1. To gain a thorough understanding of the pathophysiology of the disease state and 
considerations for effective drug delivery.  
2. To review the current research ideologies and systems intended to improve treatment 
of ovarian cancer, from a novel drug delivery perspective.   
3. To investigate formulation methods of NLB preparation and indentify a single effective 
and industrially viable method to be employed. 
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4. To conduct extensive preformulation studies on various biocompatible and 
biodegradable formulatory components and delineate independent variables, and the 
minima and maxima thereof, for successful NLB formulation. 
5. To experimentally synthesize variants of NLB formulations according to an appropriate 
experimental design followed by a systematic physicochemical and 
physicomechanical analysis of the variants. 
6. To statistically optimize formulation parameters for the synthesis of CPT-loaded, 
passively targeted NLB. 
7. To elucidate the physicochemical and physicomechanical dynamics of the optimized 
NLB formulation. 
8. To investigate the potential and feasibility of phytochemical incorporation into the NLB 
formulation, as well as, polymer coating of the NLB-DDS and the influence thereof on 
the physicochemical and physicomechanical properties of the formulation. 
9. To undertake ex vivo studies on a human ovarian cancer cell line to determine the 
uptake, efficacy and safety of the NLB-DDS. 
 
1.9 Novelty of this study 
Nanobubbles have been extensively investigated for their tumour imaging potential as a 
result of their inherent echogenicity. In addition, the use of ultrasound in conjunction with 
nanobubbles has displayed potential for combined imaging and destruction of tumour 
tissue (i.e. therapy). This study aims to extend this paradigm to antineoplastic therapeutics 
by loading NLB with an antineoplastic agent. These NLB will be passively targeted to 
tumour tissue, thereby favorably altering the biodistribution, and hence the efficacy and 
side-effect profile, of the antineoplastic agent. The incorporation of a phytochemical with 
anti-tumour activity will be explored to attain synergistic therapeutic activity.  
 
1.10 Overview of this dissertation 
Chapter 1 of this dissertation provides a concise introduction into ovarian cancer as a 
disease state. Furthermore, this chapter provides a detailed description of the intended 
nano-DDS and rationalizes the undertaking of this study by outlining the challenges in 
current clinical therapy that can potentially be overcome by the development of this nano-
enabled DDS. A diagrammatic illustration of the NLB-DDS is provided to better 
demonstrate the mechanism of passive targeting and drug release. The aim, and the 
objectives outlined to achieve this aim are presented herein.  
 
Chapter 2 focuses on the potential and current application of nanotechnology to imaging, 
detection, diagnosis and treatment of various tumours, with particular reference to ovarian 
cancer. The potential of nanotechnological approaches in addressing the shortfalls of 
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several antineoplastic compounds is explored, corroborated by research data from 
particular studies, further highlighting the vast potential of nanotechnology in reducing the 
burden attached to this morbidity. A brief insight on currently available and pre-clinical 
nanosystems is provided to demonstrate the clinical relevance of nanomedicine research. 
 
Chapter 3 delves into the rational selection of formulation materials for preliminary 
investigation as well as the step-wise approach adopted in the ultimate formulation of the 
NLB-DDS. The investigations involved in the delineation of a single, effective method of 
nano-liposomal preparation are expounded. In addition, the preformulation studies 
undertaken in the identification of key formulation variables affecting the size, zeta 
potential and efficiency of drug incorporation of the nano-liposomes will be explicated.   
 
Chapter 4 explores the generation of a Face-Centered Central Composite Design for 
each of the two lipid combinations delineated from preformulation studies described in 
Chapter 3, to strategically elucidate the effect of independent variables on measured 
response parameters. In addition, this chapter expounds the selection of relevant 
measured responses and the effects of independent variables on these measured 
responses. Finally, the optimal formulation parameters with respect to the desired 
measured responses are described.   
 
Chapter 5 presents the measured responses of candidate formulations predicted through 
statistical optimization whilst providing a comparison to the results derived experimentally. 
Conversion of nano-liposomes to NLB is described, as well as modifications of formulated 
NLB in the form of phytochemical incorporation and polymeric coating. Physicochemical 
and physicomechanical characterization of the formulated NLB formulations is explored to 
determine the feasibility of the modifications undertaken as well as generate a tangible 
evaluation of the formulation in relation to the aim of the study. 
 
Chapter 6 explores the undertaking of ex vivo analyses on a human epithelial ovarian 
cancer cell line and blood products. Cellular uptake, the degree of cytotoxicity and the 
hemolytic activity of formulated DDS is evaluated through qualitative and quantitative 
investigations. 
 
Chapter 7 highlights the conclusions of this study and the recommendations for future 
work in this potentially revolutionary research area. 
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CHAPTER 2 
INNOVATIVE NANOTECHNOLOGICAL APPROACHES TO THE DETECTION AND 
TREATMENT OF OVARIAN AND OTHER SOLID TUMOURS 
      
2.1 Introduction 
Nanomedicine refers to research into and development of technologies, devices and drug 
delivery systems for prevention, diagnosis and treatment of disease at the nano-scale 
(Khosravi-Darani et al., 2007, Rai et al., 2010). Strictly speaking, nanostructures are 
defined as varying geometrical configurations with at least one dimension in the range of 
10-100 nm. However, nanostructures up to 250 nm have found applicability in the medical 
setting by the Enhanced Permeability and Retention (EPR) effect, active targeting, 
enhanced residence time and increased cellular uptake (Bawarski et al., 2008; Bawa et 
al., 2012; Etheridge et al., 2013). Nanosystems combine the fields of medicine, chemistry, 
pharmacology, biology, mathematics and engineering to provide unique properties that 
are yet to be fully explored (Farokhzad and Langer, 2006; Rai et al., 2010). Nanosystems 
with biomedical application are currently a highly researched field and have exhibited 
immense potential, particularly in the diagnostic, imaging and therapeutic domains 
(Dominguez and Lustegarten, 2010). Numerous benefits of nanosystems are related to 
the augmented surface area:volume ratio, which has the potential to favorably influence 
the solubility, bioavailability, pharmacokinetic and biodistribution profile of drugs, as well 
as, their inclination toward modification and functionalization (Khosravi-Darani et al., 2007; 
Chen et al., 2011; Vizirianakis, 2011, Ji et al., 2012). Nanomaterials have been shown to 
exhibit properties vastly different from the bulk material from which they are synthesized 
(Chen et al., 2010(a); Chen et al., 2011). In addition, the vast array of structural 
arrangements make nanosystems incredibly versatile, while their minute dimensions often 
belie an astonishing robustness. These devices offer the unequivocal advantage of 
interacting with cells, biological processes and other targets at a molecular level, allowing 
for inter- and intra-cellular manipulation and monitoring, the benefits of which are beyond 
our full comprehension at this point. The continued development of novel nanosystems is 
expected to have extensive applicability at all levels of healthcare, including disease 
initiation, progression, treatment and monitoring.  
 
Nanosystems are envisaged to: 
• Enable superior detection of molecular changes that precede pathogenesis, 
thereby enabling early detection, pro-active treatment and monitoring as well 
as expanding the knowledge base on mechanisms of disease progression. 
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• Enhance selectivity and sensitivity for pathological states to advance disease 
diagnosis and imaging. 
• Transform drug delivery and therapy by capitalizing on the unique properties of 
the nano-scale size range. 
• Effectively combine diagnostic, therapeutic and efficacy monitoring applications 
in a multi-functional nanosystem. 
• Contribute to, and perhaps transform, scientific approaches to all of the above 
as well as the processes involved in drug discovery, purification and 
modification (Farokhzad and Langer, 2006).  
 
Research and development into nanosystems applicable to cancer diagnosis, imaging 
and therapy has emerged as one of the largest fields in nanomedicine (Etheridge et al., 
2013). The substantial burden of cancer on the global population and the indiscriminate 
nature of the condition underscores the considerable interest of governmental, industrial, 
healthcare and academic entities in exploring and developing the applicability of this 
technology to the oncology field. This chapter aims to discuss the exciting role and 
immense potential of nanotechnology in the diagnosis, imaging and treatment of solid 
tumours, with particular focus on ovarian cancer as a backdrop to the study undertaken. 
For the purpose of this dissertation the terms nanosystem and nano-enabled drug delivery 
system shall be used interchangeably and will encompass nanoparticles, micelles, 
liposomes, quantum dots, nanotubes and all other drug delivery and imaging systems 
where at least one dimension is of the nano-scale.   
 
 
Figure 2.2 Illustrative summary of the potential benefits that nanosystems may offer with regards to 
tumour diagnosis and treatment. 
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2.2 Application of nanotechnology in tumour diagnostics and imaging 
Early diagnosis and precise imaging of carcinogenesis is critical to successful therapeutic 
outcomes. However, highly sensitive and specific technologies are required to detect 
slight biological changes that may characterize early stage disease, as well as to 
accurately classify the stage and dissemination of tumours. One of the major setbacks in 
the early detection of ovarian cancer is lack of suitable detection technologies and 
imaging techniques. Accurate imaging techniques will assist in the early diagnosis of 
ovarian cancer, accurate staging of the tumour as well as monitoring the efficacy of 
treatment and early determination of resistance to therapy being used. Recurrence is an 
enormous problem in ovarian cancer, resulting in atrocious 5-year survival rates, as well 
as the emergence of resistance to antineoplastic drugs. However, when ovarian cancer is 
diagnosed in the early stages (when it is confined to the ovary), the 5-year survival rate is 
approximately 90% (Fishman et al., 2005). 
 
Current systems employed in the detection of tumour cells or cancer biomarkers include 
surface plasmon resonance, nuclear magnetic resonance, quartz crystal microbalance 
resonators and polymerase chain reaction, amongst others, which require augmentation 
of the signal, the expression of fluorescent protein biomarkers and antibodies in the cell or 
the enhancement of target cells in the sample (Wu et al., 2010). Transvaginal sonography 
is currently the imaging modality utilized in the imaging detection of ovarian cancer 
(Fishman et al., 2005; Kim et al., 2011). However, views on the sensitivity and accuracy of 
this technique in the detection of early stage ovarian cancer have been incongruent 
(Fishman et al., 2005). In view of this, a detection system that is minimally invasive, 
sensitive and does not require augmentation or labeling of the sample would be highly 
beneficial (Wu et al., 2010). Nano-scale detection and imaging devices have the capacity 
to demonstrate substantial sensitivity and specificity, which could revolutionize the clinical 
course of cancers. The nano-scale offers the advantage of interacting and detecting 
changes at intra- and intercellular levels and is thus unsurpassed in analyzing most 
biological moieties such as cells, viruses, proteins and nucleic acids (Chen et al., 2011).  
 
2.2.1 Biosensors in cancer detection 
Biosensors consist of a bioreceptor that interacts with specific analytes within the body, 
producing a change which is detectable through conversion by a transducer (constituent 
of biosensor) to a measurable signal (Vo-Dinh et al., 2001). Figure 2.2 outlines the 
interactions that are responsible for changes that occur and the types of signals that are 
measured after transduction. 
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Figure 2.2 Illustrative representation of the various types of interactions between bioreceptors and 
analytes, as well as the measurable signals that are produced. 
 
Nanofibers have been applied to the field of biosensors, coining the term nano-biosensors 
(Vo-Dinh et al., 2001). The initial application of nanofibers to biosensors was an antibody-
based system for the detection of benzo[a] pyrene tetrol in the body, which indicates 
exposure to benzo[a]pyrene (BaP) (Vo-Dinh et al., 2001). BaP, a common environmental 
pollutant, as well as a component of tobacco smoke, is a known human carcinogen (Vo-
Dinh et al., 2001; Wu et al., 2010). Early detection of exposure to BaP could have 
remarkable implications in the detection and treatment of, particularly, lung cancer, which 
is a leading cause of cancer death worldwide (Wu et al., 2010).  
 
Wu and colleagues (2010) combined biocompatible and biodegradable poly(lactic acid) 
(PLA) nanofibers with gold (Au) nanoparticles, which have been applied extensively in the 
field of biosensors, to form nanocomposites (Wu et al., 2010). These nanocomposites 
were subsequently used on modified indium tin oxide (ITO) electrodes and investigated 
for their ability to detect drug-sensitive and drug-resistant leukemia cells. These Au/PLA 
nanocomposite modified ITO electrodes exhibited promising sensitivity in detection of the 
leukemia cells as well as differentiating between the cell types (Wu et al., 2010). This 
nano-biosensor has potential for the rapid and early detection of cancer cells, which will 
be of considerable value in clinical practice. 
  
Angiogenesis (the development of new blood vessels in the human body) is essential to 
the growth and preservation of living tissue (Kwon et al., 2010). However, this process 
occurs at an elevated rate in tumour tissue and is related to proliferation and metastasis of 
cancer cells (Kwon et al., 2010). Vascular endothelial growth factor (VEGF) is a potent 
pro-angiogenic agent, pivotal to the angiogenic process and thus an attractive target for 
cancer therapy as well as a useful means for early cancer detection (Kwon et al., 2010). 
Current methods for the detection and quantification of VEGF include enzyme-linked 
immunosorbent assay (ELISA), VEGF receptors and field-effect transistor biosensors 
(Kwon et al., 2010). There, however, exists a room for improvement in the sensitivity and 
ease of use of these tests. To this end, Kwon and fellow researchers (2010) combined 
conducting polymer (polypyrrole) nanotubes with aptamers (nanosize molecules with a 
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great degree of sensitivity and specificity for target molecules) bonded to the nanotubes, 
in a modified biosensor for the detection of VEGF (Kwon et al., 2010). Two carboxylated 
polypyrrole carbon nanotubes (CPNT) were synthesized (CPNT 1=190-220 nm; CPNT 
2=100-130 nm), attached to biosensors and evaluated. Although both CPNT’s displayed a 
high degree of sensitivity in detecting VEGF, CPNT 2 exhibited approximately two-fold 
higher sensitivity, highlighting the significance of size in this detection method. The 
increased sensitivity of the transducer with CPNT 2 was attributed to increased 
conductivity as a result of the augmented surface area exposed in CPNT 2, a 
consequence of the smaller dimensions (Kwon et al., 2010). The presence of aptamer on 
CPNT 2 produced superior sensitivity compared to non-aptamer based biosensors and 
the larger size of CPNT 1 (Kwon et al., 2010). In addition, the rapid real time detection 
adds another favorable dimension to this system, since biological events detected can be 
converted directly into a measurable signal and no labeling of samples is required (Kwon 
et al., 2010; Chen et al., 2011). Kwon and team (2010) were successful in detecting 
previously unprecedented low levels of VEGF, which could have enormous implications 
for the early detection of several cancers. Furthermore, the modified biosensor system 
developed is reusable, enhancing the practicality and attractiveness of this detection 
device (Kwon et al., 2010). 
 
Telomerase is regarded as a general biomarker for cancer due to a significant up-
regulation (85-90%) in its expression in human tumour cells. The detection of this 
biomarker, thus, has enormous potential in early cancer detection, as well as monitoring 
the efficacy of chemotherapeutic interventions (Zheng and Li, 2010). Telomerase is 
located in trace amounts within cell nuclei, therefore the ideal detection of telomerase will 
involve ultrasensitive single cell analysis of living cells. Nanofiber biosensors conjugated 
with anti-telomerase antibody are capable of intracellular detection of telomerase on 
account of its size and direct interaction between conjugated anti-telomerase and 
telomerase by penetration of the cell nucleus (Zheng and Li, 2010). The significance of 
the nanoscale was once again highlighted in this study, whereby detection of telomerase 
was attempted by employing the cytoplasm of cancer cells. There was no significant 
detection of telomerase, emphasizing the importance of nucleus penetration for 
telomerase detection (Zheng and Li, 2010). This would be impossible with larger devices. 
Furthermore, fluorescence was significantly reduced when cells expressing low levels of 
telomerase were assayed. The nanofiber biosensor is thus able to differentiate normal 
cells from telomerase over-expressing cancer cells, making telomerase detection by 
nanosystems a superior detection technique.  
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2.2.2 Quantum dots for tumour detection and imaging 
Quantum dots (QD) are semiconductor, fluorescent nanocrystals that have received 
considerable attention in the biomedical field, particularly for their potential as imaging 
agents (Geszke et al., 2001; Schroeder et al., 2007; Pan and Feng, 2009). The 
advantages of quantum dots over the conventional dyes employed for imaging include: 
 
• The spectrum of emission can be altered by changes in the size and composition 
of QD (Geszke et al., 2001; Schroeder et al., 2007; Pan and Feng, 2009). 
• QD exhibit a high quantum yield of fluorescence and superior brightness (Geszke 
et al., 2001; Pan and Feng, 2009; Papagiannaros et al., 2009). 
• A high degree of photostability and resistance to photobleaching (Geszke et al., 
2001; Schroeder et al., 2007; Pan and Feng, 2009; Papagiannaros et al., 2009). 
• A broader spectrum of excitation (Pan and Feng, 2009).  
• More rapid imaging (Papagiannaros et al., 2009).  
 
However, use has been restricted as a consequence of toxicity from semiconductor QD 
(particularly cadmium based QD) and inadequate in vivo and physical stability profiles, 
partly due to their hydrophobic nature (Geszke et al., 2001; Pan and Feng, 2009; Setua et 
al., 2010). Modifications to QD have therefore been attempted in the form of surface 
coating and entrapping QD in water soluble nanoparticles and lipid micelles (Geszke et 
al., 2011). These methods have shown potential in increasing the stability of QD as well 
as improving the biocompatibility, biodistribution and reducing toxicity (Pan and Feng, 
2009). As outlined with previously discussed nanosystems, biocompatible and stable QD 
can then be functionalized for selectivity and site-specific targeting (Chin et al., 2010). 
This will prove beneficial in the early detection and diagnosis of cancer, which forms the 
basis of successful therapeutic interventions. Furthermore, QD have shown promise in the 
detection of sentinel lymph nodes, which is exceptionally beneficial in rapidly 
metastasizing cancers, such as ovarian cancer.   
 
Encapsulation of QD in lipid micelles has been investigated as a means of addressing the 
drawback of instability, as well as investigating the efficacy of targeting, by further 
functionalization of these micelles (Schroeder et al., 2007). The aforementioned 
preparation  formulated by Schroeder and co-workers (2007) proved non-toxic to cells 
when compared to cells incubated in the absence of the formulation and cells that were 
incubated with a non-targeted formulation, as well as highly selective for target cells (80-
90%) (Schroeder et al., 2007). As a practical consideration, entrapped quantum dots 
displayed impressive stability over a prolonged period of time with preservation of 
fluorescent capacity, making them viable for clinical use. Analysis of pegylated lipid 
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micelles entrapping quantum dots one year after preparation by Schroeder and co-
workers (2007), displayed no difference in structure, optical properties and physical 
stability (aggregation or precipitation) (Schroeder et al., 2007). This favorable stability 
profile was demonstrated in other studies for variable periods (3 months) (Papagiannaros 
et al., 2009). Differing results on fluorescence intensity was reported by Schroeder and 
team (2007) and Papagiannaros and team (2009) after encapsulation of QD in micelles 
(Schroeder et al., 2007; Papagiannaros et al., 2009). The first group observed a decrease 
in fluorescence intensity of encapsulated QD compared to single QD, which was attributed 
to a quenching effect by adjacent QD. However, the stability of the formulation acted to 
counter this effect and ultimately the fluorescent capacity was sufficient for the intended in 
vivo application (Schroeder et al., 2007). In contrast, the second group reported a greater 
intensity in fluorescence of QD-encapsulating-micelles (Papagiannaros et al., 2009). 
Despite this disparity, both research groups demonstrated clear and precise tumour 
imaging. Hence the systems described by Schroeder and co-workers (2007) and 
Papagiannaros and co-workers (2009) addressed many of the in vivo shortfalls 
established by previous work on QD and served to further highlight the feasibility of this 
nanosystem in the domain of cancer detection and imaging.  
 
The nanoscale of QD is essential to the imaging function, since it affects biodistribution. 
Larger QD may be confined to the blood vessels, thereby producing diffuse fluorescence 
and poorly differentiated tumour tissue and organs.  By contrast, the nano-size will allow 
extravasation from blood vessels and accumulation of the QD in tumour tissue, resulting 
in clearly contrasted and delineated tumoural images, with high intensity fluorescence and 
reduced background noise (Papagiannaros et al., 2009). Furthermore, differential QD 
accumulation in organs has the potential to highlight distant metastasis.  
 
In the domain of cancer, imaging techniques are utilized to stage tumours as well as to aid 
surgeons undertaking cytoreductive surgery. For this application, emission spectra should 
be between 400-650 nm to enable visibility without the use of specialized equipment (Chin 
et al., 2010). Currently, imaging in the near infra-red region is widely used as it is a 
minimally invasive process that enables clear, detailed imaging at a molecular level 
(Papagiannaros et al., 2009). This technique has been applied in tumour imaging, as well 
as mapping of tumour biomarkers, and sentinel lymph nodes as an aid in surgical 
resection. Furthermore, this technique has been utilized to monitor the response of 
tumours to chemotherapy. However, tissue penetration is limited (Papagiannaros et al., 
2009). The emission spectrum of nanosystems such as QD can be tailored for specific 
applications. However, the imaging of tumours and metastatic tissue requires sufficient 
tissue penetration, which usually occurs at emission wavelengths that are out of the 
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visible spectrum. Therefore modifications are required to satisfy the two requirements 
pivotal to successful tumour and metastatic tissue imaging.   
 
Multispectral imaging is an emerging technique that involves the splitting of signals for the 
detection of different moieties by a single excitation (Chin et al., 2010). This will allow 
simultaneous superficial as well as deep tissue imaging, while minimizing the photo-
damage of surrounding tissue (Chin et al., 2010; Geszke et al., 2011). Indium 
phosphide/zinc sulphide QD have been formulated with an exciton emission and a defect 
emission which allows for simultaneous superficial imaging and deep tissue penetration 
(Chin et al., 2010).  
 
2.3 A nanotechnological approach to cancer therapy 
Challenges to successful antineoplastic therapy are several-fold. Firstly, poor aqueous 
solubility poses significant formulatory and delivery challenges. Secondly, the 
physiological environment presents barriers to high drug bioavailability. Serum proteins 
can attach to drug molecules, rendering them unavailable for absorption and cellular 
internalization to exert their antineoplastic activity. Physiological instability, metabolic 
degradation and renal clearance may further compromise drug concentration at the site of 
action. However, it is the indiscriminate activity of antineoplastic drugs and the resultant 
side-effects that portray possibly the greatest challenge. These side-effects can be dose-
limiting, thereby compromising therapeutic efficacy and outcome, or may themselves 
prove fatal.  
  
The potential of nanosystems in addressing and overcoming the aforementioned 
drawbacks associated with current antineoplastic therapy reside in their ability to, firstly, 
encapsulate lipophilic drugs within the nanosystem or employ a nanovehicle to 
successfully deliver these drugs in vivo (Kim et al., 2011). Formulation as nanosystems, 
particularly encapsulation within a nanosystem, serves a protective function from 
inactivation and metabolic degradation (Kim et al., 2011). Secondly, nanosystems below 
300 nm are able to circumvent the reticuloendothelial system (RES), thereby increasing 
the circulation half-life and improving the pharmacokinetic profile of antineoplastic drugs. 
Thirdly, and one of the foremost benefits in the application of nanomedicine to cancer 
therapeutics lies in the passive targeting and accumulation attributes of nanosystems to 
tumour tissue due to the EPR phenomenon displayed by tumour tissue. In addition, the 
large surface area:volume ratio of nanosystems facilitates the attachment of targeting 
moieties for active targeting to tumour sites. Active and passive targeting favorably alter 
the biodistribution of antineoplastic drugs, simultaneously reducing side-effects and 
increasing the concentration of drug within tumour tissue for the augmentation of 
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therapeutic antineoplastic effect (Cirstoiu-Hapca et al., 2010; Kim et al., 2011). Finally, 
formulation as nanosystems have enabled direct uptake of the nanosystems into tumour 
cells by endocytic pathways and by-passing of the cellular efflux pump, thereby 
overcoming a mechanism of drug resistance (Lei et al., 2011; Kim et al., 2011). 
 
The potential of nanotechnological engineering and manipulations in addressing the 
various challenges limiting the success of antineoplastic therapy will be herein addressed 
with reference to poor aqueous solubility of antineoplastic drugs, passive and active 
targeting of nanosystems in enhancing therapeutic efficacy and the increasing problem of 
emergent drug resistance.    
 
2.3.1 Poor aqueous solubility: A cascading pharmaceutical challenge 
Considering water constitutes over 50% of the human body, administered drugs are 
bound to encounter an aqueous environment on their path to the site(s) of interest 
(Guyton, 1997). Furthermore, most routes of administration, particularly intravenous 
administration, require solubilization in an aqueous medium. However, the problem of 
administering poorly aqueous soluble drugs continues to plague scientists. Approximately 
40% of new chemical entities are poorly aqueous soluble or aqueous insoluble, hindering 
formulation development and the use of potent drug molecules (Merisko-Liversidge et al., 
2003; Beig et al., 2012; Buckley et al., 2012). Moreover, new drug development has been 
stifled due to unsatisfactory biopharmaceutical properties, not least of all being problems 
related to aqueous solubility (Savić et al., 2003; Pathak et al., 2006). Poor aqueous 
solubility is one of the fundamental problems of antineoplastic drugs and has thus been 
the stimulus for the development of carrier systems for these drug molecules, among 
other modifications.  
 
The aforementioned augmented surface area:volume ratio exhibited by nanosystems has 
drastic effects on aqueous solubility (Pathak et al., 2006, Lu and Park., 2012). This 
approach has been widely exploited, particularly in the realm of drug administration in 
cancer therapeutics. In addition to improving aqueous solubility of antineoplastic drug 
molecules, the nano-size range allows for more rapid dissolution of the drug within the 
body allowing for easier absorption and greater propensity to exert its effect (Pathak et al., 
2006; Lu and Park, 2012). These favorable effects of nano-sizing can be succinctly 
explained by the Noyes-Whitney and Ostwald-Freundlich principles, which associates the 
nano-scale size range to an amplified particle dissolution velocity as well as saturation 
solubility, ultimately favoring increased drug bioavailability (Ganta et al., 2009; Lu and 
Park 2012).    
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2.3.2 Targeted therapy: The future of medicine  
The idea of targeted therapy was first postulated by Paul Ehrlich (1906), with the objective 
being the attainment of therapeutically effective doses while preserving the state of 
healthy tissue (Rapoport, 2007; Hernot and Klibanov, 2008; Husseini and Pitt, 2008). As 
previously highlighted, the path to effective drug delivery to tumour tissue and successful 
treatment outcomes is marred by a multitude of factors, not least of all being compromised 
bioaccessibility and thereby poor bioavailability of antineoplastic drugs at tumour sites 
(Shapira et al., 2011).  
 
2.3.2.1 Passive targeting of cancer nanotherapeutics 
Nano-drug delivery systems (nano-DDS) have the capacity for passive targeting to tumour 
sites by nature of their size and the exceptional qualities this size range confers on the 
system itself (Lei et al., 2011). Characteristic of tumour tissue is a phenomenon termed 
the EPR effect. Of particular significance are the structural differences in the 
microvasculature of tumour tissue relative to that of vessels found in normal tissue. 
Tumours grow at an accelerated pace, rendering their demand for nutrients supplied via 
the vascular system greater than that of normal, healthy cells. In an effort to satisfy this 
amplified demand, rapid and hyper-vascularization occurs within tumour tissue (Cho et al., 
2007; Geusens et al., 2009; Pan and Feng, 2009). However, this microvasculature lacks 
the structural organization of normal blood vessels, exhibiting irregular diameters and 
branching patterns that compromise the integrity of the vessels (Brannon-Peppas and 
Blanchette, 2004; Cho et al., 2007). The endothelial cells found in the blood vessels of 
normal tissue may have spaces between them that are approximately 7-10 nm in size, 
and are thus referred to as tight junctions. In tumour microvasculature however, these 
spaces can range up to a few hundred nanometers, allowing the preferential extravasation 
of nanosystems into tumour tissue (Cho et al., 2007; Geusens et al., 2009; Pan and Feng, 
2009; Lei et al., 2011). Moreover, recovery of macromolecules via the vascular and 
lymphatic systems is severely reduced in tumour tissue, effectively resulting in retention of 
these macromolecules within tumour tissue (Cho et al., 2007; Geusens et al., 2009; Pan 
and Feng, 2009). Passive targeting is thus a very efficient means of targeting with regards 
to tumour site-specific drug delivery and nano-DDS are able to capitalize on this 
phenomenon.  
 
2.3.2.2 Enhancing therapeutic efficacy through active targeting 
Nanosystems are particularly amenable to the attachment of targeting moieties as a result 
of their augmented surface area:volume ratio. The targeting nature of nanosystems can 
be tailored for specific targets and functions by the inclusion of targeting moieties such as 
peptides, antibodies and carbohydrates (Cirstoiu-Hapca et al., 2010; Guo et al., 2011; Kim 
25 
 
et al., 2011; Lei et al., 2011;Shapira et al., 2011). These functionalized nanosystems are 
thereby able to capitalize on the presence of receptors that are over-expressed, or 
expressed specifically, on the surface of the specific cancer subtype that is being 
targeted, by the formation of a ligand-receptor complex (Brannon-Peppas and Blanchette, 
2004; Cho et al., 2007; Cirstoiu-Hapca et al., 2010; Kim et al., 2011; Viziranakis, 2011). 
Ideally, the target for antineoplastic drugs should be essential to the survival of tumour 
cells as well as specific to tumour cells (Blagosklonny, 2003; Cho et al., 2007). However, 
targets that fulfill these characteristics are scarce and immensely difficult to isolate. The 
formulation constituents of the nanosystem, such as polymers, can also add to the 
targeting nature, by responding to micro-environmental conditions or other physiological 
stimuli in tumour tissue. These are termed “smart” or stimuli-responsive polymers and are 
able to modulate drug delivery in response to physiological changes that characterize the 
pathological tissue, such as the lower pH (~pH 6.5) of tumour tissue (Lehner et al., 2012; 
Meng et al., 2012). Substantial research has been concentrated on isolating receptor 
targets specific to tumours, in general and for specific tumour subtypes, which can be 
utilized for drug delivery and imaging agents.  
 
2.3.2.2.1 Folate receptor- α 
Folate is a low molecular weight vitamin essential to cellular function through its role in 
mitochondrial protein synthesis, amino acid metabolism and the synthesis of nucleic acid 
precursors (Leamon and Low, 2001). Animals are unable to synthesize this micronutrient, 
hence, the absorption of folate from exogenous sources is essential to satisfactory cellular 
function. Folate receptors, ubiquitously present throughout the body, facilitate cellular 
uptake of folate by endocytosis.  
 
Folate receptor-α has been one of the most prevalent receptors investigated for targeting, 
despite its ubiquitous presence in the body, as a result of the significant over-production 
and presence of this receptor on the surface of a wide spectrum of tumours (Geszke et 
al., 2001; Vauthier et al., 2003; Pan and Feng, 2009; Rastogi et al., 2011). Folic acid, the 
ligand responsible for binding to this receptor, is a popular ligand as it is smaller, non-
immunogenic and hardly problematic to procure (Setua et al., 2010). Table 2.1 briefly 
outlines different nanosystem configurations that have been functionalized for targeting to 
the folate receptor.  
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Table 2.1 Tabulated nanosystems functionalized for folate receptor targeting in cancer 
therapeutics. 
Type of Nanosystem Brief Description Reference 
Magnetic nanoparticles Superparamagnetic nanoparticles coated with 
temperature sensitive polymer and folic acid, for 
tumour imaging and treatment. 
Rastogi et al., 2011 
Quantum dots Stabilized core/shell ZnS:mNZnS QD, 
functionalized with folic acid for tumour imaging.  
Geszke et al., 2011 
Nanocrystals Rare-earth oxide nanocrystals functionalized with 
folic acid, for bi-modal tumour imaging.  
Setua et al., 2010 
Thermosensitive 
magnetic liposomes 
Folate targeted liposomes that respond to 
induced localized hyperthermia, for biological and 
physical tumour targeting. 
Pradhan et al., 
2010 
Supramolecular vesicle 
aggregates 
A self-assembling polymeric system containing 
gemcitabine, conjugated to folic acid for targeted 
cancer therapy. In vivo studies highlighted 
superior activity of the targeted system relative to 
a non-targeted system. 
Paolino et al., 2012 
Targeted nannoparticle A nanoparticle consisting of a heparin-folate-
paclitaxel conjugate with paclitaxel in the core of 
the nanoparticle. This system was designed to 
minimize P-glycoprotein mediated tumour 
resistance to therapy and demonstrated 
promising results in the treatment of head and 
neck cancers in an animal model. 
Wang et al., 2009 
 
2.3.2.2.2 Heat shock protein 90 (Hsp90) 
Hsp90, an intracellular molecule involved in signal activation, is widely present throughout 
the body, yet over-expressed in several cancers, such as ovarian cancer, head and neck 
cancers, esophageal cancers and leukemia (Önyüksel et al., 2009; Landriscina et al., 
2010). This pro-carcinogenic molecule is thus an attractive target as a treatment modality 
for cancer. 17-allylamino-17-demethoxy geldanamycin (17-AAG) has been identified as an 
inhibitor of Hsp90, due to binding to the ATP-binding site on the N-terminus of Hsp90, 
thereby blocking the activity of this compound and, in turn, preventing tumour cell 
proliferation (Önyüksel et al., 2009). Yet again, poor aqueous solubility and hepatotoxicity 
renders this compound clinically non-viable. The favorable characteristics that define 
nanosystems, though, augur well for the future use of this compound in cancer therapy.  
 
It was this aim that drove the study by Önyüksel and fellow researchers (2009), which 
formulated 17-AAG in long-circulating, sterically stabilized phospholipid nanomicelles 
(SSM) (Önyüksel et al., 2009). These SSM were further functionalized with vasoactive 
intestinal peptide (VIP), the receptor for which is over-expressed on the tumour membrane 
of many cancers (Önyüksel et al., 2009). Firstly, the successful solubilization of 
therapeutically significant concentrations of 17-AAG was achieved with the SSM. 
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Secondly the functionalized SSM’s displayed superior toxicity as a result of increased 
cellular uptake (Önyüksel et al., 2009). Unexpectedly, targeted nanosystems displayed 
sub-optimal cytotoxic properties in the testing period, compared to free 17-AAG. However, 
this may be due to delayed release of SSM-associated 17-AAG. It must be borne in mind 
though that ex vivo cytotoxicity was not the challenge with 17-AAG, rather stability and 
toxicity challenges needed to be overcome. The nanosystem addressed these 
shortcomings, while the functionalized system retained the cytotoxic capacity. The size 
range achieved (~16 nm) allowed this DDS to escape clearance by the RES, while the 
properties of PEG contributed to the long circulation lifespan, which cumulatively allowed 
greater chance for interaction with, and internalization into, target cells (Önyüksel et al., 
2009). In addition to the above-mentioned ATP-binding site, a second ATP-binding site is 
present on the C-terminus. This site has displayed affinity for other antineoplastic agents 
such as cisplatin, novobiocin and epigallocatechin-3-gallate (Landriscina et al., 2010).  
 
2.3.2.2.3 Human epidermal growth factor receptor (HER)-2  
HER-2 has emerged as a prominent receptor target over-expressed in breast and ovarian 
cancer. Breast cancer is one of the most prevalent tumour types among women, with 20-
30% presenting with HER-2 positive tumours which demonstrate chemoresistance to 
some antineoplastic agents, and an overall poor prognosis (Mi et al., 2012). 
Trastuzumab® is a humanized monoclonal antibody developed by Genentech in the late 
1980’s to target HER-2 and has been successfully used clinically in the treatment of HER-
2 positive breast cancer (Bazell, 1998; Mi et al., 2012).  
 
Lei and co-workers (2011) highlighted the increased uptake of functionalized 
nanoparticles containing doxorubicin by ovarian cancer cell lines (Lei et al., 2011). These 
nanoparticles were conjugated with an anti-HER-2 ligand to form a complex with the HER-
2 receptor that displays preferential expression on the surface of ovarian cancer cells. The 
functionalized nanoparticles exhibited increased uptake by the cancer cells, due to a 
receptor-mediated endocytosis, compared to their non-functionalized counterparts (Lei et 
al., 2011). 
 
Several other receptors have also been identified as potential targets in cancer 
chemotherapy. Epithelial cell adhesion molecule (EpCAM) is a transmembranous 
glycoprotein that is over-expressed on the surface of solid tumours, but not on normal 
tissue (Das and Sahoo, 2011). Upon binding, the receptor-ligand complex is rapidly 
internalized, which is particularly advantageous for the delivery of drugs with intracellular 
targets (Das and Sahoo, 2011). Vasoactive intestinal peptide (VIP) is over-expressed on 
the tumour membrane of many cancers and is therefore a possible target (Önyüksel et al., 
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2009). Other potential targets that have been identified include TAG 72 glycoprotein, 
luteinizing hormone-releasing hormone receptor, follicle stimulating hormone receptor, 
transferrin receptor and heparin-binding glycoprotein’s such as VEGF (Schroeder et al., 
2007; Cirstoiu-Hapca et al., 2010; Kim et al., 2011; Paszko et al., 2011). 
 
2.3.2.2.4 Aptamer-based targeted nanosystems 
Aptamers are a class of oligonucleotides comprising synthetic single-stranded DNA or 
RNA molecules that can be incorporated into DDS for highly specific targeting to various 
molecular targets present on tumour cells (Li et al., 2013). Aptamers may be conjugated 
to drug molecules or DDS by intercalation of covalent bonding. Various nano-constructs 
have been assessed for aptamer functionalization, such as nanorods, nanoparticles and 
carbon nanotubes, to improve targeting and uptake of the DDS by tumour cells.  
 
AS1411 was the first DNA aptamer to enter clinical oncology trials (Soundararajan et al., 
2009). This aptamer has demonstrated extraordinary specificity as well as binding affinity 
for its plasma membrane target receptor, nucleolin, which is over-expressed in tumour 
cells. Yang and co-workers (2012) formulated a gold nanorod DDS with a mesoporous, 
AS1411 surface-functionalized silica framework (Yang et al., 2012). This photothermal 
DDS is activated by illumination in the near infra-red region resulting in structural changes 
and consequent drug release. In vitro results highlighted versatility of the DDS, as well as 
biocompatibility, high tumour specificity and appropriate drug release for intracellular 
targets (Yang et al., 2012).     
 
Functionalization of a liposomal DDS with the sgc8 aptamer which is specifically targeted 
to protein tyrosine kinase present on CEM-CCRF leukemia cells was undertaken by Kang 
and team (Kang et al., 2010). The high aptamer load resulted in increased binding affinity 
to target tumour cells with no compromise on formulation stability. In vitro studies 
confirmed the selectivity of the functionalized liposomal DDS for the target cell as well as 
intracellular delivery of the drug to tumour cells (Kang et al., 2010). However, this system 
did not include in vivo studies, which is essential to the critical assessment of targeting 
efficacy of DDS.   
  
2.3.3 Tumour drug resistance: A progressive challenge 
Multidrug resistance (MDR) has emerged as an acute problem contributing to the already 
diverse and significant challenges compromising the success of cancer chemotherapy (Lo 
Y-L, 2000; Vauthier et al., 2003). MDR can manifest as a failure of initial treatment 
protocols to adequately reduce tumour size or, as is the case most often with ovarian 
cancer, as a relapse/recurrence after successful therapy (Vauthier et al., 2003; Kim et al., 
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2011). The high rate of recurrence in ovarian cancer is the primary contributing factor to 
the poor prognosis associated with ovarian cancer and the low 5-year survival rate. MDR 
currently accounts for treatment failure in over 90% of patients presenting with metastasis 
which, in the case of ovarian cancer, is the majority of patients (Gao et al., 2012). 
 
Drug resistance displayed by tumours can be classified as follows (Shapira et al., 2011; 
Gao et al., 2012): 
• Decreased drug influx into tumour cells. 
• Increased drug efflux out of tumour cells. 
• Activation of DNA repair.  
• Metabolic degradation of antineoplastic drugs.  
• Simultaneous inactivation of apoptotic pathways and activation of protective 
mechanisms of cellular anti-apoptotic pathways. 
 
The application of nanotechnology has shown immense potential in overcoming or 
circumventing the extra- and intra-cellular mechanisms associated with drug resistance. 
The most significant application has been to overcome the resistance to doxorubicin, 
which has displayed substantial success and will be discussed later. Among the extra-
cellular resistance mechanisms that nanosystems will find applicability in, is the 
inactivation of drug molecules prior to their reaching the site of action. Several 
nanosystems offer protection from unsuitable environments and metabolic and enzymatic 
degradation, as well as protection against early clearance from the body. Coating with 
compounds such as poly(ethylene glycol) (PEG) allows nanosystems to navigate the body 
undetected by clearance systems, thereby increasing the circulation half-life (Vauthier et 
al., 2003).  
 
The internalization of free drug into tumour cells is primarily through passive diffusion, 
whilst the mechanism of nanosystem entry into tumour cells involves non-specific 
endocytosis (Gao et al., 2012). A primary mechanism of resistance in cancer cells is 
increased drug efflux out of cells by efflux pumps. The passive diffusion of free drug 
allows for recognition by and activation of efflux pumps, reducing cellular drug 
concentration and compromising antineoplastic therapy (Gao et al., 2012). However, the 
mechanism of nanosystem internalization facilitates undetected entry into cells, bypassing 
the increased drug efflux mechanism of drug resistance in tumour cells, as illustrated in 
Figure 2.3 (Gao et al., 2012).    
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Figure 2.3 A: is a diagrammatic comparison of the internalization mechanisms of free drug and 
nano-DDS's in normal tumour cells and MDR tumour cells (Adapted with permission from Gao et 
al., 2012). B: confocal micrographs highlighting the cellular internalization mechanisms of free drug, 
a nano-DDS and a functionalized nano-DDS. In this image the drug is indicated in red while the cell 
nuclei are highlighted in blue. The distinct difference is drug concentration within the cell after 
incubation for 2 hours denotes a difference in mechanism of cellular uptake. The significant 
reduction of free drug after 6 hours and complete absence of free drug after 24 hours indicates 
efflux of the drug out of the cell. However, drug administered in nanosystems persist within the cell 
for over 24 hours, indicating a by-pass of the cellular efflux mechanism. Moreover, functionalized 
nanosystems display superior cellular drug concentration (Source 2.3B: Wate et al., 2012).     
 
Small interfering ribonucleic acids (siRNA) provide an interesting alternative therapeutic 
strategy for MDR tumours, however successful in vivo delivery presents a challenge to 
clinical application, due to the size, molecular weight and poor stability profile of these 
compounds (Ganesh et al., 2013). Ganesh and co-workers (2013) synthesized hyaluronic 
acid based, self assembling, CD44 targeting nanostructures with outstanding siRNA 
encapsulation as well as appreciable stability (Ganesh et al., 2013). CD44 is a 
glycoprotein that is over-expressed on the surface of various tumours and stem cell 
tumour precursors, is a recognized biomarker in non-small cell lung cancer (NSCLC) and 
hence, provides an attractive target in cancer therapy (Ganesh et al., 2013). This 
extensive study demonstrated high cellular uptake of the nanosystem by receptor 
mediated endocytosis in a tumour cell line over-expressing CD44, contrasted by severely 
reduced uptake in a control tumour cell line expressing low levels of this glycoprotein 
(Ganesh et al., 2013).  
   
2.4 Antineoplastic drug challenges: Innovative nanotechnological 
solutions 
2.4.1  Doxorubicin 
Doxorubicin (DOX), an anthracycline antibiotic is one of the most efficacious drugs in the 
treatment of several solid tumours, including breast and ovarian cancers (Brannon-
Peppas and Blanchette, 2004; Dreis et al., 2007; Cai et al., 2010; Lei et al., 2011). 
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However, clinical application of DOX has been severely hindered as a result of the critical 
toxicity profile, the foremost of which being cardiotoxicity (Brannon-Peppas and 
Blanchette, 2004; Dreis et al., 2007). Formulation as nanoparticles has been investigated 
as a possible means of reducing detrimental side-effects, as well as increasing the 
efficacy of DOX, in order to preserve the use of this potent, widely applicable 
antineoplastic agent (Dreis et al., 2007). Several materials have been examined for their 
potential in this application, with DOX being incorporated into, or bound to the 
nanoparticles. Among these materials are poly(butyl cyanoacrylate), poly(lactic-co-glycolic 
acid) (PLGA), poly(isohexal cyanoacrylate) and gelatin (Wartlick et al., 2004; Dreis et al., 
2007). Formulation of DOX as nanoparticles has been immensely successful, with 
formulations displaying passive targeting on account of the nano-scale sizing, ability to 
cross the blood-brain-barrier for the treatment of brain tumours, as well as success 
against several lines of drug-resistant cancer cells (Dreis et al., 2007). Human serum 
albumin (HSA) has also been explored as a nanoparticulate carrier for DOX, with 
appreciable success (Dreis et al., 2007). Currently there are two commercially available, 
registered HSA-based formulations, namely Albunex and Abraxane, which drove research 
into the viability of this material as a nanocarrier (Dreis et al., 2007).   
 
The development of multi-drug resistance in cancer cells has further compromised the 
feasibility of DOX utilization (Vauthier et al., 2003; Lei et al., 2011). MDR is most often due 
to the over-expression of the transmembranous protein, P-glycoprotein (P-gp), which 
compromises the therapeutic efficacy of DOX (Das and Sahoo, 2011; Lei et al., 2011). 
Increasing the dose of DOX to overcome this drawback is not viable due to the above-
mentioned dose-related side-effects (Lei et al., 2011). Lei and team (2011) developed 
DOX-encapsulated  nanoparticles and observed a significant increase in cellular uptake of 
the nanoparticulate DDS compared to free DOX which was attributed to a difference in the 
mechanism of cellular uptake. The free form of DOX passes into the cell via diffusion, 
while the nano-enabled DDS was taken up via endocytosis, which proved more favorable 
in cells displaying an over-expression of P-gp (Lei et al., 2011). 
 
The capacity of targeted nano-enabled DDS’s to accumulate in target tissue has further 
proved beneficial with regards to the administration of DOX in P-gp-negative cells. Drug 
resistance can also be a consequence of alteration of the intracellular pH-gradient, which 
results in drugs being trapped in cellular components from where they cannot exert their 
action (Lei et al., 2011). Cytotoxic studies undertaken by Lei and team (2011) highlighted 
the increased cytotoxic effect of functionalized and non-functionalized DOX-containing 
PLGA nanoparticles compared to free DOX at higher concentrations (Lei et al., 2011). The 
research team rationalized that the DOX-containing nanoparticles were entrapped in 
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lysosomes or endosomes within the cell and the release of DOX into the cytosol was 
limited by an unfavorable pH-gradient. The DOX was therefore unable to reach the site of 
action, the cell nucleus. This resulted in limited cytotoxicity at low concentrations. 
However, at elevated concentrations, the concentration of the DOX from the nanoparticles 
surpasses the cells lysosomal and endosomal capacity, resulting in increased DOX in the 
cytosol of the cell, with uninhibited movement to the cell nucleus, where it can exert its 
effect (Lei et al., 2011).  
 
Poly(alkyl cyanoacrylate) (PACA) nanoparticles have also shown tremendous potential in 
overcoming MDR to DOX. However, the mechanism to overcome drug resistance appears 
to differ from that of PLGA nanoparticles, in that PACA nanoparticles are not endocytosed 
into cells, but rather adhere to the surface of tumour cells (Vauthier et al., 2003). The drug 
is subsequently released and combines with the degradation products of the 
nanoparticles, forming an ion-pair that diffuses into the tumour cell undetected by P-gp 
(Vauthier et al., 2003).  
 
Yet another attempt at overcoming tumour cell resistance to DOX was the co-
encapsulation of DOX and, the chemo-sensitizing agent, Cyclosporin A within a single 
nanoparticle (Vauthier et al., 2003). DOX formed the core of the nanoparticle, covered by 
the Cyclosporin A. This configuration allowed for the rapid release of Cyclosporin A and 
resulting sensitization, followed by the release of DOX. Formulation as a nanoparticle 
ensured both agents reached the desired site of action via passive targeting, thereby 
potentiating the activity of the individual agents and their synergistic activity, while 
reducing harmful effects on healthy tissue (Vauthier et al., 2003).  
 
2.4.2 Camptothecin  
Camptothecin (CPT) is a potent antineoplastic drug which has demonstrated 
antineoplastic activity against a vast array of solid tumours including ovarian, gastric, 
breast, cervical, melanoma, skin and lung cancers (Koo et al., 2005; Mu et al., 2005; Fang 
et al., 2009). CPT inhibits and stabilizes the topoisomerase I enzyme which is required for 
cell replication and transcription and is over-expressed in certain cancer cells but not in 
normal tissue, thereby inducing apoptosis of the cancer cells (Shenderova et al., 1997; 
Ertl et al., 1999; Koo et al., 2005; Zhang et al., 2007). However, use of this drug in clinical 
practice has been diminished due to its poor aqueous solubility and insolubility in most 
biocompatible organic solvents, instability under physiological conditions and severe 
toxicity profile (Hafeti and Amsden, 2002; Koo et al., 2005; Zhang et al., 2007; Fang et al., 
2009). The chemical composition of CPT contains an active lactone group, which is 
responsible for its insolubility and physiologically-labile properties, yet crucial to its 
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antineoplastic activity (Shenderova et al., 1997; Ertl et al., 1999; Koo et al., 2005; 
Ziomkowska et al., 2010). It is therefore essential to protect this lactone group in the 
formulation and delivery of CPT preparations. Although derivatives of camptothecin are 
utilized, they lack the potency of CPT (Zhang et al., 2007; Fang et al., 2009). Furthermore, 
camptothecin and its derivatives usually require continuous infusion over a period of time, 
or multiple injections over a short period, which is a great disadvantage with regards to 
patient comfort and acceptability (Cortesi et al., 1997). In addition, prolonged 
administration results in intolerable side-effects, including neutropenia, anemia and other 
related hematologic manifestations, altered gastric function and dermatological 
manifestations (Cortesi et al., 1997).  
 
Several methods have been investigated to improve the solubility profile of CPT (Zhang et 
al., 2007). Whilst formulation of CPT as liposomes, microemulsions and polymeric 
microspheres have enjoyed a degree of success, incorporation into a nano-DDS may hold 
greater potential for the clinical use of this drug (Cortesi et al., 1997; Shenderova et al., 
1997; Zhang et al., 2007). An emphasis has also been placed on the development of 
controlled release DDS’s, as it is hypothesized that the properties of these systems will be 
able to adequately address the factors limiting CPT utilization clinically (Cortesi et al., 
1997). 
  
Micelles are composed of amphiphiles that take on a spherical form spontaneously in 
aqueous conditions, above the critical micellar concentration (Koo et al., 2005). These 
moieties consist of a hydrophobic core and hydrophilic corona, thereby enabling the 
solubilization of poorly aqueous soluble drugs and their delivery in an aqueous medium, 
the likes of which will be required for intravenous delivery (Savić et al., 2003; Mu et al., 
2005). In addition, the nano-dimensions of micelles allow for their easy passage through 
the more permeable vasculature that predominates in cancer tissue, making them 
valuable in cancer therapy (Mu et al., 2005).The ease of manufacture, reproducibility and 
stability of micelles make them attractive systems for drug delivery. 
 
Aiming to investigate methods of safely and effectively delivering CPT to the intended site 
of action, i.e. tumour tissue, Koo and colleagues (2005) developed SSM of 
distearoylphosphatidylethanolamine (DSPE) conjugated to polyethylene glycol 2000 
(PEG-2000) (Koo et al., 2005). This study demonstrated, firstly, an approximately 25-fold 
increase in solubility of CPT in the optimized formulation, compared to free CPT, as well 
as increased aqueous stability with preservation of the active lactone moiety as a result of 
drug encapsulation within the hydrophobic core of the SSM, rather than being exposed to 
the aqueous environment where hydrolytic degradation can occur (Koo et al., 2005). 
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Since CPT acts on cells in the S-phase of the cell-cycle, formulations with a longer half-life 
will have a greater cytotoxic effect. The SSM formulation, due to its increased stability and 
circulation half-life, displayed three-fold greater cytotoxicity than free CPT after 24 hours 
when tested against breast cancer cells, due to a larger proportion of tumour cells being 
exposed to CPT. The augmented cytotoxicity may also be attributable to increased 
cellular uptake and accumulation of the nanosystem within tumour tissue (Koo et al., 
2005). The aforementioned findings were supported by results obtained by Mu and team 
(2005), which produced mixed micelles as CPT delivery systems (Mu et al., 2005).  In 
addition to demonstrating ease of preparation and favorable pharmacokinetic properties, 
Koo and colleagues highlighted the potential of this DDS for practical application in a 
clinical setting. The SSM developed displayed negligible alterations in size, solubility and 
the wavelength of peak fluorescence emission after lyophilization and reconstitution (Koo 
et al., 2005). This has significant implications for storage and use in a clinical setting. The 
incorporation of PEG was attributed to the stability to freeze-drying, since PEG has 
cryoprotectant and lyoprotectant properties (Koo et al., 2005). The CPT-loaded SSM 
prepared in this study displayed immense potential for application in clinical practice due 
to superior efficacy and practicality of use. 
 
To address the above-mentioned shortfalls of CPT, Fang and co-workers (2009) 
formulated a camptothecin-containing nanoemulsion DDS (Fang et al., 2009). Although 
the primary focus of this study was investigation of physicochemical properties of the 
nanoemulsions prepared, their in vitro and ex vivo studies delineated promising results. 
Varying cytotoxic profiles were obtained for the nanoemulsions prepared, as a function of 
changes in formulatory composition. In addition, the study did not take into account the 
effect of metabolism, enzymatic degradation and other processes, which the system will 
undergo in the body and which will greatly affect the nature of the DDS that ultimately 
reaches the target site. However, the superior drug-loading capacity (90%) and low 
hemolytic destruction highlights the potential of a nano-enabled DDS to effectively deliver 
CPT.  
 
CPT-containing nanoparticles have been vigorously investigated in the quest to develop 
an efficacious DDS (Miura et al., 2004; Kunii et al., 2007; Zhang et al., 2007; Martins et 
al., 2012). This nanosystem flaunts prolonged vascular circulation, particularly when 
coated with PEG, allowing for greater interaction between tumour tissue and 
antineoplastic drug, as well as superior cellular uptake of CPT resulting in tumour cells 
being bombarded, thereby having enhanced cytotoxic effect (Zhang et al., 2007). 
However, CPT loading capacity of nanoparticles remains the limiting factor in successful 
formulation (Zhang et al., 2007).  
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2.4.3 Paclitaxel 
Paclitaxel (PTX) is a microtubule-stabilizing agent, which acts to disrupt cell division, 
causing cell death (Brannon-Peppas and Blanchette, 2004; Vergara et al., 2012). It is 
currently considered first line treatment for ovarian cancer. PTX is a strongly hydrophobic 
compound, which poses significant formulation problems for intravenous administration 
(Fonseca et al., 2002; Cirstoiu-Hapca et al., 2010). Solubilization in Cremophor EL has 
been successful, with the only currently available PTX formulation being the intravenously 
administered Taxol® (Fonseca et al., 2002). However, this compound causes significant 
side-effects, making the development of delivery systems not requiring solubilisation in 
Cremophor EL appealing (Vergara et al., 2012). Nanoparticles have been the most widely 
explored nanosystem for the delivery of paclitaxel, with a variety of materials and 
functionalization techniques having been explored (Fonseca et al., 2002; Xu et al., 2005; 
Akhlaghi et al., 2010; Cirstoiu-Hapca et al., 2010; Lee et al., 2012). PTX nanoparticles 
have been widely successful in addressing the problems associated with PTX 
administration and efficacy, that is (Cirstoiu-Hapca et al., 2010): 
 
• The nanoparticles have successfully solubilized PTX and displayed adequate drug 
loading capacity. 
• Drug delivery is more targeted, even in non-functionalized NP’s due to passive 
diffusion. 
• Increased therapeutic efficacy in vivo, as a result of targeted delivery, increased 
cellular uptake, protection of PTX from enzymatic degradation and inactivation and 
an increase in circulation half-life.  
 
The immense allure of PTX incorporation into nanoparticles is attributed to the favorable 
outcomes, particularly with regards to the biodistribution and pharmacokinetic profile of 
PTX associated with nanosystems, relative to that of free PTX and Taxol® (Fonseca et 
al., 2002). PLGA nanoparticles have been successfully prepared in an appropriate size 
range (117-160 nm) for extravasation into tumour tissue, with extremely high loading 
efficiencies (Fonseca et al., 2002; Brannon-Peppas and Blanchette, 2004). Furthermore, 
when tested against human small cell lung cancer cell lines, this nanosystem displayed an 
approximately 70% loss of cell viability (Fonseca et al., 2002). The ability of nanoparticles 
to overcome resistance mediated by P-gp is particularly beneficial to its application in PTX 
delivery, since there is already evidence of acquired resistance to this drug (Fonseca et 
al., 2002). 
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2.4.4 Nutlin-3a 
Nutlin-3a, a promising antineoplastic drug currently under investigation, acts to inhibit the 
inactivation of the p53 tumour suppressing protein (Sonnemann et al., 2011; Das and 
Sahoo, 2011). A significant fraction of tumours display altered or inactivated p53 genes, 
which results in loss of the tumour suppressing function (Das and Sahoo, 2011). 
Inactivation of the p53 protein is also via attachment by human double minute 2 (HDM2) 
oncoprotein, which causes inactivation of p53 (Das and Sahoo, 2011). Nutlin-3a shares a 
binding site with p53 on the HDM2 oncoprotein, thereby preventing the attachment and 
inactivation of p53 (Das and Sahoo, 2011). The potential of this drug in restoring the 
tumour suppressing capacity of p53, and hence in treating cancer, is vast.  
 
However, there are also many shortfalls limiting the use of this drug, such as poor 
solubility, non-specific targeting, systemic toxicity, low bioavailability in tumour tissue, 
efflux by transmembranous proteins and degradation by cellular lysosomes, resulting in 
decreased cellular concentration (Das and Sahoo, 2011). Nanosystems have the 
propensity to overcome the above-mentioned shortfalls, allowing for the optimal use of 
this potentially valuable drug. Das and Sahoo (2011) formulated non-functionalized nutlin-
3a-containing PLGA nanoparticles (nutlin-PLGANP) and EpCAM-functionalized nutlin-
PLGANP for the treatment of colon and lung cancer (Das and Sahoo, 2011). The 
effectiveness of nanosystems is a function of the drug loading efficiency, target cell uptake 
and release of drug in the target cell. The functionalized and non-functionalized 
nanoparticles prepared by Das and Sahoo (2011) exhibited a high loading efficiency of 
nutlin-3a (~78% and 81%, respectively) as well as significantly increased cellular uptake, 
compared to free Nutlin-3a. This team reported a 5-fold and 16-fold increase in cellular 
uptake of nanoparticulate nutlin-3a and the functionalized counterparts, respectively, 
compared to the free form (Das and Sahoo, 2011). Finally, Das and Sahoo (2011) 
demonstrated augmented cytotoxicity by the unconjugated nanoparticles and a further 
increase by the conjugated nanoparticles, compared to native nutlin-3a (Das and Sahoo, 
2011). Although non-drug-loaded nanoparticles were not used as a control in this study to 
ascertain the effect of the system itself on cytotoxicity, other studies have demonstrated 
non-cytotoxic activity by PLGA nanoparticles.  This work requires further in vivo analysis, 
however the presented in vitro results are indeed promising.  
 
2.4.5 Indisulam 
Indisulam is a sulphonamide drug that interrupts the cell cycle at the G1/S phase (Cesur 
et al., 2009). The cytotoxic effects have been established, particularly against breast 
cancer. However, upon reaching clinical trials, dose-related toxicities unfavorably tipped 
the risk:benefit scale, rendering the drug unsuitable for clinical use (Cesur et al., 2009). 
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Aqueous indisulam formulations extravasate freely from the vascular system, resulting in 
toxicity to healthy tissue. Furthermore, they bind to erythrocytes and plasma proteins, 
causing haemotoxicity (Cesur et al., 2009). Thus, indisulam requires a delivery vehicle to 
prevent interaction with plasma proteins and erythrocytes, as well as, ideally, to promote 
preferential accumulation in tumour tissue.  
 
To this end, Cesur and team (2009) formulated a nanomicellar DDS incorporating 
indisulam for targeted delivery to breast cancer tissue. This simple, cost-effective method 
of preparation resulted in uniform, reproducible and stable nanomicelles of ~15 nm in size 
(Cesur et al., 2009). This size range will allow for preferential accumulation of the DDS in 
tumour tissue as a result of extravasation from leaky vasculature. Solubility of indisulam in 
aqueous medium was substantially increased (~8-fold), allowing for the intravenous 
delivery of a greater concentration of drug. Cytotoxicity against the chosen breast cancer 
cell line was augmented in the nanomicellar DDS compared to indisulam in dimethyl 
sulphoxide (DMSO). In addition, the prepared formulation could be lyophilized to facilitate 
long-term storage, without significant alteration of the properties (Cesur et al., 2009). 
Inspite of these promising results, this DDS will have to be subjected to in vivo evaluation 
and clinical trials before the full potential and safety can be ascertained.  
 
2.4.6 Curcumin 
An emerging alternative in antineoplastic therapy is the utilization of phytochemicals, 
either as a therapeutic modality on its own, or in conjunction with commercially available 
antineoplastic drugs as a means of sensitizing tumour cells to conventional treatment 
(Mohanty and Sahoo, 2010). Curcumin, a hydrophobic polyphenol derived from the 
Curcuma longa herb, is one such entity that has displayed antineoplastic activity, among 
its wide range of therapeutic applications, as a result of interaction with the cell cycle 
process, angiogenesis, apoptosis and metastasis (Das et al., 2010; Mohanty and Sahoo, 
2010; Anitha et al., 2011). Furthermore, the clinically established safety profile of this 
phytochemical favor its use in cancer chemotherapy, with large doses proving tolerable 
(Mohanty and Sahoo, 2010). However, several pharmacokinetic challenges plague the 
successful clinical use of curcumin. Poor aqueous solubility poses formulatory and 
administration challenges, while degradation, poor tissue penetration and absorption, as 
well as rapid systemic elimination culminate in severely reduced bioavailability (Das et al., 
2010; Mohanty and Sahoo, 2010; Anitha et al., 2011).  
 
Since the obvious potential of this compound cannot be disregarded, particularly in the 
face of growing exigency for successful antineoplastic treatment, efforts to overcome the 
above-mentioned challenges to curcumin use have produced nanosystems incorporating 
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curcumin (Tiyaboonchai et al., 2007; Das et al., 2010; Mohanty and Sahoo, 2010; Anitha 
et al., 2011). PLGA nanoparticulate DDS’s have shown variable yet significant increases 
in curcumin bioavailability, whilst other approaches have included incorporation in a 
phospholipid complex as well as bioadhesive DDS (Mohanty and Sahoo, 2010). A 
particularly outstanding study conducted by Mohanty and Sahoo (2010) formulated highly 
stable glycerol monooleate (GMO) based curcumin nanoparticles that displayed a highly 
favorable pharmacokinetic profile (Mohanty and Sahoo, 2010). These nanoparticles 
displayed approximately 90% curcumin entrapment, as well as biphasic release (~46% in 
24 hours and ~66% over 10 days) the characteristic of which would be favorable in cancer 
therapy. The nanoparticulate system exhibited greater aqueous solubility and stability than 
native curcumin, indicating the protection from hydrolytic degradation conferred on 
curcumin by the nanosystem (Mohanty and Sahoo, 2010). Nanoparticulate curcumin 
showed augmented cellular uptake compared to free curcumin (5.9-7.7 times greater), 
substantially greater antiproliferative effect on tested cancer cell lines as well as 3.8 times 
greater induction of apoptosis (Mohanty and Sahoo, 2010). Toxicity studies of non-drug-
loaded nanoparticles proved the safety of this carrier system and the materials employed. 
The study was further extended to in vivo analysis, where higher levels of systemic 
curcumin were detected for longer periods of time after the administration of 
nanoparticulate curcumin (Mohanty and Sahoo, 2010). The findings by Mohanty and 
Sahoo (2010) were far superior to those from previous studies on PLGA nanoparticulate 
curcumin. This was attributed to the controlled and prolonged manner of release from 
GMO nanoparticles.  
 
Anitha and colleagues (2011) employed a straight-forward, easily up-scalable method to 
formulate modified chitosan nanoparticles (<200 nm) incorporating curcumin to address 
the aforementioned shortfalls of curcumin bioavailability (Anitha et al., 2011).  The 
substantially favorable drug entrapment was comparable to that achieved by Mohanty and 
Sahoo (2010) (87% versus 90%), with controlled drug release achieved over several 
days. Furthermore cell viability studies indicated the retention of anti-tumour activity by 
curcumin despite loading into nanoparticles, whilst fluorescence spectroscopy confirmed 
the release of curcumin within cancer cells with resultant apoptosis. The results of the 
studies presented above have been corroborated by several other studies reporting on 
various nano-DDS’s which successfully addressed the challenges limiting the use of 
curcumin and highlighted the feasibility of nano-enabled curcumin as an antineoplastic 
agent (Tiyaboonchai et al., 2007; Anand et al., 2010; Das et al., 2010; Dhule et al., 2012; 
Kundu et al., 2012; Liu et al., 2012). 
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As the annals of nanomedicine research expand, it is the translation of nanosystems from 
bench-top to bed-side that substantiates the clinical relevance of this field of research. 
Although currently small in number, the nanosystems that have received approval by the 
United States Food and Drug Administration (FDA) have demonstrated considerable 
clinical success and are now firmly embedded in the treatment protocol of specific tumour 
subtypes. Moreover, the significant number of nanosystems undergoing pre-clinical 
investigations inspires an expectation of the imminent approval and clinical availability of 
more innovative nanosystems for cancer treatment. Table 2.2 provides a brief overview of 
currently available as well as pre-clinical nanosystems for cancer therapy.      
 
2.5 Nano-enabled antisense oligonucleotides in cancer therapeutics 
Antisense oligonucleotides are fragments of deoxynucleotide that are complementary in 
sequence to a defective portion of mRNA, and acts to interrupt the translation of defective 
proteins from mRNA (Bogunia-Kubik and Masanori, 2002). Hence, antisense 
oligonucleotides have potential in cancer therapeutics, by blocking the expression of 
defective genes. However, these moieties are labile and display poor cell penetration, 
necessitating a suitable carrier system for their successful clinical application (Bogunia-
Kubik and Masanori, 2002; Fattal and Bochot, 2008). Formulation as nanoparticles and 
liposomes has been investigated to address these shortcomings of antisense 
oligonucleotides. Furthermore, the capacity of nanosystems for targeting aids in the 
utilization of antisense nucleotides, as it will prevent non-specific binding  
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Table 2.2 A brief outline of commercially available and pre-clinical nanosystems with application in the oncology field. 
In Clinical Use 
Product Type of 
Nanosystem 
Manufacturer, Year of 
FDA Approval  
Indication Notes References 
Doxil® Liposome 
(~100 nm) 
Alza Corporation (1995) Refractory ovarian 
carcinoma, 
Kaposi’s sarcoma, 
First marketed product employing stealth technology. 
Significant reduction in cardiotoxicity associated with 
DOX.  
Barenholz, 2001; 
Nishiyama and 
Kataoka, 2006   
DaunoXome® Liposome  
(60-80 nm) 
NeXstar Pharmaceutical 
(1996) 
Kaposi’s sarcoma Intravenous liposomal formulation of anthracycline 
daunorubicin exhibiting reduced cardiotoxicity in vivo, 
due to a passive targeting mechanism.  
Bellot et al., 
2001 
Emend® Nanocrystal Merck and Co., Inc. 
(2003) 
Chemotherapy-
associated nausea 
Nanocrystals of the substance P antagonist, 
aprepitant, formulated as such to enhance the water 
solubility and maximize bioavailability from the 
narrow absorption window of this drug. 
Junghanns and 
Müller, 2008 
Abraxane™ Albumin 
nanoparticle 
(~130 nm) 
American 
Pharmaceutical Partners 
Inc. And American 
BioScience (2005) 
Refractory 
metastatic breast 
cancer, NSCLC 
Injectable formulation containing paclitaxel, 
employing innovative nanoparticle albumin bound 
technology to achieve tumour targeting. 
Nijhara and 
Balakrishnan, 
2006;  Hawkins 
et al., 2008; 
Kratz, 2008 
Undergoing Pre-Clinical Investigations 
Product Drug Size Company Description References 
NK911 DOX 40 nm Nippon Kayaku Polymeric micellar system consisting of a block co-
polymer of PEG and poly(aspartic acid). 
Nakanishi et 
al., 2001; 
Tsukioka et al., 
2003 
Genexol® PTX <50 nm Samyang Micellar DDS formulated with the amphiphilic polymer 
monomethoxy-PEG-b-poly(D,L-lactide). Response rate 
of metastatic breast cancer to Genexol® was superior 
to Abraxane® and Taxol® in Phase II and III clinical 
trials. Efficacy against NSCLC and pancreatic ductal 
adenocarcinoma has also established in clinical trials. 
Shea et al., 
2011; Lu and 
Park 2012 
SP1049C DOX 30 nm Suprateck A non-ionic surfactant-based micellar DDS comprising 
Pluronic® L61 and F127. This nanosystem has 
demonstrated efficacy against multi-drug resistant cells 
and is currently in Phase III clinical trials. 
Alakhov et al., 
1999; Danson 
et al., 2004 
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2.6 Nano-theranostics 
Nano-theranostics, an area of research still in its infancy, refers to the simultaneous use of 
one nanosystem for diagnostic and therapeutic purposes (Rai et al., 2010; Veiseh et al., 
2010; Vizirianakis, 2011). One of the primary benefits of these systems is the 
individualization of treatment (Rai et al., 2010; Vizirianakis, 2011). Therapeutic regimens 
can be designed and assessed according to the disease presentations of individual 
patients, thereby achieving optimized treatment outcomes with regards to safety and 
efficacy (Rai et al., 2010).  Furthermore, invasive procedures are minimized by the 
combination of diagnosis and therapy. Various nano-constructs have been created and 
investigated for potential theranostic application in solid tumours, such as liposomes, 
nanoparticles, micelles and emulsions (Shiraishi et al., 2011). Thus far, ultrasound has 
been largely investigated in combination with the nano-constructs since it allows for the 
safe and effective imaging of solid tumours as well as being capable of disrupting the 
nano-constructs resulting in targeted drug release (Shiriashi et al., 2011).     
 
2.6.1 Magnetic nanoparticles 
Magnetic nanoparticles (MNP) have received considerable attention for application in the 
field of biomedical imaging and therapy, particularly with regards to cancer (Veiseh et al., 
2010; Mahmoudi et al., 2011; Rastogi et al., 2011). At room temperature these 
nanoparticles undergo strong magnetization in the presence of a magnetic field, which is 
reversed at the removal of the magnetic field (Rastogi et al., 2011). This allows for 
external manipulation to achieve a specific result, be it imaging of a specific region or 
body system or stimuli-responsive drug release. In addition, the high surface area:volume 
ratio makes them ideal for the conjugation of targeting moieties to tailor the application 
(Mahmoudi et al., 2011). In vivo, biological barriers pose a significant challenge to the 
accessibility of imaging and drug delivery systems to the target site (Veiseh et al., 2010). 
MNP are particularly adept at overcoming this challenge. The well-controlled narrow size 
range of MNP formulations allow them to traverse physiological barriers on their path to 
the intended site, aided by the application of the external stimulus. However, 
agglomeration due to dipole interaction of these nanoparticles poses a problem. Several 
modifications have been investigated to overcome this problem, such as polymer coating. 
Moreover, the chosen polymers often had properties that were advantageous to the 
function of the MNP, such as increasing circulation life-span in vivo (PEG) and 
temperature- and pH-responsiveness (poly(N-isopropylacrylamide), Chitosan) (Rastogi et 
al., 2011). Modification of MNP attempted by Rastogi and co-workers (2011) included the 
use of thermo-sensitive polymers for hyperthermia-induced drug release, as well as folic 
acid conjugation for active tumour targeting (Rastogi et al., 2011). Magnetic resonance 
imaging conducted with the formulation attested to its applicability to in vivo use, while 
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drug-release was determined to be site-specific due to folic acid targeting, the nanosize 
capitalizing on the EPR effect, and an externally applied thermal stimulus.   
 
Superparamagnetic iron oxide nanoparticles (SPION) are a popular subtype of magnetic 
NP’s that have been widely studied due to their targeting ability via the application of an 
external stimulus, as well as the favorable safety profile (Veiseh et al., 2010). SPION 
consist of an iron oxide core that is responsible for the magnetic targeting ability, which is 
either coated with a biocompatible polymer or is precipitated into the pores of a porous 
polymer (Mahmoudi et al., 2011). Superparamagnetic nanoparticles are localized by i) 
passive targeting as a result of their size, which is only applicable in certain conditions 
such as solid tumours, ii) active targeting through the attachment of ligands and iii) by the 
process of the externally applied magnetic force over-coming the force exerted on the NP 
by blood flow. The NP are then able to extravasate out of the blood vessel and 
accumulate at the intended site of action, where imaging can be conducted or drug 
release can occur (Mahmoudi et al., 2011). SPION formulations of note is the 
commercially available Combidex®, that finds application in the imaging of lymph node 
metastasis, as well as Lumiren® for bowel imaging which will be useful in the detection of 
colonic and colorectal  tumours (Veiseh et al., 2010).  
  
2.6.2 Photodynamic therapy 
Photodynamic therapy (PDT) involves the administration of a non-toxic agent that acts as 
a photosensitizer (PS). Photo-excitation of the PS leads to the generation of free radicals, 
which destroy tumour tissue (Tsay et al., 2007; Spyratou et al., 2012). An alternative 
method of PDT involves the transition of the PS from a singlet to an excited triplet state. 
Transfer of energy from the excited PS to oxygen molecules results in the production of 
singlet oxygen species, which destroy cellular components, causing cell death (Tsay et 
al., 2007).  The irradiation of tumours with light of a pre-determined wavelength ultimately 
causes the generation of cytotoxic products through the interaction of the PS and light in 
the presence of oxygen, as illustrated in Figure 2.4 (Rai et al., 2010). These cytotoxic 
products result in tissue destruction and cell death (Paszko et al., 2011). The chosen 
wavelength of irradiating light should ideally be one that is absorbed to a greater degree 
by the tumour tissue relative to the surrounding healthy tissue.   
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Figure 2.4 Illustrative representation of the mechanism of PS cytotoxicity for PDT (Adapted with 
permission from Spyratou et al., 2012). 
 
PS have been extensively investigated for application in cancer imaging and therapy 
(Tsay et al., 2007; Rai et al., 2010; Spyratou et al., 2012). One such PS is hypericin, 
which has gained attention for its potential in the diagnosis of bladder and oral tumours as 
well as in combination with bevacizumab for the treatment of bladder cancer (Rai et al., 
2010). When combined with other imaging techniques, PDT can also be used as an aid in 
cytoreductive surgery. However the potential for clinical application of these agents is 
marred by pharmacokinetic problems such as non-selective distribution of PS, which may 
prove dangerous in widely disseminated tumours, as is often the case with ovarian cancer 
by the time of diagnosis (Rai et al., 2010; Paszko et al., 2011). The hydrophobic nature of 
most PS result in a tendency to aggregate in biological environments, consequently 
altering the optical properties of PS, as well as oxygen production (Rai et al., 2010; 
Paszko et al., 2011). The solubility profile also poses challenges to delivery of PS (Rai et 
al., 2010). PS display sub-optimal tissue half-life in vivo, and the possibility of toxicity in 
the absence of irradiation, i.e. dark toxicity (Allison et al., 2008). In addition, PS exhibit a 
limitation on the targeting depth due to attenuated intensity of irradiation following 
propagation through skin and tissue (Allison et al., 2008). 
 
It is the above-mentioned shortcomings that have triggered the emergence of 
nanoparticulate-based PDT. Formulation of PS in a nanosystem can greatly influence its 
activity by altering the pharmacokinetic properties, localization and cellular uptake of the 
PS (García-Díaz et al., 2012). Selectivity for tumour tissue is pivotal to the safety and 
efficacy of PDT. As previously highlighted, the preferential distribution of nanosystems into 
tumour tissue is advantageous as a method of targeting. Furthermore, nanosystems are 
amenable to the attachment of targeting moieties, which will facilitate a greater targeting 
capacity. Incorporation of the hydrophobic PS into nanosystems that exhibit outward 
hydrophilicity will stabilize the formulation in physiological environments and minimize the 
challenges associated with PS administration. Table 2.3 highlights a few examples of 
nanosystems that have been investigated for PDT. 
Illumination at 
specific λ
Tumour cell with internalized nano-
photosensitizer
ROS-mediated DNA damage  = 
Targeted Cell Death
O2
1O
2 X
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An investigation undertaken by García-Díaz and co-workers (2012) succinctly illustrates 
the unprecedented influence of nanotechnological manipulation may have on the 
effectiveness of PDT in cancer therapy (García-Díaz et al., 2012). Determining the in vitro 
and in vivo activity of novel PS, temocene, in relation to drug delivery vehicles containing 
the active molecule, this team was able to demonstrate the enhanced safety and in vivo 
activity of temocene incorporated into liposomes and micelles (García-Díaz et al., 2012). 
This work also emphasized the stability of liposomal and micelle drug delivery vehicles, 
with respect to lyophilization and aggregation. A highlight of this study to be noted was the 
toxic effects of free temocene in vivo, as a result of vascular aggregation of the PS. This 
resulted in the discontinuation of in vivo studies on free temocene. Liposomal temocene, 
however demonstrated greatest tumour selectivity and cell internalization. Micellar 
temocene, although lacking in activity in vitro, was the most effective in vivo when 
combined with a short drug-to-light interval, due to targeting of tumour vasculature that is 
absent in cell cultures used for in vitro analysis (García-Díaz et al., 2012).   
 
A particularly fascinating study by Ling and team (2012) describes the formulation of a 
nuclei targeting lipid-nanocarrier for PDT (Ling et al., 2012). Whilst PDT has become a 
widely accepted diagnostic and therapeutic mechanism for certain tumours, there remains 
some challenges with regards to larger and more deeply located tumours, namely the 
dependence of PDT efficacy on light dose, which is compromised for larger and deeper 
tumours (Ling et al., 2012). Since the mechanism of action of the singlet oxygen 
generated in PDT is DNA damage and inactivation of enzymes responsible for DNA 
repair, the logical cellular target for PS in PDT would be the nucleus (Sobolev et al., 2000; 
Ling et al., 2012).   The generation of these cytotoxic singlet oxygen species beyond the 
cell and the ultimate target, the nucleus, leads to reduced efficacy due to the short 
diffusion range of the singlet oxygen (Ling et al., 2012). Hence, intracellular delivery, 
distribution and accumulation of the PS are fundamental to the efficacy of PDT (Sobolev 
et al., 2000). To address this challenge, Ling and co-workers (2012) formulated a lipid 
nanoparticle coated with folate-containing pullulan, which would be stable in plasma and 
targeted to the over-expressed folate receptor on tumour cells, thereby accumulating 
preferentially in tumour cells following endocytosis (Ling et al., 2012). Enzymatic 
degradation of the pullulan-folate coating releases lipid and drug, which form lipid-drug 
complexes, the lipophilicity of which facilitates transport into the nucleus of the cell.  A 
focal point of this study was the demonstration of enhanced nuclei accumulation of the 
model and other drugs, indicative of the potential for enhanced PDT that is more widely 
applicable in clinical cancer therapy, as well as the versatility of this nanosystem.  
Furthermore, augmented cytotoxicity was exhibited at low irradiation intensity, highlighting 
applicability to treatment of deeply-located tumours (Ling et al., 2012). 
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Table 2.3 Nanosystems investigated for use in PDT, with therapeutic and/or imaging potential. 
 Nanosystem  Imaging 
potential 
Therapeutic 
potential 
In vitro/ Ex vivo/ 
In vivo study 
Features 
Mesoporous silica 
nanoparticles 
X X In vitro; Ex vivo Drug and imaging molecules can be incorporated into the pores of 
the NP’s. In-vitro studies demonstrated successful tumour cell uptake 
and cytotoxicity (Roy et al., 2003). 
Foslip®, liposomal 
preparation 
 X In vitro; Ex vivo Liposomal preparation containing Foscan (temoporfin). Has exhibited 
enhanced efficacy and reduced dark toxicity relative to Foscan 
(Kiesslich et al., 2007; Paszko et al., 2011). 
Zinc(II)phthalocyanine 
(ZnPc) containing 
micelles 
X X In vitro Micellar formulation proved more stable with an enhanced lifetime of 
the triplet oxygen excited state (cytotoxic), augmented fluorescence 
quantum yield and protection of the hydrophobic compound ZnPc 
(Sibata et al., 2004). 
Peptide coated-Quantum 
dots conjugated to PS’s 
X X In vitro Water soluble QD that retains the photo-physical properties of the QD 
and PS. Efficient generation of singlet oxygen through Fluorescence 
Resonance Energy Transfer (Tsay et al., 2007).    
Aerosol OT-alginate 
nanoparticles containing 
doxorubicin and PS 
methylene blue. 
 X In vitro; Ex vivo Combination of PDT with chemotherapy by incorporating methylene 
blue, a PS, into DOX-containing nanoparticles displayed enhanced 
in-vitro cytotoxicity in a resistant tumour cell line (Khdair et al., 2009). 
Pullulan-folate coated lipid 
nanoparticles 
 X In vitro; Ex vivo Pullulan-folate coated lipid nanoparticles demonstrated enhanced 
nuclei targeting and accumulation, the desired site for enhanced PDT 
efficacy, and enhanced efficacy at low intensity irradiation, for 
treatment of deep-seated tumours. In addition, DOX substitution 
highlighted the versatility of the system, enhancing the already 
present nuclei accumulation DOX (Ling et al., 2012). 
Organically modified silica 
(ORMOSIL) nanoparticles 
 X In vitro; Ex vivo; In 
vivo 
ORMOSIL nanoparticles covalently liked to a PS, to avoid release of 
the PS in systemic circulation. Spectroscopic and functional 
properties were retained by this system. This system has the 
potential for bi-functional diagnostic and therapeutic value with slight 
modification (Ohulchanskyy et al., 2007). 
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2.7 Concluding Remarks  
Successful nanotechnological innovations that transcend medical ideologies decades 
ahead of time demand the amalgamation of several individual specialties including, but 
not limited to, biology, chemistry, engineering, mathematics and pharmacology. Nano-
scale dimensions have demonstrated characteristics that are vastly different from identical 
compounds at micro- and macro-scale. Exploitation of these characteristics has been 
extensively investigated for application in the detection and treatment of ovarian and other 
solid tumours. The potential of nanotechnology highlighted during these studies brings 
forth innovations that could revolutionize the incidence, prognosis, mortality and burden of 
ovarian cancer. Nanosystems have exhibited potential at the pathophysiological level in 
terms of passive targeting to tumour tissue, transportation into tumour cells and bypassing 
mechanisms of tumour resistance, as well as at the biopharmaceutical level, by enhancing 
drug solubilization, efficacy and hence clinical relevance. In addition, nanosystems have 
proven to be immensely feasible in addressing the shortfalls of therapeutically active 
phytochemicals whose cost-effectiveness and ease of procurement render them 
invaluable treatment options.  
 
The escalating incidence of cancer worldwide and the increased exposure to carcinogens 
necessitates radical advancements in cancer detection and treatment to improve 
therapeutic outcomes as well as reduce the burden on healthcare systems. Hence, this 
disease state has dominated nanotechnological investigations. Commercially available 
nanosystems for the detection and treatment of ovarian cancer, as well as those in late 
stage clinical trials validate the feasibility of research in the field of nanotechnology for 
ovarian cancer. Moreover, the development of drug delivery systems to improve the 
pharmacokinetics, biodistribution, bioavailability, and safety profiles of existing drug 
molecules is particularly attractive as it is usually a shorter, more economical process 
relative to that involved in the identification and registration of new drug compounds.  
 
Nanosystems elevate the paradigm of targeted therapy to another echelon, surpassed 
only by the potential to combine tumour detection, therapy and monitoring mechanisms 
into one system. While the current outlook on the role of nanotechnology in addressing 
cancer detection and treatment shortfalls that plague medical experts is promising, our 
understanding on the mechanisms, fate and impact of nanosystems and their 
development is far from absolute. These issues will need to be intensely investigated for 
the responsible development of widely employed nanosystems to thrive.  With that said, 
we may indeed be only a few nanometers away from comprehensive, multimodal 
solutions to the ‘cancer plague’. 
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CHAPTER 3 
PRELIMINARY STUDIES FOR THE DESIGN AND DEVELOPMENT OF A PARENTERAL 
ANTINEOPLASTIC NANO-LIPOBUBBLE FORMULATION 
 
3.1 Introduction 
Liposomes and nanobubbles have been intensely researched particularly for their 
application in the oncology field (Tardi et al., 2007; Bawarski et al., 2008; Allen and Cullis, 
2013; Etheridge et al., 2013). The resemblance of liposomal membranes to biological 
phospholipid membranes and their ability to deliver poorly aqueous soluble drugs (which 
constitutes a large proportion of new drug compounds) as well as aqueous soluble drugs, 
validates the appeal of this drug delivery system (DDS) (Mertins et al., 2005; Lesoin et al., 
2011; Zalba et al., 2012). However, storage and in vivo stability as well as premature drug 
leakage have presented major challenges to their clinical use and addressing these 
drawbacks has been the focus of several studies (Mertins et al., 2005).  
 
Doxil®, the first United States Food and Drug Administration (FDA) approved nano-drug 
delivery system (nano-DDS), is a pegylated liposomal formulation containing the broad-
spectrum antineoplastic drug doxorubicin. First approved in 1995, during the largely 
infantile stage of nanomedicine, the development of this revolutionary therapeutic 
formulation validated the potential of nanotechnology in medical applications and 
instigated greater resource investment toward research in this field. This was rapidly 
followed by the approval of Optison™ (1998), a microbubble diagnostic imaging agent 
utilized mainly in cardiology. As understanding of the in vivo mechanistics of nanosystems 
evolved, the potential to confer nanotechnological ingenuity to a similar diagnostic 
modality that could be used in the imaging of solid tumours became apparent (Wang et 
al., 2010). The preferential accumulation of nano-scale echogenic bubbles (nanobubbles) 
within tumour tissue, as a result of the Enhanced Permeability and Retention (EPR) 
phenomenon, enhances accurate visualization of solid tumours for the purposes of tumour 
diagnosis, staging and resection. However, challenges with regards to in vivo persistence 
of the nanobubbles soon presented, compelling research into modifications such as 
polymeric coating and pegylation to increase the lifespan of the nanobubbles.  
 
When discussing advancements in translational oncology nanomedicine one would be 
amiss not to mention Abraxane, an albumin-bound nanoparticulate formulation approved 
by the FDA in 2005 for the treatment of metastatic breast cancer and recurring ovarian 
cancer (Bawarski et al., 2008). The novel mechanism of action of Abraxane and resultant 
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clinical success was substantiated by expansion of the FDA approved indications to 
include non-small cell lung cancer in 2012 (FDA, 2012). It is on this meticulous foundation 
the paradigm dictating the development of the proposed novel nano-lipobubble drug 
delivery system (NLB-DDS) was established. 
    
3.2 Preliminary Studies in the Development of the NLB-DDS 
The extensive range of pharmaceutical materials currently available makes investigation 
of all pharmaceutical excipients a counter-productive undertaking, with respect to cost and 
time implications. A comprehensive literature review to identify a narrower range of 
materials that are pertinent to the intended application is, thus, a viable undertaking 
preceding the initiation of pre-formulation studies. The intention of pre-formulation studies 
was to investigate material and methodology variations that result in a successful 
formulation and that have significant effect on measured responses, as this can be 
manipulated to tailor the properties of the intended DDS.  
 
Successful formulation of a DDS and subsequent drug delivery compels a comprehensive 
understanding of, firstly, the desired properties of the DDS and, secondly, the fundamental 
properties of the drug to be delivered and thus the materials to be employed in the 
formulation of the DDS. Intravenously administered DDS demand stringent 
biocompatibility of materials employed in the formulation process and this consideration 
presents the focal point in the selection of materials for investigation. The demand for a 
successful formulation that can be employed clinically will be substantial, hence a further 
consideration in material selection was the source (natural, naturally derived or synthetic) 
as well as ease of procurement and cost of the materials. Figure 3.1 represents a concise 
illustration of the key considerations in developing the NLB-DDS, as well as the ideal 
properties of the intended system.  
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Figure 3.1 Illustrative representation of the ideal properties and key considerations of the intended 
NLB-DDS 
 
This Chapter highlights the initial stages of the study, including the processes involved in 
and the rationale behind 1) the choice of formulatory components, 2) methodology design 
for the NLB-DDS and 3) the preliminary tests conducted on formulated NLB. Moreover, 
the effects of each of the formulation components, and their interactions, on the 
physicochemical and physicomechanical properties of the NLB are elucidated in the quest 
to ascertain the optimal formulation parameters for the DDS. 
 
3.2.1 Rational Selection of Materials 
3.2.1.1 Lipid Components 
As previously highlighted, an inherent property of most antineoplastic drugs, not least of 
all, the model drug in this study, is vastly poor aqueous solubility. A fundamental 
formulation challenge was to incorporate these hydrophobic compounds into a suitable 
carrier, whilst ensuring hematological compatibility of the DDS (i.e. compatibility with, and 
stability in, an aqueous environment) for intravenous administration. Hence, the use of 
amphiphilic compounds as an initial structural component of the intended NLB-DDS was a 
rational choice. Phospholipids are amphiphilic compounds ubiquitously present in the 
body, as major components of biological membranes and pulmonary surfactant (Lo, 2000; 
Kent, 2005). Furthermore various phospholipids, such as egg phosphatidylcholine, 
soybean phosphatidylcholine, phosphatidylserine, and phosphatidylethanolamine have 
been extensively highlighted in the literature as critical components in the successful 
formulation of intravenously administered lipid emulsions, micelles, non-drug-loaded 
nanobubbles, as well as nanoliposomes - an initial stage to the preparation of the NLB-
DDS in this study (Shimizu et al., 2005; Chou et al., 2006; Wang et al., 2006). The 
different properties of each phospholipid can be used to tailor the desired physical and 
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chemical properties of the DDS. The ratio of the polar:non-polar components can have a 
notable influence on the drug loading capacity of the DDS, depending on the affinity of the 
drug. One of the major formulation considerations is the predilection of lipid-based drug 
carriers for uptake by the reticuloendothelial system (RES). The presence of 
phospholipids has been highlighted to reduce the propensity of DDS for phagocytosis by 
decreasing the adsorption of opsonic proteins (Hadinoto et al., 2007). Phospholipids are 
biocompatible and biodegradable materials, the metabolic breakdown products of which 
will not have adverse biological effects. In addition, phospholipids have been investigated 
for their role in overcoming resistance in some tumour cell lines, a property that will prove 
tremendously beneficial to the intended DDS (Lo, 2000). A study by Lo (2000) highlighted 
the physicochemical similarities between some zwitterionic phospholipids, such as 
phosphatidylcholine and phosphatidylethanolamine, and hydrophobic cationic drugs. The 
aforementioned drugs are rendered ineffective in resistant cells due to efflux by P-
glycoprotein (P-gp) present on the cell membrane. The study proceeded to successfully 
exploit these similarities to employ phospholipids as a substrate for P-gp, thereby 
saturating this efflux pump. The antineoplastic drugs are subsequently able to exert their 
effects, due to the modulatory effects of phospholipids on tumour cell resistance (Lo, 
2000). To this end, two phospholipids, namely distearolyphosphatidylcholine (DSPC) and 
distearolyphosphatidylethanolamine (DSPE), were investigated as primary components of 
the NLB-DDS. In addition, the use of cholesterol (CHO) and coconut oil were also 
explored for their potential as components of the NLB membrane.  
 
3.2.1.1.1 Distearoylphosphatidylcholine  
Phosphatidylcholines (PC) are a class of phospholipids that possess a choline head group 
and are widely available from natural sources such as egg-yolk and soy beans 
(Kawaguchi et al., 2008; Patil et al., 2010; Cole et al., 2012). This neutral or zwitterionic 
phospholipid is located in the exoplasmic leaflet of mammalian cell membranes and 
functions in membrane-mediated cell signaling (Kent, 2005; Fernández-Murray and 
McMaster, 2007; Aktas et al., 2010). Furthermore, PC is the principle phospholipid 
present in plasma lipoproteins, highlighting the safety of this lipid in intravenously 
administered formulations (Cole et al., 2012). PC has been vastly explored in drug 
delivery applications with noteworthy success with regards to solubilization of poorly 
aqueous soluble drugs, enhanced cell permeation and drug absorption as well as 
characterization and classification of new drug entities (Kapitza et al., 2007). A study by 
Kapitza and co-workers (2007) further established the immense safety and compatibility of 
PC to cells, by highlighting the maintenance of cell membrane integrity following exposure 
to high concentrations of PC-containing liposomes (Kapitza et al., 2007). The tolerability of 
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such excessive PC concentrations can have remarkable consequences on the quantity of 
drug successfully deliverable by PC-containing DDS. DSPC has been cited extensively for 
incorporation into DDS, particularly liposomes (Santos et al., 2002; Shimizu et al., 2005; 
Kawakami et al., 2006; Suzuki et al., 2008; Haeri et al., 2011; Hossann et al., 2012). 
Clinical studies of a pegylated liposomal doxorubicin formulation containing DSPC 
exhibited favorable characteristics such as low clearance rate, enhanced stability and 
longer half-life when compared to a similar formulation containing hydrogenated soybean 
phosphatidylcholine (Chou et al., 2006; Hsiao et al., 2009). This formulation (Lipo-Dox®) is 
used extensively in Taiwan in the treatment of recurrent ovarian cancer, metastatic breast 
cancer and Kaposi’s sarcoma (Hsiao et al., 2009)     
 
3.2.1.1.2 Distearoylphosphatidylethanolamine 
Phosphatidylethanolamine (PE) is a zwitterionic molecule (between pH 2-7) present in the 
inner leaflet of biological membranes in mammalian cells, however to a lesser degree than 
PC (Marconescu and Thorpe, 2008). PE is associated to a larger extent with nervous 
tissue and neural cells in humans and is the primary phospholipid present in bacterial 
cells, such as E.coli (Wang et al., 2000; Welti et al., 2007). From a chemistry perspective, 
PE is a combination of glycerol esterified with two fatty acids, in the 1,2 or 1,3 positions, 
and phosphoric acid, with a small ethanolamine head group resulting in a cone-shaped 
molecule. DSPE-methoxy-polyethylene glycol (DSPE-m-PEG) is a highly beneficial 
amphiphilic conjugate that is regularly employed in the formulation of liposomes due to the 
ability to circumvent opsonization by plasma proteins and immunoglobulins, thus 
achieving prolonged circulation lifespan of the liposomes in vivo, and enhanced 
pharmacokinetics of the drugs being delivered (Santos et al., 2002; Chou and Chu, 2003; 
Ishida et al., 2005; Shehata et al., 2008; Hossann et al., 2010; Hossann et al., 2012). In 
chemotherapeutic studies the popularity of this compound can be attributed to its ability to 
carry poorly aqueous soluble antineoplastic drugs and release the drug load in a 
controlled manner, due to the long fatty acyl chains which minimizes mobility of entrapped 
drug molecules (Gill et al., 2011; Wang et al., 2012).  
 
In this study DSPE-m-PEG was employed for the steric benefits it may provide to 
liposomal systems. Steric stabilization describes the inhibition of opsonization of the 
liposomes, thereby extending the in vivo residence time of the liposomes (Song et al., 
2002). As previously described, increased in vivo residence time enables greater 
accumulation of the envisaged DDS within tumour tissue, favorably altering the 
biodistribution of the drug and hence, the therapeutic efficacy and side-effect profile (Song 
et al., 2002). A study conducted by Sezgin and co-workers (2008) demonstrated the 
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successful development of a DSPE-micellar intravenous DDS containing poorly aqueous 
soluble porphyrins commonly used in photodynamic therapy of solid tumours (Sezgin et 
al., 2008). In addition, comparative analysis with Pluronic micelles highlighted a more 
favorably negative zeta potential for the DSPE micelles (Sezgin et al., 2008). Several 
other studies have demonstrated the value of DSPE incorporation in micellar and 
liposomal DDS displaying effective loading and controlled release of hydrophobic drugs 
(Ishida et al., 2001; Charrois and Allen, 2004; Sawant et al., 2008; Gao et al., 2009; Gill et 
al., 2011; Katragadda et al., 2011).  
 
3.2.1.1.3 Cholesterol 
Cholesterol (CHO), a primary lipid component of mammalian plasma cell membranes, has 
been widely cited for use in various DDS, particularly those employed in cancer therapy 
(Róg and Pasenkiewicz-Gierula, 2006; Jia et al., 2008; Cai et al., 2011; Haeri et al., 2011; 
Sato et al., 2012). Ease of procurement also favorably influenced the choice of this 
material. The addition of CHO to formulations has been noted to have a stabilizing effect 
on liposomes in-vitro and upon storage as well as a substantial decrease in drug leakage 
out of liposomes, particularly when combined with DSPE (Chou and Chu, 2003; Evjen et 
al., 2010). Furthermore, the presence of CHO may favorably affect the mechanism and 
efficiency of DDS internalization and ultimately enhance drug delivery. Combination with 
phospholipids may result in more ordered packing of the phospholipid chains and 
consequently a more rigid liposomal/NLB membrane (Zalba et al., 2012). Moreover, the 
presence of CHO may reduce activation of the complement pathway of the immune 
system, thereby enhancing retention of the NLB in vivo (Vonarbourg et al. 2006).  
Incorporation of CHO into liposomal structures contributed to decreased aggregation of 
liposomes and preservation of the size characteristics when exposed to serum, which 
could favorably impact the in vivo stability and biodistribution of passively targeted 
nanostructures (Zalba et al., 2012). Tardi and co-workers (2007) demonstrated the 
versatility of CHO combined with phospholipids in the formulation of liposomes by tailoring 
the ratios of these components to maximally encapsulate two antineoplastic agents as 
well as co-ordinate their release in vivo (Tardi et al., 2007). Suzuki and co-workers (2008) 
established the applicability of CHO in liposomes exhibiting active and passive targeting to 
tumour tissue (Suzuki et al., 2008).   
 
3.2.1.1.4 Coconut oil 
Coconut oil is a vegetable oil, constituted primarily of capric acid and lauric acid (Wang et 
al., 2006). Vegetable oils are widely considered safe for intravenous use, with coconut oil 
in particular being a source of essential medium-chain fatty acids employed in parenteral 
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nutrition (Tamilvanan, 2009). The addition of coconut oil to formulations has resulted in 
exceptionally high drug encapsulation efficiency of antineoplastic drugs and 
phytochemicals (Fang et al., 2007). Fang and co-workers also demonstrated a significant 
retardation in drug release with increasing concentrations of coconut oil in formulated 
lipospheres (Fang et al., 2007). Moreover, the addition of oil components such as coconut 
oil to intravenous formulations has been associated with reduced hemolytic activity (Fang 
et al., 2007).  
 
3.2.1.2 The model drug: Camptothecin 
Camptothecin (CPT) is a naturally occurring plant indole alkaloid with a highly unsaturated 
pentacyclic ring structure, initially isolated in 1966 from the bark of the Chinese tree 
Camptotheca accuminata (van Hengel et al., 1992; Hatefi and Amsden, 2002; Ishii et al., 
2004; Liu et al., 2009). The cellular target of CPT is DNA topoisomerase I, an enzyme vital 
to the process of DNA replication (Yurkovetskiy and Fram, 2009). The double helical 
structure of DNA causes supercoiling during the transcription, replication and repair 
processes, which is counter-productive to these processes and can damage the DNA 
strands. Topoisomerase I transiently severs the phosphate backbone of DNA and forms a 
cleavable complex with DNA, thereby relieving the torsional stress caused by supercoiling 
and enabling effective transcription. The enzyme is subsequently cleaved and the severed 
DNA strand is annealed. However, the binding of CPT to topoisomerase I stabilizes the 
enzyme-DNA complex, inhibiting cleavage of the enzyme and ultimately arresting DNA 
replication (Lee et al., 2009; Yurkovetskiy and Fram, 2009). CPT activity is thus more 
pronounced at the S-phase of the cell cycle.  
 
The potent antineoplastic activity of the drug has found application against a wide 
spectrum of solid tumours, including small cell lung cancer, cervical, colorectal, and 
ovarian tumours (Hatefi and Amsden, 2002; Koo et al., 2005; Lee et al., 2009; Liu et al., 
2009; Jó et al., 2010). Native CPT, however, displays very poor aqueous solubility 
(~2µg/mL) as well as poor solubility in most organic solvents, which poses an initial 
challenge with regards to pharmaceutical formulation and administration (Hatefi and 
Amsden, 2002; Liu et al., 2009, Martins et al., 2012). Additionally the high degree of 
protein binding in vivo compromises the achievement of therapeutically significant levels 
of CPT at the site of action (Yurkovetskiy and Fram, 2009). Furthermore CPT displays a 
short half-life approximating 1 hour in PBS (pH 7.4), which can be extrapolated to in vivo 
conditions (Kang et al., 2002). Moreover, CPT exhibits a deleterious side-effect profile as 
well as physiological instability (Jó et al., 2010). Hence, the challenge to successfully 
employ this potent drug clinically is a significant yet relevant one, in an era where ovarian 
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cancer and other solid tumours are responsible for significant morbidity and mortality 
globally. 
  
Structure-activity relationship studies have highlighted an active lactone group which is 
responsible for the insolubility and physiologically-labile properties of CPT, yet crucial to 
its antineoplastic activity (Hatefi and Amsden, 2002). At and above physiological pH, ring-
opening of this lactone group occurs, resulting in reversible conversion to an inactive 
carboxylate form as illustrated in Figure 3.2 (Hatefi and Amsden. 2002). This 
compromises the bioavailability of the active lactone form. Moreover, human serum 
albumin (HSA) has a particular affinity for the carboxylate form of CPT. Binding to HSA 
unfavorably affects the lactone-carboxylate equilibrium, further compromising the 
bioavailability of the active lactone form of CPT (Liu et al., 2009). Thus an essential 
consideration in the development of DDS for successful CPT delivery is preservation of 
the lactone form of CPT from hydrolytic and pH-dependant degradation. 
 
 
Figure 3.2 Structural illustration of the reversible chemical degradation of CPT from the active 
lactone form to the poorly active carboxylate form, under physiological conditions. 
 
3.2.1.3 Emulsifiers/Surfactants 
The inclusion of an emulsifier/surfactant was critical in the formulation of a stable NLB-
DDS since the shape and size of the intended DDS is influenced largely by surface 
tension characteristics, which can be modulated by the inclusion of surfactants (Pilkington 
and Briscoe, 2012). Stability of the initial emulsion prepared, as outlined later in Section 
3.3.2.2, is dependent on adequate interaction between aqueous and organic phases and 
is a significant contributor to the desired properties of the final formulation. The inclusion 
of a surfactant reduces the surface tension which was significant in the facilitation of 
particle partitioning during the ultrasonication processes outlined below in Sections 3.3.2.1 
and 3.3.2.2, thereby reducing the size of formulated nano-liposomes (NLS) and 
subsequently NLB. The merits of employing ionic and non-ionic surfactants, and their 
effect on the ultimate surface charge of formulations, have been widely explicated in the 
literature, with respect to physical stability and size of formulations, effects of the 
Physiological pH
• Poor aqueous solubility
• Extremely potent antineoplastic activity
• Low affinity for HSA
• Increased aqueous solubility
• Severely diminished antineoplastic activity
• High affinity for HSA
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physiological environment, cellular adsorption, cellular internalization, and 
haemocompatibility. Hence, this study investigates the inclusion of non-ionic and ionic 
surfactants, the properties of which are outlined in Table 3.1, in formulating the NLB-DDS.     
     
3.2.1.3.1 Non-ionic Surfactants: Tween 80™ and Span 80™ 
Tween 80™, from the polysorbate group of surfactants, is a non-ionic surfactant commonly 
employed in the food and pharmaceutical industries due to its low cost and excessive 
tolerability (Simões et al., 2005; Wang et al., 2008; Weiszhár et al., 2012). Tween 80™ is 
the foremost surfactant used in FDA-approved parenteral formulations (Alvarez-Núñez 
and Yalkowsky, 2000; Weishár et al., 2012). Pharmaceutically, the wide ranging 
applications of Tween 80 include stabilization of formulations such as liposomes, 
emulsions and micelles, enhancing oral drug absorption and skin permeation of topical 
preparations as well as protein delivery (Simões et al., 2005; Wang et al., 2008).  
 
Span 80, sorbitan monooleate, is a low HLB, biodegradable, sorbitan ester derived from 
sugars and vegetable oils. Span 80 has proven highly effective in the production of water-
in-oil emulsions as well as a dispersion and wetting agent (Kumar and Rajeshwarrao, 
2011). However, combination with polysorbates enables tailoring of emulsification 
properties for the formulation of oil-in-water or double emulsion systems. This lipophilic 
compound is routinely employed as a food additive, as well as in the cosmetic and 
pharmaceutical industries, due to the safety profile and easily accessible nature (Kumar 
and Rajeshwarrao, 2011).  
  
3.2.1.3.2 Ionic surfactant: Dioctyl sulfosuccinate  
As an anionic surfactant, the incorporation of dioctyl sulfosuccinate, (DOS) has the 
capacity to provide electrostatic stabilization of the intended NLB-DDS against 
agglomeration (Cerdeira et al., 2010; George and Ghosh, 2013). DOS has demonstrated 
stability in neutral as well as acidic medium (Dai et al., 2010). Contrasting results have 
been reported on the adsorption of cationic and anionic molecules to cellular membranes. 
The larger anionic domains present on cellular surfaces dictates an electrostatic repulsion 
to anionic molecules. However, some studies have reported the non-specific adsorption of 
anionic DDS’s, and enhanced cellular internalization, which was attributed to reduced 
tendency of anionic molecules for opsonization (Wilhelm et al., 2003; Xiao et al., 2011). 
Use of surfactants in parenteral dosage forms is subject to stringent control. Negatively 
charged nanosystems have demonstrated haemocompatibility following intravenous 
administration, whilst a dose-dependent hemolysis has been observed for cationic DDS’s.  
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Table 3.1 Tabulated summary of the properties of surfactants investigated. 
 
 
3.3 Materials and Methods 
3.3.1 Materials 
Camptothecin (CPT) (≥90%; Mw=348.35), 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC) (≥99% purity; Mw=790.15), L-α-distearoylphosphatidylethanolamine-methoxy-
polyethylene glycol conjugate (DSPE-m-PEG) (≥98%; Mw=2748.1), cholesterol (CHO) 
(≥99% purity, Mw=386.65), dioctyl sulfosuccinate sodium salt (DOS) (≥99% purity; 
Mw=444.56), polysorbate 80 (Tween 80TM) and sorbitan monooleate (Span 80TM) were 
procured from Sigma Chemical Company (St Louis, MO, USA). Dimethyl sulphoxide 
(DMSO) was purchased from Merck Chemicals. Coconut oil was of BP grade and 
obtained from a pharmacy. Millipore filters (pore size=0.22µm) were procured from Micro 
Filtration cc. (KZN, South Africa). De-ionized water was obtained from a Milli-Q water 
purification system (Milli-Q, Millipore, Billerica, MA, USA). Chloroform, methanol, buffer 
salts and all other reagents were of analytical grade and used without further modification. 
In addition, all A-grade glassware was employed in the preparation and analyses of 
formulations.   
 
3.3.2 Methods 
A step-wise approach was adopted in the preparation of drug-loaded NLB. Since NLS are 
a formulation precursor to NLB, two methods of nano-liposomal preparation were initially 
investigated, namely the Film Hydration Method (FHM) and a modified Reverse Phase 
Solvent Evaporation Method (RPSE). Following delineation of the most suitable method, 
NLS were initially formulated employing the various materials outlined in Section 3.2.1 to 
identify suitable independent variables and the maxima and minima parameters for each 
variable. These parameters were central to the generation of an experimental design. The 
NLS of this design were prepared and further characterized for optimization. Gas 
incorporation was performed on optimized NLS formulations, to formulate NLB. These 
optimized NLB were subsequently subjected to physicochemical and physicomechanical 
characterization. In addition, the feasibility of further modifications such as polymeric 
coating and phytochemical incorporation were investigated on the NLB-DDS, with further 
characterization ensuing. All formulations were prepared and analyzed in triplicate (n=3). 
Surfactant Molecular Weight HLB Solubility 
Tween 80™ 1310 15 Freely soluble in water 
Span 80™ 428.61 4.3 
Insoluble in cold water. Soluble 
in organic solvents, mineral and 
vegetable oils 
DOS 444.56 10.2 Soluble in water and less polar 
solvents 
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3.3.2.1 Preparation of Nano-liposomes by the film hydration method 
The FH method is perhaps the most widely employed method in the formulation of 
liposomes, as has been described extensively in the literature (Sadzuka et al., 2002; 
Lesoin et al., 2011; Sakai et al., 2008; Zalba et al., 2012). Briefly, varying quantities and 
combinations of synthetic phospholipids, CHO and coconut oil were simultaneously 
dissolved in a chloroform:methanol  (9:1; 10mL) solvent system under constant agitation 
employing a magnetic stirrer. CPT was then added to the solution, under continued 
stirring. This organic solution was subjected to rotary evaporation (Multivapor™, Buchi 
Labortechnik AG, Switzerland) under vacuum at 60°C-65°C, until the formation of a 
uniform thin lipid film. The film was maintained under a fume hood overnight to ensure 
complete evaporation of organic solvents. The lipid film so formed was subsequently 
hydrated with phosphate buffered saline (PBS) (pH 7.4; 25°C) with the incorporation of a 
surfactant under ultrasonication employing a Vibracell probe ultrasonicator (Sonics and 
Materials Inc., Newtown, CT, USA). The resultant NLS suspension was subjected to three 
cycles of freezing (at -70°C) and thawing (at 37°C), to convert multilamellar NLS to 
unilamellar NLS with filtration through 0.22µm millipore filters after each freeze-thaw cycle. 
All analyses were undertaken in triplicate (n=3) 
 
3.3.2.2. Preparation of Nano-liposomes by the reverse phase solvent evaporation 
method 
NLS formulations were formulated by an adapted reverse-phase solvent evaporation 
method, as described elsewhere (Cortesi et al., 2002; Guinedi et al., 2005; Mertins et al., 
2005; du Toit et al., 2011; García-Jimeno et al., 2011; Zalba et al., 2012). Briefly, organic 
solutions of lipids and drug were prepared as outlined in section 3.3.2.1 (Preparation of 
NLS by the Film Hydration Method). PBS (pH 7.4, 25°C; 10mL) and the relevant 
surfactant were subsequently added to the organic solution under ultra-sonication 
(Amplitude=80%; 90 seconds), over an ice-bath, employing a Vibracell probe 
ultrasonicator (Sonics & Materials Inc, Newtown, CT, USA). This culminated in the 
formation of a stable emulsion which was subsequently subjected to evaporation under 
vacuum (60-65°C) for 2-3 hours, employing a Multivapor™ (Buchi Labortechnik AG, 
Switzerland). PBS (pH 7.4, 25°C; 5mL) was then added periodically during the 
evaporation process and the formulation was subjected to ultra-sonication as previously 
outlined for 30 seconds, following each addition. Complete evaporation of the solvent 
resulted in an aqueous NLS suspension. The resultant NLS suspension was subjected to 
three cycles of freezing (at -70°C) and thawing (at 37°C), to convert multilamellar NLS to 
unilamellar NLS with filtration through 0.22µm millipore filters after each freeze-thaw cycle. 
All ensuing modifications and analyses were conducted on these unilamellar NLS. 
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In both methods described above (Sections 3.3.2.1 and 3.3.2.2) preset rotary evaporation 
parameters were maintained, as outlined in Table 3.2. 
 
    Table 3.2 Fixed conditions of rotary evaporation undertaken in the formation of NLS 
Parameter: Setting: 
Temperature 60°C-65°C 
Heating Medium Water 
Rotational speed setting 5 
Pressure ~360mBar 
Evaporation time 2-3 hours 
  
3.3.2.3 Morphological characterization of nano-liposomal formulations 
The shape of formulated NLS was confirmed by Transmission Electron Microscopy 
(TEM). Briefly, formvar-coated copper grids were coated with the nano-liposomal 
suspension, employing a micro-pipette and allowed to dry for approximately one hour. The 
grids were then inserted into the loading chamber of a Transmission Electron Microscope 
(TEM-100S, Jeol Ltd., Japan). TEM employs energized electron beams to produce high 
resolution images at significantly high magnifications, which is essential in the imaging of 
nanostructures. Photomicrographs were obtained at different magnifications to illustrate 
the structure of individual NLS.  
 
3.3.2.4 Construction of a standard curve for the photospectroscopic quantification 
of camptothecin 
Due to the solubility characteristics of CPT, serial dilutions of CPT were prepared in 
DMSO:PBS (pH7.4; 37°C) (1:1). A stock solution of CPT (3mg) in DMSO (200mL) was 
prepared. Dilutions were prepared as outlined in Table 3.3. Following a UV wave-scan to 
determine the optimal wavelength for CPT detection, vortexed aliquots of the above serial 
dilutions were analyzed at the appropriate wavelength, employing a Cecil CE 3021 
spectrophotometer (Cecil Instruments Ltd., Milton, Cambridge, UK). Analyses were 
undertaken in triplicate on two consecutive days to determine the reproducibility of results.  
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Table 3.3 Serial dilutions of CPT in DMSO:PBS (pH 7.4; 37°C) (1:1) for the construction of a 
standard curve 
Dilution Stock Solution (mL) DMSO (mL) PBS (mL) 
1 1 4 5 
2 2 3 5 
3 3 2 5 
4 4 1 5 
5 5 0 5 
  
3.3.2.5 Determining favorable camptothecin loading 
The substantial cost of antineoplastic drugs dictates the relevance of attaining a balance 
between achieving maximal drug loading and minimizing drug wastage. Moreover, the 
quantity of CPT added to all formulations should remain constant. Therefore establishing 
the most suitable quantity of CPT to be added to formulations was an initial consideration. 
An investigation of increasing quantities of CPT between 3mg to 10mg, determined 
suitable from previous studies, was added to the formulation, and the resulting drug 
incorporation was determined on several preliminary formulations (Hatefi et al., 2004; 
Fang et al., 2009; Liu et al., 2009).  
 
The efficiency of drug incorporation into the DDS was determined by a novel method 
derived for this DDS. The NLS formulated by both methods described in sections 3.3.2.1 
and 3.3.2.2 were ultimately suspended in an aqueous phase. Hence, it was hypothesized 
that the NLS would orientate with the non-polar group of the phospholipids directed inward 
in the liposomal bi-layer of the NLS and the polar head group directed outwards, towards 
the aqueous suspending medium. CPT will therefore either be incorporated within the 
NLS bi-layer, or will precipitate out. Unincorporated drug, due to insolubility in the 
suspending medium, will be present primarily as a precipitate. Therefore, it was 
rationalized that the unincorporated precipitated drug could be removed by double 
filtration through a 0.22µm filter. 
 
Formulated NLS suspensions were double filtered through 0.22µm filters to remove free 
drug. The filtrate was subsequently sonicated (Amplitude = 80%, 5 minutes) and, 
thereafter, dissolved in DMSO (1:1) to prevent precipitation of CPT. Drug incorporation 
efficiency was elucidated, in triplicate, by UV photospectroscopy with reference to a 
constructed standard curve of CPT in PBS (pH7.4; 37°C). Equation 3.1 was employed to 
determine the drug incorporation efficiency (DIE) as a percentage of the quantity of drug 
(CPT) incorporated into the NLS relative to the total quantity of drug (CPT) initially added 
during formulation: 
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                where, DIE 
% =
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 x 100   (Equation 3.1) 
 
Whilst a greater quantity of CPT (by weight) was determined to be incorporated in the 
NLS following the addition of 8mg-10mg CPT, the optimal drug incorporation efficiency 
was demonstrated for an initial CPT quantity of 5mg. All other formulation parameters 
remained constant during these investigations. Eight formulations (in triplicate) were 
employed during this study which were representative of all the initial materials 
investigated during pre-formulation studies. Henceforth, the quantity of CPT added to all 
formulations will be a fixed parameter (5mg).  
   
3.3.2.6 Size and size distribution characterization of nano-liposomes 
The aqueous NLS suspensions were analyzed for size and size distribution data 
employing a Zetasizer NanoZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK). 
Samples were filtered through a 0.22µm filter into a suitable cuvette and analyzed by 
dynamic light scattering, enhanced by a non-invasive back scatter technology. Size and 
size distribution profiles were elucidated based on the diffusional velocity of particles in 
the sample by Brownian motion. Particle size is represented by the hydrodynamic 
diameter, calculated by application of the Stokes-Einstein equation (Equation 3.2): 
 
                                       !
" =
#$
%&'(
      (Equation 3.2) 
where d(H) represents the hydrodynamic diameter of the particle, k is the Boltzmann’s 
constant, T represents the absolute temperature of the sample, η is the viscosity of the 
sample and D is the translational diffusion coefficient.  
 
Measurements were derived from two different angles, thereby increasing accuracy of the 
measurements. All size measurements were conducted in triplicate at 37°C over a three 
hour period, whilst being maintained at 37°C in an orbital shaker bath (20rpm). 
 
3.3.2.7 Investigating the influence of ultrasonication on the size characteristics of 
nano-liposomes 
Initial investigations intimated the noteworthy effect of duration and amplitude of 
ultrasonication during the emulsification process in the RSPE method on the stability of 
resultant emulsions and size characteristics of NLS formulated. Ultrasonication 
undertaken during the hydration of films formed by the FH method appeared to be of 
equal relevance in terms of resultant NLS size and size distribution characteristics. The 
effect of a range of ultrasonic amplitudes (40-80%) and durations (1-10 minutes) was 
investigated to determine the ultrasonication conditions that achieved the optimum 
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balance between formulation stability and size characteristics of the formulation. Resultant 
emulsions were initially observed macroscopically to determine formulation stability as a 
function of phase separation of the emulsion. Stable formulations were characterized for 
size and size distribution patterns as outlined in Section 3.3.2.6.    
 
3.4 Results and Discussion 
3.4.1 Morphological analysis of nano-liposomes 
Transmission electron microscopy proved to be a suitable means of imaging the intimate 
structure of the NLS and proved the formation of regular, consistent NLS as illustrated in 
Figure 3.3. 
 
 
Figure 3.3 Transmission Electron Micrographs of NLS at A) 30000x magnification, B) 40000x 
magnification and C) 50000x magnification. 
 
3.4.2 Generation of a standard curve for quantification of camptothecin 
A UV wave-scan was initially performed between 250-600 nm to determine the optimum 
wavelength at which CPT was detected. The spectrum represented in Figure 3.4 
highlighted 366 nm as the wavelength of maximal CPT detection, which was employed for 
the ensuing photospectroscopic quantification of CPT.  
 
 
Figure 3.4 Three dimensional absorption spectrum of CPT in DMSO:PBS (pH 7.4; 37°C) (1:1)  
A) B) C)
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Displayed in Figure 3.5 below is the calibration curve of CPT in DMSO:PBS (pH 7.4; 
37°C) (1:1) at 366 nm, which was used for the quantification of CPT for DIE 
determinations, as well as the corresponding regression co-efficient and  y-value. In 
addition 95% confidence and prediction bands are depicted. The standard deviation for 
each of the serial dilutions was <0.025 on the first day and <0.03 on the second day, 
confirming the precision of the instrument and the reproducibility of results.  
  
  
Figure 3.5 Standard curve of the absorbance of CPT in DMSO:PBS (pH 7.4; 37°C) (1:1), as well 
as 95% confidence and prediction bands (in all cases n=3 and SD<0.02). 
 
3.4.3 Delineation of the most feasible method of nano-liposome preparation  
The FH method, also known as the Bangham method, is perhaps the most widely used 
method of liposomal preparation. However, in this study the RPSE method proved most 
beneficial as it was less time consuming since samples did not require overnight 
evaporation. The most significant disparity, however, was noted in the DIE of formulations 
prepared by both methods. NLS formed by the RPSE method exhibited significantly 
higher (~15-20%) DIE than those formed by the FH method. This is congruent with results 
from other studies employing different drugs (Xia and Xu, 2005; Zhang et al., 2012). The 
size distribution of NLS formed by the FH method also appeared to be greater than those 
formed by the RPSE method. However, this distinction was only marginally significant.  
Moreover, a principal aim of this study was the formulation of a clinically relevant DDS. 
With the consideration of taking this formulation from bench-top to bedside, it was 
concluded that a lyophilized powder that could be reconstituted as and when needed, 
would be the most feasible form of presenting this DDS. Employing the FH method would 
thus involve two drying steps (film formation and lyophilization) which makes for 
protracted preparation, in relation to the RPSE method. Consequent to the above-
mentioned findings and considerations, the RPSE method was determined the preferred 
[CPT] (mg/mL)
0.000 0.001 0.002 0.003 0.004 0.005 0.006 0.007
Ab
so
rb
a
n
ce
 
0.0
0.1
0.2
0.3
0.4
0.5
y = 51.03x 
R2 = 0.997 
 63 
 
method of NLS formulation and was the method used for fabrication of further NLS 
formulations.  
 
3.4.4 Influence of ultrasonication on the properties of formulated nano-liposomes  
Initially ultrasonication during the emulsification step of the RPSE method was undertaken 
for 5-10 minutes at amplitudes of 40-80%. However, most formulations were negatively 
affected as evidenced by the macroscopic examination of the formulations post-
ultrasonication. The resultant emulsions separated rapidly, indicative of instability. Upon 
zeta sizing, large size distributions (PdI>0.5) were observed. Radical shortening of the 
ultrasonication time as well as undertaking ultrasonication over an ice bath had a 
substantial effect on the stability of the formulation as well as the size and size distribution 
characteristics. However, decreasing sonication amplitude (≤ 65%) resulted in marginally 
larger NLS. Extensive investigation in this respect culminated in the delineation of 
ultrasonication duration of 90 seconds initially, followed by 45 seconds following PBS 
addition in the RPSE method, at an amplitude of 80%.   
 
A similar trend was observed in the influence of ultrasonication parameters during the 
hydration of lipid membranes formed by the FH method. An amplitude of 80% was 
determined feasible for successful NLS formation. Ultrasonication duration below 3 
minutes resulted in NLS larger than 200 nm, whilst prolonged ultrasonication resulted in 
unstable formulations with high PdI values. Investigations culminated in the determination 
of 5 minutes as the most feasible duration of ultrasonication for the formulations under 
investigation.   
 
3.4.5 Establishment of the influence of formulation variations on nanoliposomes 
characteristics for the selection of favorable parameters  
The use of single lipids was ruled out early in the study, due to inconsistent, poorly 
reproducible NLS. A review of literature further highlighted the beneficial effects of 
combining lipids in achieving the desired characteristics of DDS’s. Varying combinations 
of each of the four lipid phases, i.e. DSPC, DSPE-m-PEG, CHO and coconut oil produced 
NLS of vastly different characteristics. The combination of coconut oil with all other lipids 
proved unsuccessful, mainly due to large NLS size and wide size distribution, the likes of 
which were unsuited to the intended application of the DDS, as indicated in Figure 3.6 (A-
D). Furthermore, the change in NLS size was measured over time, as a measure of NLS 
stability. Coconut oil-containing formulations exhibited drastic and inconsistent size 
changes over the analysis period. Fang and team (2007) also demonstrated an increase 
in size of formulated lipospheres with increasing coconut oil concentration. However their 
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observations were of more consistent, reproducible size increases. The increase in 
liposphere size with increasing coconut oil concentration in this study was attributed to 
smaller emulsifier-to-oil ratio, which is largely responsible for reducing interfacial tension 
(Fang et al., 2007). Notably, the higher viscosity of coconut oil in comparison to the other 
formulatory components, which bear similarity to the materials used in the present study, 
resulted in higher viscosity of the emulsion preceding liposphere (and NLB) formation, and 
hence was identified as a contributor to increased liposphere size. The combinations of 
DSPC and CHO as well as DSPE-m-PEG and DSPC proved promising for the 
achievement of suitable NLS size and size distributions, which were the central focus of 
pre-formulation studies, due to the dependence of passive targeting efficacy on the nano-
scale size range of the intended DDS. In addition NLS formulations employing both these 
lipid combinations displayed adequate DIE (>40%). However, it was observed that total 
lipid concentrations above 0.4%w/v resulted in wider size distributions. This was postulated 
to result from the precipitation of lipid during the transition from organic to aqueous solvent 
phase. Therefore a total lipid concentration of 0.4%w/v was a further fixed parameter 
maintained during NLS formulation.  
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Figure 3.6 Typical Size/Intensity profiles for varying ratios of the following lipid combinations, 
DSPC-coconut oil NLS: A and B; CHO-coconut oil NLS: C and D; DSPC-CHO NLS E and F; 
DSPC-DSPE-m-PEG NLS G and H. 
 
Variation in surfactants had a considerable influence on every aspect of NLS formulation. 
The addition of Tween 80™ and Span 80™ individually to formulations resulted in unstable 
emulsions that separated rapidly, produced NLS with large size distributions and poor 
reproducibility. This is analogous to the results achieved by Simões and co-workers 
(2005) in their investigations relating to the effect of Tween 80™ on model soybean 
phosphatidylcholine (SPC) bi-layer vesicles, where significant size inconsistency was 
observed (Simões et al., 2005). Combining Tween 80™ and Span 80™ proved 
considerably beneficial, as was immediately apparent upon the achievement of a stable 
emulsion and adequate sizes approximating 160-217 nm. The addition of DOS resulted in 
appreciably stable formulations of a significantly smaller size range (125-145 nm) and 
narrow size distributions. In addition, formulations containing DOS demonstrated superior 
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DIE. These factors concluded in the selection of DOS as a qualitative fixed parameter for 
NLS formulation.  
 
3.5 Concluding Remarks 
The initial consideration of pre-formulation studies was the selection of the most 
advantageous method for NLS formulation with the considerations of formulation time, 
simplicity, NLS size and DIE. The RSPE method was deemed the most feasible method of 
NLS preparation for this study. 
 
A thorough literature review culminated in the selection of suitable materials for 
investigation. Preliminary studies provided a framework for formulation variables to be 
chosen. The consistent, reproducible formulation of nanostructures can be affected by 
minute changes in several formulation parameters. It was thus essential to highlight the 
variations in methodology and formulation constituents that had significant effect on the 
measured outcomes and those which could be optimized and maintained during 
formulation. Hence, fixed formulation parameters were outlined so as to minimize the 
extent of formulation variables under investigation. Fixed method parameters included 
total phospholipid concentration, amplitude and time for ultrasonication, quantity of CPT 
added to the formulation and rotary evaporation conditions. The combinations of DSPC-
CHO and DSPC-DSPE-m-PEG were highlighted as the main lipid components of the 
NLS. The relative ratios of these phospholipids were quantitative parameters the will be 
statistically optimized through the formulation of NLS variants of the experimental design. 
The ultimate selection of DOS as the surfactant was also a fixed parameter, however the 
concentration to be employed in the candidate formulations was a quantitative parameter 
that was subjected to statistical optimization, as outlined in Chapter 4. 
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CHAPTER 4 
FORMULATION AND STATISTICAL OPTIMIZATION OF A CAMPTOTHECIN-LOADED 
INTRAVENOUS NANO-LIPOSOMAL DRUG DELIVERY SYSTEM 
 
4.1 Introduction 
The estimated average time from drug discovery to development and registration of a 
clinically relevant product spans over 10-12 years (Pien et al., 2005; Amir-Aslani, 2008). 
The substantial risk of failure of new drug compounds is exceptionally costly and does not 
go unnoticed by pharmaceutical companies in their research endeavours. Studies 
demonstrate on average only 1 in 5000 compounds initially investigated will result in a 
pharmaceutically viable product (Curry, 2008).  Maximizing profitability and return on the 
investment in R&D involves capitalization on the protection offered by patents during the 
20 year lifespan of the patent. Extended developmental stages result in shorter 
marketable periods before expiration of the patent which may negatively impact 
profitability of the drug compound.  
 
The formulation of a drug delivery system (DDS) that enhances the clinical usefulness of 
existing drug compounds has proven to be a shorter, less risky undertaking with the 
requirements for these DDS being less stringent than those for new drug molecules. The 
propagation of research and development demands substantial consideration and 
appreciation of the economic viability of this undertaking as industrial and governmental 
financial investment is a pivotal enabling factor in pharmaceutical research and 
development.     
 
In general, the requirements for the intended DDS include (Petrak, 2005; Murday et al., 
2009): 
• Biocompatibility and biodegradability of the formulated nano-lipobubble-DDS 
(NLB-DDS). 
• Stability of the NLB-DDS under physiologic conditions. 
• Ability of the NLB-DDS to reach the tumour tissue in order to increase the 
concentration of drug in target cells. 
• Controlled release of the incorporated drug/s in accordance with the requirements 
of the drug being delivered, in order to maximize therapeutic efficacy of the 
drug/s. 
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• Prevention or minimization of the pharmacological action of camptothecin (CPT) 
at sites other than the target site so as to minimize the undesirable side-effects 
that have compromised the clinical viability of CPT. 
• Resistance to premature degradation and immunologic reactions of CPT and the 
NLB-DDS.  
• Rate of elimination < rate of delivery to tumour tissue site. 
• Rate of CPT release at target site should result in sufficient drug concentration to 
exert its pharmacological action.  
 
‘Intelligent’ DDS have been gaining momentum exponentially since inception of the 
concept, due to the therapeutic and financial advantages of these innovative DDS to 
patients and the pharmaceutical industry, respectively. The complexity of innovation of 
these specialized DDS has been accompanied by the influence of wide ranging 
experimental and formulation parameters that need to be evaluated and understood. With 
the growth of this competitive market, the need to obtain maximal and precise information 
by expending the least resources and time became a pivotal factor. Hence, the 
development of experimental designs has been a major advancement in the development 
of DDS. The application of an experimental design allows for the arrangement of 
investigations in a manner that maximizes the acquisition of relevant data in the most 
efficient manner, thereby reducing the materials and time involved in acquiring the 
information. The development of an experimental design requires firstly, an intimate 
understanding of the formulation and experimental variables that affect the formulation. 
Secondly, the measured outcomes that are pertinent to the specific DDS should be 
identified, as the effect of variables will be analyzed relative to the effect on measured 
outcomes. Moreover, the choice of experimental design chosen is dictated by the number 
and type of variables under investigation, since the confidence level of predicted 
responses may vary accordingly.  
 
4.2 Statistical modeling employing a Face-Centered Central Composite 
Design 
Following preliminary studies outlined in Chapter 3, independent variables were 
delineated, as well as the minima and maxima parameters of these independent 
variables. A two-factor three-level Face-Centered Central Composite Design (FC-CCD) 
was generated by Minitab®, V15 (Minitab® Incorporated, PA, USA), for each of the two 
lipid combinations, i.e. an experimental design for the combination of DSPC-CHO and 
DSPC-DSPE-m-PEG. Central Composite Design (CCD) has proved to be a relevant and 
invaluable tool in pharmaceutical dosage design, particularly in the design of 
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nanoparticulate formulations (Hao et al., 2012). Analysis of independent variables is 
undertaken at three levels, designated as -1; 0; and 1, which are equidistant from the 
center point creating a rotatable design.  
 
The independent variables in each of the experimental designs generated were 
quantitative in nature. Table 4.1 outlines the three levels at which each independent 
variable was assessed. These levels are further illustrated in Figure 4.1. Each 
experimental design consisted of 13 experimental runs, the compositions of which are 
outlined in Tables 4.3 and 4.4. Generation of these experimental runs aims to minimize 
the number of formulations required to generate maximum significant information to 
enable prediction of the measured responses and statistically optimize the intended DDS.   
  
Table 4.1 Summary of the minima and maxima of independent variables established from pre-
formulation studies and the translation to three analyses levels employed in the experimental 
design. 
Independent Variable 
Levels 
-1 0 1 
Lipid Ratio 
(DSPC:CHO or DSPE) 1:3 2:2 3:1 
DOS concentration 0.1%w/v 0.2%w/v 0.3%w/v 
 
 
Figure 4.1 Schematic representation of the experimental runs designated at each of the three 
levels of the FC-CCD. 
 
4.3 Determination of suitable measured responses 
As previously stated, the nanometer size range is pivotal to the desired characteristics of 
this intravenous formulation. To achieve successful extravasation and accumulation within 
tumour tissue for effective passive targeting, an average size range below 160 nm was 
initially delineated for pre-formulation of the nano-liposomes (NLS). In addition, size 
distribution had to be controlled within a very narrow range. Polydispersity relates the 
standard deviation to the mean NLS size and is an indication of the size uniformity of 
formulated NLS. Hence, low polydispersity indices (PdI) denote high size uniformity of the 
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formulated NLS. A PdI ≤ 0.2 was considered favorable. Nano zeta-sizing was, therefore, 
defined as a pivotal measured response (dependent variable). 
 
Ensuring formulation stability of intravenous DDS’s, with particular regard to minimizing 
NLS aggregation, is an essential consideration during the fabrication process. Zeta 
potential is an indication of the surface charge of the formulated NLS and, as such, 
signifies the propensity of the NLS for aggregation. A highly charged (positive or negative) 
surface displays an aversion to NLS aggregation due to stronger electrostatic repulsive 
forces surmounting the attractive van der Waals forces, thereby having a stabilizing effect 
on the formulation. This concept was succinctly described by Derjaguin, Verwey, Landau 
and Overbeek in the DLVO theory. Formulation constituents can have a significant effect 
on zeta potential. Thus zeta potential was identified as a pertinent measured response.  
 
The efficacy of a DDS is strongly associated with the concentration of drug at the site of 
action, which in turn is highly influenced by the quantity of drug initially incorporated into 
the DDS. The nanoscale of the proposed DDS may influence the capacity for drug 
incorporation into the DDS. However, the achievement of appreciably high concentrations 
of drug incorporated into the nano-DDS is central to the efficacy and viability of the 
proposed DDS. Low drug incorporation will necessitate the administration of larger 
quantities of the DDS in order to achieve therapeutically significant drug concentrations. 
This may limit the therapeutic, manufacturing, and financial benefits of the DDS. 
Therefore, drug incorporation efficiency (DIE) was denoted a critical response for 
evaluation during pre-formulation studies.  
 
Lastly, the success of any DDS cannot be fully established without assessing drug release 
patterns. Drug release patterns provide an indication of undesirable premature drug 
release, as well as whether a therapeutically effective concentration of drug will be 
achievable at the site of action as a result of the release pattern of drug from the DDS. To 
this end, drug release, and subsequently mean dissolution time (MDT), was evaluated. 
 
Table 4.2 presents the upper and lower limits of measured responses, as derived from 
pre-formulation studies, for each of the 2 experimental designs, as well as the objective in 
this study with respect to each of the measured responses.    
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Table 4.2 Delineation of the lower and upper limits of the chosen measured responses, and the 
objective for optimization with respect to each measured response. 
 
4.4 Materials and Methods 
4.4.1 Materials 
Camptothecin (CPT) (≥90%; Mw=348.35), 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC) (≥99% purity; Mw=790.15), L-α-distearoylphosphatidylethanolamine-methoxy-
polyethylene glycol conjugate (DSPE-m-PEG) (≥98%; Mw=2748.1), cholesterol (CHO) 
(≥99% purity, Mw=386.65), dioctyl sulfosuccinate sodium salt (DOS) (≥99% purity; 
Mw=444.56), polysorbate 80 (Tween 80TM) and sorbitan monooleate (Span 80TM) were 
procured from Sigma Chemical Company (St Louis, MO, USA). Dimethyl sulphoxide 
(DMSO) was purchased from Merck Chemicals. Coconut oil was of BP grade and 
obtained from a pharmacy. Millipore filters (pore size=0.22µm) were procured from Micro 
Filtration cc. (KZN, South Africa). De-ionized water was obtained from a Milli-Q water 
purification system (Milli-Q, Millipore, Billerica, MA, USA). Chloroform, methanol, buffer 
salts and all other reagents were of analytical grade and used without further modification. 
In addition, all A-grade glassware was employed in the preparation and analyses of 
formulations.   
 
4.4.2 Methods 
4.4.2.1 Formulation of camptothecin-loaded nano-liposomes 
Two sets of NLS formulations were prepared in accordance with the experimental designs 
generated, as previously discussed. The formulation components of these experimental 
designs are outlined in Tables 4.3 and 4.4, whilst the formulation parameters that were 
maintained across all formulations are outlined in Table 4.5.  Henceforth, NLS from these 
two experimental designs will be referred to as CHO-NLS and DSPE-NLS, respectively, a 
reference to the major compositional difference distinguishing these two sets of 
experimental designs.  
Dependent Variable Lower Limit Upper Limit Objective 
DSPC/CHO-NLS 
Size (d.nm) 125 135 Minimize 
Zeta Potential (mV) -42 -32 Minimize 
DIE (%) 65 75 Maximize 
MDT (hours) 7.5 21 Maximize 
DSPC/DSPE-NLS 
Size (d.nm) 85 95 Minimize 
Zeta Potential (mV) -8 -5 Minimize 
DIE (%) 37 44 Maximize 
MDT (hours) 7 18 Maximize 
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Table 4.3 Composition of formulations for each experimental run of the CHO-NLS experimental 
design  
Experimental Run Independent Variables 
DSPC (%w/v) CHO (%w/v) DOS (%w/v) 
A1 0.2 0.2 0.1 
A2 0.1 0.3 0.3 
A3 0.2 0.2 0.2 
A4 0.3 0.1 0.3 
A5 0.1 0.3 0.2 
A6 0.2 0.2 0.3 
A7 0.3 0.1 0.1 
A8 0.2 0.2 0.2 
A9 0.3 0.1 0.2 
A10 0.1 0.3 0.1 
A11 0.2 0.2 0.2 
A12 0.2 0.2 0.2 
A13 0.2 0.2 0.2 
 
Table 4.4 Composition of formulations for each experimental run of the DSPE-NLS experimental 
design. 
Experimental Run 
Independent Variables 
DSPC (%w/v) DSPE (%w/v) DOS (%w/v) 
B1 0.1 0.3 0.1 
B2 0.2 0.2 0.3 
B3 0.2 0.2 0.2 
B4 0.2 0.2 0.1 
B5 0.2 0.2 0.2 
B6 0.1 0.3 0.3 
B7 0.1 0.3 0.2 
B8 0.2 0.2 0.2 
B9 0.3 0.1 0.3 
B10 0.2 0.2 0.2 
B11 0.3 0.1 0.1 
B12 0.2 0.2 0.2 
B13 0.3 0.1 0.2 
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Table 4.5 Fixed formulation parameters maintained during the preparation of NLS. 
Fixed Formulation Parameters 
CPT concentration 0.05% w/v 
Total initial lipid concentration 0.4%w/v 
Solvent system chloroform:methanol (9:1) 
Evaporation temperature 60-65°C 
Ultrasonication amplitude 80 
 
4.4.2.2 Determination of the size, size distribution and surface charge 
characteristics of formulated nano-liposomes 
Size and size distribution characterization was undertaken as previously described in 
Chapter 3, Section 3.3.2.6. Zeta potential of the NLS suspensions were also analyzed 
employing the Zetasizer NanoZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK). 
Briefly, this system employs a laser doppler micro-electrophoresis technique to determine 
the velocity of the particles in the sample in response to an applied electric field. This 
enables the elucidation of electrophoretic mobility and consequently zeta potential of the 
sample. As outlined above, all zeta potential measurements were conducted in triplicate at 
25°C over a three hour period, whilst the sample was maintained at 37°C in an orbital 
shaker bath (20rpm). 
 
4.4.2.3 Elucidation of camptothecin incorporation efficiency 
Systematic investigation of the efficiency of CPT incorporation of the formulations in each 
of the two experimental designs was conducted as detailed in Chapter 3, Section 3.3.2.5. 
Briefly, the formulated NLS suspended in phosphate buffered saline (PBS) was double 
filtered through 0.22µm filters to remove unincorporated CPT. Ultrasonication was 
employed to breakdown the NLS, followed by the addition of DMSO to the NLS 
suspension (1:1) to dissolve the hydrophobic drug. Elucidation of DIE ensued in triplicate 
by UV spectroscopy with reference to the previously generated standard curve of CPT in 
DMSO:PBS (pH 7.4; 37°C) (1:1).  
  
4.4.2.4 In vitro camptothecin release analysis   
Following removal of free drug from the NLS suspension, 5mL samples were enclosed in 
treated dialysis tubing (Mw cut-off=12000Da) and suspended in PBS (pH 7.4; 37°C; 
500mL). The receptacle was maintained at 37°C in an orbital shaker bath rotating at 
20rpm. At pre-determined intervals, 5mL aliquots were removed from the external PBS 
phase and added to DMSO (5mL), creating a 1:1 ratio, to prevent precipitation of the drug. 
Fresh buffer (5mL) was replaced to the external phase to maintain sink conditions. 
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Vortexed samples were analyzed by UV spectroscopy at 366nm, against previously 
constructed standard curves of CPT in DMSO:PBS (pH7.4; 37°C) (1:1).   
 
4.4.2.5 Micro-ultrasound imaging of formulated nano-liposomes 
In addition to the aforementioned TEM imaging technique described in Chapter 3, micro-
ultrasound imaging employing a Vevo® 2100 (Visualsonics, Toronto, Ontario, Canada) 
was employed to confirm the overall appearance of the NLS. This technique, further, 
highlights behavioral characteristics such as aggregation of the NLS, which is a vital 
indicator of stability. A 10%w/v carrageenan hydrogel was prepared, onto which ultra-
sound gel was applied. The NLS were injected into the hydrogel and an ultra-sound beam 
was applied, producing images of the NLS as they dispersed through the hydrogel. 
   
4.5 Results and Discussion 
In an attempt to facilitate understanding of the data obtained and the mathematical 
modeling thereof, the experimental results will initially be simultaneously represented for 
both experimental designs. The ensuing sections, presenting the process of mathematical 
modeling and statistical optimization of the NLS formulations, will be divided into CHO-
NLS and DSPE-NLS.     
 
4.5.1 Experimental results 
4.5.1.1 Size and size distribution analysis of fabricated nano-liposomes 
As previously outlined, the benefits of the DDS presented rely largely on the nano-scale 
size of the NLS. The nano-size scale will be principally responsible for the passively 
targeted nature of the DDS and the efficiency thereof. Furthermore, nano-sizing enables 
the solubilization of poorly aqueous soluble antineoplastic drugs, such as the model drug 
CPT. Hence, assessment of NLS size was fundamental in this study. A benchmark size of 
160 nm was established. Figure 4.2 typifies the size-intensity profiles obtained for the 
smallest and largest NLS from each design. The experimental size data for CHO-NLS and 
DSPE-NLS is represented in Table 4.6, along with the PDI for each experimental run. 
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Figure 4.2 Typical size profiles representing CHO-NLS at the minimal (A) and maximal (B) 
presenting sizes and DSPE-NLS at the minimal (C) and maximal (D) presenting sizes. 
 
Table 4.6 Tabulated representation of the average size of NLS for each of the two experimental 
designs 
 
All formulations fell within the desired size range. The foremost contributor to size 
variations between the various formulations was concentration of DOS. Higher 
concentrations of DOS resulted in a reduction of NLS size as well as a narrower size 
distribution, indicated by the lower PdI. In addition, CHO-containing NLS formulations 
were generally of a larger size than DSPE-containing NLS formulations, as indicated in 
Figure 4.2 and Table 4.6. This was attributed to firstly, the bulkiness on the CHO molecule 
and secondly, the lateral stabilization mechanism of DSPE. Moreover, strong hydrogen 
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Size (d.nm)
A) B)
C) D)
CHO-NLS Average Size (d.nm) Average PdI DSPE-NLS 
Average Size 
(d.nm) Average PdI 
A1 162.79 0.223 B1 89.75 0.265 
A2 125.06 0.167 B2 80.24 0.166 
A3 144.88 0.197 B3 94.59 0.173 
A4 132.88 0.136 B4 100.86 0.202 
A5 120.04 0.200 B5 94.59 0.173 
A6 118.53 0.147 B6 100.36 0.187 
A7 131.31 0.212 B7 92.61 0.214 
A8 144.88 0.197 B8 94.59 0.173 
A9 142.95 0.185 B9 72.14 0.154 
A10 137.13 0.215 B10 94.59 0.173 
A11 144.88 0.197 B11 136.2 0.251 
A12 144.88 0.197 B12 94.59 0.173 
A13 144.88 0.197 B13 144.1 0.198 
 76 
 
bonding and electrostatic interaction exists between the head groups of PE molecules, 
creating reduced volume in the region of the head group (Borba et al., 2009).  
 
4.5.1.2 Surface charge characterization of formulated nano-liposomes 
Zeta potential is an indication of the surface charge of the NLS formulated, and hence the 
propensity of these NLS for aggregation. Zeta potential is thus considered a suitable 
indicator of formulation stability. All NLS formulations displayed negative zeta potential, 
which may be attributed to the anionic nature of the surfactant (DOS). This observation 
was corroborated with the evident favorable decrease in zeta potential with increasing 
concentration of DOS, whilst all other formulatory components remained the same, as 
illustrated in Figure 4.3.  
 
 
Figure 4.3 Graphical illustration of the relationship between [DOS] and zeta potential. Each set of 
bars represents formulations containing a particular [DOS]. 
 
However, a significant difference was noted between DSPE- and CHO-containing 
formulations. NLS formulated from the combination of DSPC and CHO exhibited 
significantly more strongly negative zeta potentials compared to NLS formulated from 
DSPC and DSPE combinations (~-45mV and ~-7mV respectively). CHO has an enormous 
stabilizing effect on phospholipid bilayers, being cited for creating a more organized 
arrangement of acyl chains on phospholipids as well as tighter packing of atoms in the 
hydrophobic core (Róg and Pasenkiewicz-Gierula, 2006;). Xia and Xu (2005) observed 
similar effects on the zeta potential of liposomes following the incorporation of CHO. This 
favorable effect on the zeta potential was also attributed to the interaction between the 
hydroxyl group on CHO and the choline group present in the phospholipid (Xia and Xu, 
2005).  
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4.5.1.3 Quantification of camptothecin incorporation efficiency 
The achievement of adequately high levels of drug incorporation into nano-enabled drug 
delivery systems is particularly challenging due to the nano-scale size range of these 
DDS. Table 4.7 provides a comprehensive view of the DIE determined for formulations in 
each of the two experimental designs, arranged so as to facilitate an understanding of the 
effect of independent variables on the DIE. 
 
Table 4.7 Tabulation of the DIE percentages obtained for formulations in Designs 1 and 2, 
highlighting the significant distinction between CHO- and DSPE-NLS. 
DSPC (%w/v) CHO (%w/v) DSPE (%w/v) DOS (%w/v) DIE (%) 
0.1 
0.3  
0.1 55.50 
0.2 62.79 
0.3 64.42 
 0.3 
0.1 28.45 
0.2 32.46 
0.3 76.31 
0.2 
0.2  
0.1 39.21 
0.2 62.59 
0.3 75.84 
 0.2 
0.1 37.95 
0.2 36.72 
0.3 37.02 
0.3 
0.1  
0.1 60.94 
0.2 64.85 
0.3 81.47 
 0.1 
0.1 28.35 
0.2 44.19 
0.3 43.16 
 
DSPC:CHO NLS demonstrated favorably high DIE, with all, except two, formulations 
displaying DIE>60%. The maximum reproducible DIE achieved was 81.47%. DSPE-NLS 
exhibited DIE ranging between 28%-45%, with only one formulation displaying a DIE of 
76.31%. Reproducibility of DIE presented a challenge, particularly with regards to DSPE-
NLS. The bulky nature of the CHO molecule, as opposed to the di-branched appearance 
of the DSPE molecule, resulted in the formation of larger NLS, thereby allowing more 
generous accommodation of CPT. Increasing DOS concentration within each 
phospholipid ratio resulted in increasing DIE for CHO-NLS. This effect could be attributed 
to the stabilizing effect of DOS on the NLS. 
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4.5.1.4 Assessment of the release characteristics of camptothecin from nano-
liposomes  
The achievement of adequate passive targeting of the DDS to tumour tissue was a 
fundamental objective in this study. Ideally, a formulation exhibiting a favorable stability 
profile coupled with a reduced rate of drug release from the DDS has the potential to 
extensively enhance the preferential accumulation of drug within tumour tissue, thereby 
reducing the adverse effects associated with non-specific distribution of antineoplastic 
drugs. Since CPT acts on the S-phase of the cell cycle, prolonged release of CPT will be 
particularly beneficial, enabling CPT to exert its antineoplastic effect on a greater 
proportion of tumor cells. The half-life of CPT in PBS was determined to approximate 1 
hour (Kang et al., 2002). Extension of this half-life is fundamental to improving the 
pharmacokinetic properties of CPT.  
 
The fractional drug release profiles of CHO-NLS in Figure 4.4, illustrate a somewhat bi-
phasic pattern of CPT release across all formulations. CPT release over the first 6 hours 
of analysis was generally slightly faster than that over the next 18 hours, as demonstrated 
by the steeper gradient of the curve over this initial period. The absence of a significant 
burst release of CPT suggests adequate incorporation of the drug into the NLS-DDS, with 
no surface adsorption. This characteristic is particularly beneficial with regards to 
intravenously administered formulations, indicating minimal drug will be released in the 
systemic circulation prior to accumulation within the target tissue. Formulation as CHO-
NLS resulted in a prolongation of the half-life of CPT to approximately 4 hours. Cumulative 
drug release from CHO-NLS over the course of the 24 hour analysis period was between 
70%-100%. Quantification of drug release was undertaken by determination of the MDT of 
each experimental run. The calculated MDT’s extended over quite a large range, from 7.5-
21. Formulations A1 and A6 exhibited the shortest and longest MDT, respectively. 
Formulation A10 appeared to be somewhat of an outlier when the pattern of fractional 
drug release was observed graphically. However, the MDT was almost a midpoint value in 
the range of MDT values obtained for this experimental design.   
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Figure 4.4 Fractional drug release profiles for CHO-NLS in PBS (pH 7.4; 37°C) (Design 1) 
undertaken over a 24 hour period (in all cases n=3 and SD ≤ 0.03). 
 
The observed fractional drug release patterns for DSPE-NLS, presented in Figure 4.5, 
were more erratic than that observed for CHO-NLS. In general, drug release in the first 
hour of analysis was noticeably more rapid, relative to that of CHO-NLS, suggestive of a 
slight burst release. This burst release was attributed to association of CPT with the outer 
membrane of the NLS, perhaps through association with PEG. All formulations in this 
experimental design demonstrated >90% release of CPT within the 24 hours analysis 
period, with maximal drug release being observed at approximately 18 hours for a large 
proportion of the formulations. The faster rate of CPT release observed could be related to 
the poor stability of DSPE-NLS, indicated by the mildly negative zeta potential. 
Formulation as DSPE-NLS did not exhibit a significant increase in the half-life of CPT. The 
MDT’s established from this experimental design was of a narrower range than that of the 
CHO-NLS, with the exception of formulation B6 which was somewhat of an outlying value. 
The shortest and longest MDT was exhibited by formulations B11 and B6, respectively. 
Interestingly, formulation B11 also demonstrated the largest average size of NLS in this 
experimental design, as well as the most unfavorable zeta potential. Formulation B6 had 
the highest DIE, which may have impacted the concentration of CPT released from the 
NLS and consequently the MDT. Formulations with a higher DSPE concentration (B1, B6, 
B7) produced very similar and consistent patterns of drug release. This was attributed to 
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the stabilization afforded to the formulations by the increased concentration of PEG 
associated with DSPE molecules.   
 
 
Figure 4.5 Fractional drug release profiles for DSPE-NLS (Design 2) in PBS (pH 7.4; 37°C) 
undertaken over a 24 hour period (in all cases n=3 and SD ≤ 0.03). 
 
Table 4.8 Calculated MDT values for each experimental run designated for each of the two 
experimental designs. 
CHO-NLS MDT (Hours) DSPE-NLS MDT (Hours) 
A1 7.513 B1 7.608 
A2 20.911 B2 12.075 
A3 10.189 B3 9.912 
A4 18.574 B4 10.937 
A5 13.981 B5 9.912 
A6 21.278 B6 17.707 
A7 11.018 B7 7.819 
A8 10.189 B8 9.912 
A9 13.901 B9 10.575 
A10 13.523 B10 9.912 
A11 10.189 B11 7.403 
A12 10.189 B12 9.912 
A13 10.189 B13 10.514 
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4.5.1.5 Behavioral characterization of formulated nano-liposomes through micro-
ultrasound imaging  
Macroscopic visual assessment of the general behavioral characteristics of CHO-NLS 
demonstrated even and adequate distribution through the prepared medium, with the 
marked absence of aggregation. The micro-ultrasound images in Figure 4.6 highlight the 
distribution of CHO-NLS following injection into a stiff carrageenan hydrogel. This 
behavior suggests high stability of the formulation, even in the presence of resistance to 
motion, and augurs well for in vivo stability.  
 
 
Figure 4.6 Micro-ultrasound images of CHO-NLS following injection into a caraggeenan hydrogel. 
 
4.5.2 Computational modeling of experimental data  
Response surface methodology (RSM) is an effective tool for mathematical modeling of 
experimental data, particularly for systems where numerous factors can influence the 
properties of the system. RSM enables simultaneous evaluation of multiple significant 
parameters, thereby reducing the experimental runs required to obtain adequate data for 
optimization (Balachandran et al., 2012). Results obtained from the experimental runs 
were processed using RSM. Employment of this statistically relevant approach resulted in 
the generation of second order polynomial equations (Equations 4.1-4.8). Each equation 
highlights the significance of the effect of each independent variable on the measured 
response, as well as the relationship/interaction between the independent variables 
(Balachandran et al., 2012). Analysis of variance (ANOVA), data correlation determination 
and regression analysis were utilized for data processing and in the assessment of the 
statistical relevance of the proposed models.     
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4.5.2.1 Experimental design and statistical optimization of CHO nano-liposomes 
4.5.2.1.1 Validation of statistical optimization through data correlation 
The relevance and robustness of the experimental design to accurately predict the most 
optimal formulation composition for the desired measured responses can be assessed by 
the intensity of the correlation between experimentally determined and statistically 
predicted measured responses. The outstanding correlation demonstrated between the 
measured responses obtained experimentally and the fitted responses predicted by 
computational modeling as presented in Figure 4.7A-D, particularly for zeta potential, 
serves to validate the applicability of this FC-CCD to the optimization of this nano-sized 
pharmaceutical formulation. The correlation established between the experimental and 
predicted outcomes with regards to average size, though significantly lower (R2=62.6%) 
than those of the other measured outcomes (~80-97%), was still adequate. In addition, the 
very close correlation between experimental and predicted average size data of particular 
formulations is noteworthy. The strongest correlation of experimental and fitted responses 
was achieved for zeta potential with a correlation coefficient of 97.3%.   
   
 
Figure 4.7 Correlation scatter plots of A) Average size (R2=62.6%); B) Zeta potential (R2=97.3%); 
C) DIE (R2=80.7%) and D) MDT (R2=85.7%) for the determination of correlation between the 
experimental and fitted measured responses for CHO-NLS. 
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4.5.2.1.2 Characterization of the relationship of independent variables relative 
to measured outcomes 
The measured outcomes were influenced by each of the two independent variables in 
different manners and to varying extents, such that thorough formulation optimization 
demanded adequate consideration and assimilation of this data. RSM enables the 
construction of contour plots and 3-dimensional response surface plots which graphically 
illustrate the inter-relationship of formulations variables (independent variables) and their 
individual and collective effect on measured outcomes. The generation of second order 
polynomial regression equations represents a central outcome in the analysis of the 
relationships between independent variables and is critical to the process of formulation 
optimization.  
 
Presented herein, Figures 4.8 and 4.9, are the contour and response surface plots for 
CHO-NLS highlighting the influence of lipid ratio (DSPC:CHO) and surfactant 
concentration ([DOS]) on each of the measured outcomes, average size, zeta potential, 
DIE and MDT in turn.  
 
 
Figure 4.8 Graphical illustrations employing A) a 3-D response surface graph and B) a contour plot 
to depict the influence of independent variables on the average size and zeta potential, 
respectively, of CHO-NLS. 
 
The ratio of DSPC to CHO had a variable effect on the average size of CHO-NLS as 
depicted in Figure 4.8A. An increase in DSPC or CHO within the ratio had a mirror effect 
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on the average size of the NLS, until the ratio of the lipids approximated 1:1, where the 
largest average sizes were noted. The increase in average size as a consequence of 
increased CHO was attributed to the bulkiness of the CHO molecule. There was a 
noteworthy inverse relationship between DOS concentration and the resultant average 
size of CHO-NLS. Increasing surfactant concentration resulted in a progressive reduction 
in the surface tension of the emulsion prior to NLS formation, thereby facilitating the 
formation of smaller NLS.   
 
The zeta potential of formulations was evidently influenced by the surfactant concentration 
in the formulation. Increase in DOS concentration resulted in a favorably heightened 
anionic surface charge, which is illustrated in the contour plot in Figure 4.8B. Moreover, 
this effect exhibited a consistent trend across all formulations, irrespective of the lipid 
ratio. Statistically, the effect on zeta potential was only partially significant (p=0.054). 
Theoretically, the presence of CHO was expected to contribute significantly to the 
negative zeta potential of CHO-NLS. Experimentally, formulations at each of the three 
levels of DOS concentration analyzed generally demonstrated a favorable decrease in 
zeta potential with increasing CHO concentration. Formulation A6 was the sole exception, 
being 0.61mV less than A2 (-49.35mV and -48.74mV respectively). In addition, the wide 
disparity in zeta potential between CHO-NLS and the significantly less negative DSPE-
NLS further corroborated this theory.  
 
There was a clear direct relationship between DOS concentration and DIE, although this 
was determined to be statistically insignificant. The contour plot (Figure 4.9A) depicting 
the influence of each of the two independent variables on DIE demonstrates a pattern of 
increasing DIE as the concentration of DOS increases, which is independent of the ratio of 
phospholipids. Formulation A4 exhibited the highest DIE. 
 
The shape of the MDT response surface plot in Figure 4.9B showed an inverse, although 
less distinct, pattern to the average size plot with regards to the effect of DSPC:CHO. 
Hence, the larger CHO-NLS exhibited the shortest MDT. Generally, higher DOS 
concentrations resulted in longer MDT. This could be attributed to the high stability of 
formulations with high DOS concentrations, which resulted in slower release of 
incorporated CPT. A general trend was observed whereby higher DIE resulted in longer 
MDT.  
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Figure 4.9 Graphical illustrations employing A) a contour plot and B) a 3-D response surface plot to 
depict the relationship of independent variables to the measured outcomes DIE and MDT 
respectively, of CHO-NLS 
 
Consideration of the relationships of independent variables and their influence on the 
measured outcomes culminated in the derivation of the following regression equations 
(Equations 4.1-4.4). These equations facilitate accurate prediction of each measured 
outcome under consideration as a function of varying independent variables. 
 
Average size = 14.4 + 42.53(X1) + (-0.74)(X2) + (-11.30)(X1)2 + (-0.02)(X2)2 + 0.341(X1)(X2)  
          (Equation 4.1)  
Zeta potential = (-24.96) + (-5.01)(X1) + (-0.98)(X2) + 3.63(X1)2 + 0.01(X2)2 + (-0.19)(X1)(X2) 
          (Equation 4.2) 
DIE = 54.08 + (-19.82)(X1) + 1.23(X2) + 4.53(X1)2 + (-0.18)(X2)2 + 0.29(X1)(X2) 
          (Equation 4.3)  
MDT = 32.99 + (-10.56)(X1) + (-1.67)(X2) + 2.45(X1)2 + 0.05(X2)2 + (-0.0002)(X1)(X2) 
          (Equation 4.4) 
where X1 = DSPC:CHO, and X2 = [DOS] 
 
4.5.2.1.3 Analysis of the fit of the derived model 
Residual plots are employed to provide an indication of the suitability and integrity of the 
model. Four different residual plots are depicted in Figure 4.10 for each of the measured 
outcomes. A well fit model will exhibit a normal distribution of points for each of the 
measured outcomes, with constant variance. The distribution of points in the normal 
probability of residuals for each of the measured outcomes lies in close proximity to the 
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straight line, indicating a normal distribution. The assumption of constant variance is 
tested by analysis of the plot of residuals versus fitted values. A random distribution of 
points above and below the zero line with no discernible pattern is indicative of a constant 
variance and the applicability of the model to all values of independent variables within the 
defined parameters. Each of the four plots of residual versus fitted values exhibited an 
arbitrary distribution of points, with only a few outlying points. Histograms prove 
particularly useful as they provide an insight into the overall characteristics of the model. 
Whilst the ideal bell-shaped histogram was not achieved for any of the measured 
outcomes, the generated histograms were, nevertheless, congruent with the previous 
conclusions of normal distribution and constant variance of data. The fourth graph is a plot 
of the residuals in the order that the data was collated (order of experimental runs) and 
provides an indication of the effect of other variables on the measured outcomes which 
may not have been identified and analyzed as well as errors that may have a pattern and 
cannot be overlooked. This plot somewhat rounds off the applicability of the model by 
confirming the comprehensiveness of the analytical process. The residuals versus order 
of data plot for each of the measured outcomes for CHO-NLS displayed slight clustering 
of consecutive points, as well as a few infrequent inversions of signs of consecutive data 
points.   
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Figure 4.10 Summary of the Residual Plots generated for the measured outcomes of CHO-NLS.
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The application of ANOVA revealed a paucity of statistical significance of the independent 
variables on the measured outcomes (p≤0.05), with the exception of [DOS] which had a 
statistically significant effect on MDT, as highlighted in Table 4.9. However, the 
concentration of DOS had a noteworthy effect on the zeta potential of the formulation.     
 
Table 4.9 Summary of the p-values for each of the independent variables relative to the measured 
outcomes. 
Measured Response DSPC:CHO [DOS] 
Average Size 0.146 0.784 
Zeta Potential 0.276 0.054 
DIE 0.222 0.434 
MDT 0.177 0.049 
 
4.5.2.1.4 Constrained optimization of the CHO nano-liposomal drug delivery 
system 
Comprehensive optimization of a formulation with regards to all four measured outcomes 
requires consideration of the significance of each of the measured outcomes and the 
range of each outcome that is considered feasible and that which is the most desirable. 
Computational modeling by Minitab®, V15 software (Minitab® Incorporated, PA, USA) 
following the application of a FC-CCD concluded in the determination that CHO-NLS 
consisting of DSPC:CHO in a 3:1 ratio and 0.3%w/v DOS would produce the greatest 
individual and collective optimization of measured responses. The predicted size and zeta 
potential of this candidate formulation were 129.29 d.nm and -41.77mV respectively. A 
substantial DIE of 82.41% and MDT=20.382 was forecast for this formulation. The 
desirability of each of the individual outcomes exceeded 0.7, with an outstanding overall 
desirability=0.91 predicted for the optimized CHO-NLS. The optimal parameters of the 
CHO-NLS formulation are depicted in Figure 4.11.   
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Figure 4.11 Optimization plots for CHO-NLS, indicating optimal levels of independent variables, 
the predicted outcomes based on these independent variables as well as the desirability of the 
predicted outcomes.  
 
4.5.2.2 Experimental design and statistical optimization of DSPE nano-liposomes 
4.5.2.2.1 Validation of statistical optimization through data correlation 
Suitability of the derived model for DSPE-NLS was assessed through analysis of 
correlation of the regression plots for each of the measured outcomes as outlined in 
Figure 4.12A-D. Correlation of the measured response data obtained experimentally to 
the modeled fitted responses for average size and zeta potential was exceptionally strong 
with correlation coefficients of 83.9% and 81.1%, respectively. Although marginally lower, 
the correlation of experimental and fitted data for DIE and MDT was highly satisfactory. 
Correlation of experimental and fitted data for DSPE-NLS validated the applicability and 
robustness of the derived model for optimization of DSPE-NLS. 
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Figure 4.12 Scatter plots of A) Average size (R2=83.9%); B) Zeta potential (R2=81.1%); C) DIE 
(R2=63.5%) and D) MDT (R2=69.3%) for the determination of correlation between the experimental 
and fitted measured responses for DSPE-NLS. 
 
4.5.2.2.2 Characterization of the relationship of independent variables relative 
to measured outcomes 
RSM was employed to characterize the individual and collective effect of phospholipid 
ratio and DOS concentration on the measured outcomes under investigation for DSPE-
NLS. The construction of 3-D response surface graphs and contour plots provided visual 
representations of these relationships. Presented in Figure 4.13 are the response surface 
graphs and contour plots generated to conceptualize the inter-relationships of 
independent variables of DSPE-NLS and the influence of these variables on the average 
size, zeta potential and MDT of DSPE-NLS. There was no observable relationship 
between either of the independent variables and DIE    
 
The average size of DSPE-NLS was discernibly affected by both the ratio of phospholipids 
in the formulation as well as surfactant concentration. The simultaneous increase in DSPC 
concentration and reduction in DSPE concentration resulted in an increase in the average 
size of NLS. DSPC tends to be a bulkier molecule than DSPE, however the presence of 
PEG attached to DSPE increases the size of the DSPE molecule. Hence, resultant 
increase in the average size was ascribed to the mechanism and strength of intercalation 
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of phospholipid chains during formation of the double membrane of the NLS. The 
presence of PEG conjugated to DSPE facilitated stronger binding and closer association 
of the phospholipid tails, thereby resulting in NLS of smaller average sizes. Moreover, the 
lateral stabilizing effect provided by DSPE resulted in reduced average sizes of NLS with 
increasing DSPE concentration. Analogous to the relationship observed in CHO-NLS, 
there appeared to be an inverse relationship between DOS concentration and the 
resultant average size of DSPE-NLS. Reduction in average size of NLS as a function of 
increasing DOS concentration was determined to be a consequence of the stabilization 
effect of the surfactant on the NLS as well as decreased surface tension in the emulsion 
that precedes NLS formation. 
 
The zeta potential of DSPE-NLS was favorably influenced by increasing DOS 
concentration. Since DSPC and DSPE are neutral phospholipids, the marginally negative 
zeta potential was attributed to the anionic surfactant. The contour plot in Figure 4.13B 
illustrates the predominant influence of DOS concentration on zeta potential relative to 
that of varying phospholipid ratio. Formulations at the 0 level of the experimental design 
exhibited the most unfavorable, almost neutral, zeta potential.  
 
The phospholipid constitution of DSPE-NLS, when considered alone, appeared to have 
minimal effect on the MDT of CPT. However, the formulation (B6) comprising of the 
highest concentration of DSPE and DOS produced the longest MDT. Whilst increasing 
DOS concentration evidently resulted in longer MDT of CPT, the MDT resulting from 
formulation B6 could not be entirely attributed to the DOS concentration.  Higher DSPE 
concentration involves a higher concentration of PEG that is attached to DSPE. PEG has 
a substantial stabilizing effect on liposomes and appears to retard and control drug 
release from the DSPE-NLS. Hence, the longest MDT achieved was a cumulative effect of 
high DSPE-m-PEG concentration as well as increasing DOS concentration. A noteworthy 
observation was the trend of increased MDT of formulations with higher DIE. Overall, the 
MDT of DSPE-NLS was significantly shorter than that of CHO-NLS.     
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Figure 4.13 Graphical illustration employing 3-D response surface graphs (A and C) and a contour 
plot (B) to depict the influence of independent variables on the average size, zeta potential and 
MDT of DSPE-NLS. 
 
Accurate and in-depth analysis of the relationship between independent variables and 
their influence on measured outcomes facilitated the derivation of regression equations 
4.5-4.8. These equations enable accurate determination of the average size, zeta 
potential, DIE and MDT that will result from variation of either or both of the independent 
variables and are thus crucial to determining the constitution of the optimal formulation 
with respect to the desired objective of each measured outcome.    
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Average size = 45.51 + (-17.71)(X1) + 6.95(X2) + 16.66(X1)2 + (-0.11)(X2)2 + (-1.86)(X1)(X2) 
          (Equation 4.5) 
Zeta potential = (-4.71) + 9.87(X1) + (-0.79)(X2) + (-2.59)(X1)2 + 0.01(X2)2 + 0.01(X1)(X2) 
          (Equation 4.6) 
DIE = 18.28 + (-3.09)(X1) + 1.41(X2) + 4.01(X1)2 + 0.03(X2)2 + (-0.83)(X1)(X2) 
          (Equation 4.7) 
MDT = 4.07 + 5.83(X1) + (-0.14)(X2) + (-1.04)(X1)2 + 0.02(X2)2 + (-0.14)(X1)(X2) 
          (Equation 4.8) 
where X1 = DSPC:DSPE, and X2 = [DOS] 
 
4.5.2.2.3 Analysis of the fit of the derived model 
Analysis of the fit of the model derived for DSPE-NLS was undertaken through evaluation 
of four residual plots for each outcome, presented in Figure 4.14. Each residual plot 
illustrates different characteristics of the model, thereby collectively allowing a 
comprehensive assessment of the model.  
 
The data points of each of the normal probability plots are closely associated with the 
straight line, indicating normal distribution of the residuals. No observable pattern was 
noted on the plots of residuals versus fitted values, thereby verifying the assumption of 
constant variance. The histograms of residuals for each of the measured outcomes 
produced plots that were bell-shaped or almost bell-shaped, which further corroborated 
the favorable distribution and constant variance of data points. Finally, the plot of residuals 
versus order of the data was employed to determine the presence of other variables that 
had not been assessed as well as to identify errors that were non-random. These plots 
displayed no clustering of data points and the alternating of positive and negative data 
points was suggestive of negative correlation. Analysis of the residual plots intimated a 
well fit model was generated for DSPE-NLS.   
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Figure 4.14 Summary of the Residual Plots generated for the measured outcomes of DSPE-NLS.
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The application of ANOVA of the data obtained for DSPE-NLS highlighted the definitive 
and statistically significant effect of DOS concentration on the average size of formulated 
NLS (p=0.039). Phospholipid ratio proved significant on the resultant zeta potential, whilst 
DOS concentration can be considered to have also had a significant influence on 
measured zeta potential. Statistically neither phospholipid ratio nor DOS concentration 
was deemed to impact significantly on DIE or MDT.  
 
Table 4.10 Summary of the p-values for each of the independent variables relative to the 
measured outcomes. 
Measured Response DSPC:DSPE [DOS] 
Average Size 0.540 0.039 
Zeta Potential 0.031 0.066 
DIE 0.905 0.590 
MDT 0.318 0.800 
 
4.5.2.2.4 Constrained optimization of the DSPE nano-liposomal drug delivery 
system 
The interplay of independent variables on measured responses was optimized employing 
Minitab®, V15 software (Minitab® Incorporated, PA, USA). Ultimately, a formulation 
constituting of 0.13%w/v DSPC, 0.27%w/v DSPE and 0.3%w/v DOS was determined to 
provide the optimal measured responses, as illustrated in Fig 4.15. The desirability for 
each measured response exceeded 0.9, with an exceptional overall desirability of the 
formulation=0.979. The predicted average size and MDT of this optimized DSPE-NLS 
formulation was particularly appealing. Whilst the predicted zeta potential is not indicative 
of a pharmaceutically acceptable stability profile, post-optimization modifications may 
simply and adequately address this drawback.      
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Figure 4.15 Optimization plots for DSPE-NLS, indicating optimal levels of independent variables, 
the predicted outcomes based on these independent variables and the desirability of the predicted 
outcomes.  
 
4.6 Concluding Remarks 
This chapter provided a systematic and in-depth exploration of the process of statistical 
optimization by experimental design. The experimental design of each NLS formulation 
was delineated so as to simultaneously maximize the data obtained and minimize the 
formulations required to obtain this data. The influence of independent variables and the 
intensity of this influence on the measured outcomes proved different for each of the two 
experimental designs. RSM facilitated the comprehensive assessment of the relationships 
between independent variables and measured responses. Mathematical modeling 
enabled the generation of regression equations that can be employed to accurately 
predict measured outcomes as a function of varying independent variable input.  
 
The independent variables determined to produce the optimal responses for CHO-NLS 
were lipid ratio DSPC:CHO=3:1 and a DOS concentration=0.3%w/v. The desirability of 
each of the measured responses predicted for this candidate formulation ranged between 
0.7 and 1.0, with a composite desirability for the formulation exceeding 0.91. For DSPE-
NLS a phospholipid ratio DSPC:DSPE=1.33:2.67 and DOS concentration of 0.3%w/v was 
determined to produce the most desirable measured responses. The measured 
responses predicted for this candidate formulation had desirability’s ranging between 0.94 
and 1, with an overall desirability=0.98. The outstanding composite desirability predicted 
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for each of the candidate formulations validates the choice and range of independent 
variables investigated and bodes well for the achievement of formulations that bear 
clinically relevant characteristics, through the achievement of stable formulations in the 
nanoscale range for passively targeted drug delivery to tumour sites.       
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CHAPTER 5 
MODIFICATION AND PERFORMANCE EVALUATION OF THE OPTIMIZED NANO-
LIPOBUBBLE DRUG DELIVERY SYSTEM 
 
5.1 Introduction 
Statistical optimization, as outlined in Chapter 4, culminated in the delineation of the 
optimal compositions for the formulation of cholesterol-containing nano-liposomes (CHO-
NLS) and distearoylphosphatidylethanolamine-containing nano-liposomes (DSPE-NLS) as 
well as the predicted measured responses for each of these candidate formulations. 
Physicochemical and physicomechanical characterization of these candidate formulations 
was pivotal in assessing the viability of the formulation and, ultimately, whether the aim of 
the study was achieved. Moreover, the aim of this study was the formulation of 
antineoplastic-loaded nano-lipobubbles (NLB) for intravenous administration. Hence, 
conversion of NLS to NLB and characterization thereof will be the focal point of this 
chapter.  
 
Further modifications were undertaken on candidate NLB formulations in an attempt to 
augment the antineoplastic activity, physicochemical, and physicomechanical properties 
of the NLB drug delivery system (NLB-DDS). The employment of phytochemicals for 
therapeutic purposes has garnered considerable attention due to a deeper understanding 
of traditional and complementary medicine (D’Incalci et al., 2005; Sun and Liu, 2006; Lee 
et al., 2013). In line with this, the incorporation of a phytochemical with established 
antineoplastic properties was explored. Phytochemicals may exhibit diverse mechanisms 
of antitumour activity such as sensitization of tumour cells to augment the activity of 
conventional antineoplastic drugs, synergistic activity with antineoplastic drugs or may 
even act as preferential substrates to enable the antineoplastic drug to exert its effect at 
the site of action (D’Incalci et al., 2005; Nabekura et al., 2010). However, the achievement 
of adequate systemic bioavailability often presents a challenge when therapeutic 
applications are intended. Hence, the incorporation of phytochemicals into DDS for 
individual or adjuvant therapy to conventional treatment regimens represents a viable 
concept (Aqil et al., 2013). This approach capitalizes on inexpensive, highly tolerable 
products that may enhance the efficacy of antineoplastic drugs when used in combination 
(D’Incalci et al., 2005). 
 
One of the fundamental drawbacks of liposomes and lipobubbles is limited life-span in 
vivo (Madrigal-Carballo et al., 2010; Chun et al., 2013). Moreover, drug leakage from 
 99 
 
liposomes during storage compromises drug delivery applications. Layer-by-layer (LBL) 
polymeric coating is a widely adopted approach to enhance the stability profile and tailor 
the drug release characteristics of liposomes (Ciobanu et al., 2007; Madrigal-Carballo et 
al., 2010; Chun et al., 2013). Electrostatic attraction between the charged liposomal 
surface and an oppositely charged polymer underscores the mechanism of sequential 
polymeric layering (Volodkin et al., 2007; Chun et al., 2013). The application of polymeric 
coating can also be employed to facilitate targeted drug release in response to micro-
environmental conditions that characterize the pathophysiology of the condition/site, such 
as changes in pH or temperature.   
 
This chapter delves into the in-depth physicochemical and physicomechanical 
characterization of each of the candidate NLS determined through statistical optimization, 
as well as conversion to NLB and the modifications undertaken thereupon, as illustrated in 
Figure 5.1. Sequential characterization will provide a basis for comparison of changes in 
NLB characteristics resulting from each modification and the contribution of each 
modification to ultimately attaining NLB formulations demonstrating the pre-determined 
characteristics of a clinically viable antineoplastic nano-DDS.  
 
 
Figure 5.3 Schematic summary of the modifications undertaken on candidate NLS formulations 
and the analytical characterization involved. 
 
5.2 Phytochemicals in antineoplastic therapy: Silibinin 
Interest into naturally occurring phytochemicals for tumour therapy have been increasing 
exponentially and investigation into these compounds has intensified over the years due 
to the demonstration of tumour prevention and growth inhibition properties in several 
studies (Gallo et al., 2003; Yang et al., 2003; Hogan et al., 2007; Ramasamy and Agarwal, 
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2008; Nair et al., 2010). Silibinin (SB) is a naturally occurring polyphenol antioxidant 
extracted from the crude seed extract of the plant milk thistle (Silybum marianum) (Bhatia 
et al., 1999; Gallo et al., 2003; Hogan et al., 2007; Cao et al., 2012). The mechanism of 
anti-tumour effect of SB has been attributed to factors such as the promotion of cellular 
antioxidant defense mechanisms, angiogenesis antagonism by a reduction in VEGF 
secretion, induction of apoptosis, and antiproliferative effects due to cell cycle arrest 
(Bhatia et al., 1999; Yang et al., 2003; Hogan et al., 2007; Ramasamy and Agarwal, 
2008). Different mechanisms of activity and combinations of the aforementioned 
mechanisms appear to predominate in different tumour models, attributing anti-tumour 
potential against a wide range of tumours such as colon, breast, prostate, ovarian, lung, 
bladder, cervical, and hepatocellular carcinomas (Ramasamy and Agarwal, 2008).  
 
Initially marketed widely for its hepatoprotective properties, the naturally occurring 
flavanoid SB has a remarkable safety profile, being well tolerated at considerably high 
doses following different routes of administration (Gallo et al., 2003). However, absolute 
oral bioavailability of SB is poor due to gastric degradation, metabolism by phase II 
conjugation, and limited aqueous solubility (0.43mg/mL) - leading to a slow absorption 
rate (Wu et al., 2009; Parveen et al., 2011; Cao et al., 2012). Classification as a Class II 
drug according to the Biopharmaceutical Classification System highlights a high degree of 
permeability of SB, despite the poor aqueous solubility. Hence incorporation into DDS that 
have the capacity to improve the aqueous solubility of SB could prove highly beneficial to 
the clinical utility of this flavonolignan. Furthermore, complexation of SB to 
phosphatidylcholine, creating silipide, has proven a successful means of improving the 
solubility and bioavailability of SB (Wu et al., 2009). This further rationalizes the 
incorporation of SB into phospholipid-based nanosystems.   
 
5.3 Materials and Methods 
5.3.1 Materials 
Materials employed during NLB formulation and the analyses that ensued were 
unchanged from those outlined in Chapter 4, Section 4.4.1. In addition, the phytochemical 
silibinin (≥98% purity; Mw=482.44), sulphur hexafluoride gas (Mw=146.06), gelatin 
(~Mw=20000-25000), poly-L-lysine (PLL) (~Mw=30000-70000), polyethyleneimine (PEI) 
(50%w/v in H2O; Mw=750000), commercial grade carrageenan (Mw=~200000), poly(acrylic 
acid) (PAA) (Mw=1800), sodium alginate (Mw=216), lactose (Mw=360.32), fructose 
(Mw=180.16), fluorescein isothiocyanate (FITC) (≥90% purity; Mw=389.38) and foetal 
bovine serum (FBS) were acquired from Sigma Chemical Company (St Louis, MO, USA). 
Chitosan (CHT) (food grade) was obtained from Wellable Group Marine Biological & 
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Chemical Co., Ltd. (Shishi City, Fujian, China) and pectin (LM-105-AS) was obtained from 
CP Kelco (Lille Skensved, Denmark). 
 
5.3.2 Methods 
5.3.2.1 Preparation of candidate CHO nano-liposomes and DSPE nano-liposomes 
DSPC, DOS and either CHO or DSPE (concentrations as per Table 5.1) were 
simultaneously dissolved in a chlororform:methanol (9:1; 10mL) solvent system under 
continuous stirring at 400rpm for 5 minutes, employing a magnetic stirrer. Camptothecin 
(CPT) (0.05%w/v) was added to the organic solution under continuous agitation. 
Phosphate buffered saline (PBS) (pH 7.4, 25°C; 10mL) was subsequently added to the 
organic solution under ultra-sonication (amplitude = 80%; 90 seconds), over an ice-bath, 
employing a Vibracell probe ultrasonicator (Sonics & Materials Inc., Newtown, 
Connecticut, USA). This culminated in the formation of a homogenous, single-phase 
emulsion. This emulsion was subsequently subjected to evaporation under vacuum (60-
65°C) for 2-3 hours, employing a Multivapor™ (Buchi Labortechnik AG, Switzerland). PBS 
(pH 7.4, 25°C; 10mL) was added periodically during the evaporation process and the 
formulation was subjected to ultra-sonication as previously outlined for 30 seconds, after 
each addition. Complete evaporation of the solvent resulted in an aqueous NLS 
suspension. The resultant NLS suspension was subjected to three cycles of freezing at -
70°C and thawing at 37°C, to convert multilamellar NLS to unilamellar NLS with filtration 
through a 0.22µm millipore filter after each freeze-thaw cycle. All ensuing modifications 
and analyses were conducted in triplicate (n=3) on these unilamellar NLS.   
 
Table 5.1 Composition of the candidate NLS systems obtained by statistical optimization. 
Materials CHO-NLS (%w/v) DSPE-NLS (%w/v) 
DSPC 0.3 0.133 
DSPE - 0.267 
CHO 0.1 - 
DOS 0.3 0.3 
 
5.3.2.2 Conversion of formulated nano-liposomes to nano-lipobubbles: Effect of 
sonication duration 
Based on previously reported methods for conversion of NLS to NLB, NLS suspensions 
(10mL) prepared as described in Section 5.3.2.1 above were filtered and injected into 
20mL vials. SF6 gas was introduced into the headspace of the vials, which were 
subsequently sealed. Sonication of the vials was undertaken in a bath type sonicator 
causing the SF6 gas to penetrate the lipid membrane of the NLS, and form a gaseous 
core, thereby creating NLB (du Toit et al., 2011).  
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Sonication was undertaken for 2, 3 and 5 minutes to determine the effect of sonication 
duration on the ultimate size and stability of the NLB. The variation in size and zeta 
potential was insignificant after sonication for 2 and 3 minutes. However, following 
sonication for 5 minutes, the PdI was unfavorably higher due to the formation of a small 
proportion (<5%) of NLB below 25nm. The zeta potential of the NLB sonicated for 5 
minutes exhibited an unfavorable deficit of ~10mV for CHO-NLB and ~4mV for DSPE-
NLB. Hence, sonication duration of 3 minutes was delineated for all further formulations.  
 
5.3.2.3 Investigating the effect of lyophilization on nano-lipobubble size and stability 
To determine the effect of lyophilization on the stability of formulated NLB, the average 
size, size distribution and zeta potential of formulated NLB prepared pre- and post-
lyophilization with and without a lyoprotectant was determined. CHO-NLS and DSPE-NLS 
were formulated as outlined in Section 5.3.2.1 and converted to NLB as outlined in 
Section 5.3.2.2. The formulated NLB were subjected to size, size distribution and zeta 
potential analysis in triplicate as described in Chapter 3, Section 3.3.2.6 and Chapter 4, 
Section 4.4.2.2, respectively, over a 3 hour period whilst being maintained at 37°C in an 
orbital shaker bath rotating at 25rpm. 
 
Simultaneously, unmodified NLS suspensions (15mL), as well as NLS suspensions 
containing lactose or fructose (~0.05%w/v) as lyoprotectants were frozen at -70°C for 48 
hours. The samples were subsequently lyophilized (Labconco, Kansas City, MO, USA) 
and the products were re-suspended in PBS (pH 7.4; 25°C; 10mL) to a concentration of 
0.5%w/v. The resultant NLS suspensions were subjected to three freeze-thaw cycles with 
filtration through 0.22µm millipore filters undertaken after each cycle. Conversion of NLS 
to NLB was undertaken according to the methodology outlined in Section 5.3.2.2. Average 
size, size distribution and zeta potential analysis ensued over a 3 hour period, whilst the 
NLB suspensions were maintained at 37°C in an orbital shaker bath rotating at 25rpm.  
 
5.3.2.4 Assessment of lyoprotectant efficacy through water content determination 
Determination of water content was undertaken by volumetric Karl Fischer (KF) titration on 
the lyophilized powder (10mg) of plain, fructose-containing and lactose-containing 
formulations employing a Karl Fischer titrator (Mettler Toledo, Columbus, Ohio, USA). 
Volumetric KF titration involves the solubilization of a sample in a KF standard titrant 
solution containing alcohol, a base, SO2 and a known concentration of I2. The reaction 
proceeds as illustrated in Equation 5.1. Water quantification is based on the oxidation of 
SO2 by I2. One mole of I2 is consumed for each mole of H2O present.  
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B·I2 + B·SO2 + B + H2O → 2BH+I− + BSO3  
BSO3 + ROH → BH+ROSO3−    (Equation 5.1) 
 
5.3.2.5 Generation of standard curves for the photospectroscopic quantification of 
silibinin 
Due to the poor aqueous solubility of SB, serial dilutions of SB were prepared in 
DMSO:PBS (pH 7.4; 37°C and pH 6.0; 37°C) (1:1) analogous to those prepared in 
Chapter 3, Section 3.3.2.4 from a stock solution of SB in DMSO (0.002%w/v). Following a 
UV scan to determine the optimum wavelength for SB detection, vortexed aliquots of the 
abovementioned serial dilutions were analyzed at 334nm for pH 7.4 and 290nm for pH 
6.0, employing a Cecil CE 3021 photospectrometer (Cecil Instruments Ltd., Milton, 
Cambridge, UK). Analyses were undertaken in triplicate on 2 consecutive days to confirm 
reproducibility of results. 
  
5.3.2.6 Determining the efficacy of phytochemical incorporation  
The addition of SB to NLB preparations initially involved the addition of 15-200mg SB 
dissolved in acetone (5mL) during the emulsification process. The ensuing methodology 
remained unchanged from that outlined in Section 5.3.2.1. The effect of SB incorporation 
on the size profile and surface charge of formulated NLB was initially investigated as 
outlined in Chapter 3, Section 3.3.2.6 and Chapter 4, Section 4.4.2.2, respectively. The 
efficiency of SB incorporation following the addition of the aforementioned range of SB 
quantities, as well as the effect of SB incorporation on the incorporation efficiency of CPT 
was subsequently determined.   
 
Quantification of SB incorporated into the NLB followed the principles of CPT 
quantification as outlined in Chapter 3, Section 3.3.2.5, due to the poor aqueous solubility 
of SB.  Following double filtration through 0.22µm filters to remove unincorporated SB, 
NLB suspensions were ultra-sonicated to disrupt the structural integrity of the NLB. DMSO 
was added to the suspensions, creating a 1:1 dilution, to solubilize the SB. SB 
incorporation efficiency was determined in triplicate by UV photospectroscopy, against a 
constructed standard reference curve of SB in DMSO:PBS (pH 7.4; 37°C) (1:1). 
 
5.3.2.7 Evaluating polymeric coating by layer-by-layer self-deposition 
LBL polymeric coating is based on the principle of electrostatic attraction between 
oppositely charged molecules, resulting in the alternate deposition of polymers onto 
charged surfaces. Candidate NLS exhibited an overall anionic surface charge, with CHO-
NLS possessing a more strongly negative zeta potential, which facilitated the 
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establishment of a polycationic primary polymeric layer, followed by the alternate 
deposition of polyanionic and polycationic polymeric layers.  
 
Summarily, unilamellar NLS suspension as prepared in Section 5.3.2.1 were added drop-
wise to a cationic polymer solution under constant agitation employing a magnetic stirrer. 
Coating was allowed for periods of 3-12 hours under ambient condition, with zeta potential 
analysis, as described in Chapter 4, Section 4.4.2.2, undertaken at regular intervals to 
determine successful polymer coating. The cationic NLS suspension was subsequently 
added drop-wise to an anionic polymeric solution under constant stirring and adsorption of 
the polymer was allowed under ambient conditions for periods of 6-18 hours, with periodic 
zeta potential analysis. Two or four polymeric layers were applied. Lactose, a 
lyoprotectant, was added to the polymer coated-NLS suspension and the suspension was 
frozen at -70°C for 48 hours, followed by lyophilization. The lyophilized powder was re-
suspended in PBS (pH 7.4; 25°C) to form polymer coated NLS, and converted to polymer 
coated NLB as outlined in Section 5.3.2.3. Table 5.2 summarizes the polymers and 
concentrations thereof investigated as suitable NLS coating materials. 
 
Table 5.2 Cationic and anionic polymers investigated for application in NLS coating by the LBL self 
deposition methodology. 
Cationic Polymers Concentration (%w/v) 
Gelatin 0.5 – 2 
PEI 1 – 3 
PLL 0.5 – 3 
CHT 0.1 – 1.0 
Anionic Polymers: Concentration (%w/v)* 
Carrageenan 0.2 - 0.4 
Pectin 0.5 – 1 
Sodium alginate 0.5 – 2 
PAA 0.5 – 2.0 
 
5.3.2.8 Determining chemical structural transitions resulting from polymeric coating 
of nano-liposomes 
Fourier Transform Infra-Red (FTIR) spectrophotometric analysis was employed to assess 
the changes in chemical structure of the CHO- and DSPE-NLS following polymeric 
coating with CHT and PAA. Lyophilized samples of uncoated CHO- and DSPE-NLS, 
optimized CHO- and DSPE-NLS, native CHT and native PAA, were analyzed under 
ambient conditions employing a Perkin Elmer Spectrum BXII FTIR spectrometer (Perkin 
Elmer Life and Analytical Sciences Inc., Shelton, CT, USA). The FTIR spectrum of each 
sample was recorded at a wavelength range of 650-4000cm-1 with a resolution of 2cm-1. 
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Changes in vibrational frequencies were used to confirm the successful adsorption of CHT 
and PAA onto the NLS surface.  
 
5.3.2.9 Elucidating the size characteristics of formulated nano-liposomes and nano-
lipobubbles 
The nano-scale size range is central to the clinical relevance and feasibility of the 
intended DDS. Variation in average size and size distribution were also highlighted as key 
indicators of formulation stability. Hence, all modifications investigated were initially 
assessed from the standpoint of the effect the modification had on the resultant size 
profile of the formulation. Average size and size distribution was examined as discussed 
in Chapter 3, Section 3.3.2.6. During initial investigations to assess the effect of each 
modification on the size profile on the formulation, analysis was undertaken over a 3 hour 
period whilst the NLB was maintained at physiological temperature in an orbital shaker 
bath rotating at 25rpm. Table 5.3 succinctly summarizes the modifications investigated for 
their effect on the average size and size distribution characteristics of the NLS and NLB. 
 
Table 5.3 Summary of average size and size distribution assessments undertaken on candidate 
NLS and NLB formulations and the modifications that ensued. 
 
 
 
 
 
 
 
 
 
5.3.2.10 Surface charge characterization of formulated nano-liposomes and 
nano-lipobubbles 
As denoted under the discussion regarding the emphasis on size characteristics, surface 
charge characteristics are of equal essence in this study due to the intravenous nature of 
the formulated DDS and the severe implications of NLB aggregation in vivo. In addition, 
the high cost of antineoplastic drugs warrant the need for a stable formulation with 
lengthened shelf-life. Consequently zeta potential determination was undertaken in 
conjunction with size analysis as described in Chapter 4, Section 4.4.2.2. In addition 
variation in zeta potential was a distinct indicator of successful polymeric coating with 
oppositely charged polymers.   
 
Modifications Assessed by Average Size and Size 
Distribution Analyses 
• Candidate NLS from experimental design 
• Impact of gas incorporation to create NLB 
• Effect of sonication time 
• Influence of lyophilization (with and without 
lyoprotectants) 
• Effect of phytochemical incorporation 
• Bearing of polymeric coating 
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5.3.2.11 Morphological characterization of formulated nano-lipobubbles 
Scanning electron microscopy (SEM) was undertaken on the lyophilized products 
following polymeric coating, employing a Phenom™ scanning electron microscope (FEI 
Company, Hillsboro, OR, USA) to qualitatively assess the resulting morphological 
structures of lyophilized products. Samples were fixed as a monolayer to a sampling stub 
and coated with gold-palladium for 30 seconds before photomicrographs were acquired.    
 
Furthermore, lyophilized powders of formulated NLS were reconstituted with PBS (pH 7.4; 
25°C) in the presence of FITC dye and subsequently converted to NLB, as outlined in 
Section 5.3.2.3. The NLB suspension was allowed to dry onto a cover-slip covered with a 
slide for 1 hour, followed by imaging employing an inverted immunofluorescence 
microscope (Olympus IX71, Olympus, Tokyo, Japan) after 100mS exposure. 
 
5.3.2.12 Investigating the efficiency of camptothecin incorporation 
Determination of the efficiency of CPT incorporation was undertaken on candidate NLS for 
comparison to predicted values, on formulated NLB, following SB incorporation and the 
application of polymer coating to NLB. Drug incorporation efficiency (DIE) of CPT was 
undertaken as described in Chapter 3, Section 3.3.2.5.   
 
5.3.2.13 Generation of a standard curve for the photospectroscopic 
quantification of camptothecin 
In addition to physiological pH, drug release was also undertaken at approximate tumoural 
pH (6.0; 37°C) to determine the effect of lower pH on CPT release characteristics. The 
analysis of CPT release characteristics at approximate tumoural pH (6.0) necessitated the 
construction of a standard curve of CPT in PBS (pH 6.0; 37°C) to enable 
photospectroscopic quantification of CPT. Preparation of a stock solution of CPT in DMSO 
and subsequent serial dilutions were undertaken analogous to the method outlined in 
Chapter 3, Section 3.3.2.4. Following a wavescan to delineate the optimal wavelength for 
CPT determination at pH 6.0, the aforementioned serial dilutions were analyzed at 345nm. 
 
5.3.2.14 Elucidation of camptothecin and silibinin release characteristics 
Drug release investigations were undertaken analogous to that outlined in Chapter 4, 
Section 4.4.2.4, at approximate tumoural and physiological pH, following reconstitution of 
lyophilized powder and conversion to NLB as explicated in Section 5.3.2.3. Quantification 
of drug release was undertaken with reference to the relevant standard curves for CPT 
and SB. Adjustment of the concentration and volume of NLB suspension was undertaken 
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in order to accommodate for the inclusion of SB and maintain sink conditions for both 
compounds.   
 
5.3.2.15 Delineation of the stability characteristics of optimized nano-
lipobubbles  
The clinical feasibility and usefulness of formulations is influenced in large part by the 
stability of formulations under various conditions. Whilst surface charge was denoted as 
the initial indicator of formulation stability, other conditions that have the potential to affect 
or be affected by stability of the formulation required further consideration. Hence, stability 
of formulations was determined through exposure to serum, behavioral changes following 
reconstitution and long term storage stability.      
  
5.3.2.15.1 Determining stability of nano-lipobubbles in the presence of serum 
For intravenously administered formulations, establishment of the characteristics of the 
formulation in the presence of serum is a vital determination. Coated and uncoated CHO- 
and DSPE-NLB (10mL) were incubated at 37°C for 1 hour with FBS (50%v/v), which is 
regarded as an appropriate concentration to adequately mimic physiologic conditions. At 
15 minute intervals, 100µL of the NLB-FBS combination was diluted with 10mL PBS (pH 
7.4, 37°C) and average size, size distribution and surface charge characterization ensued, 
employing a Zetasizer NanoZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK), 
as previously outlined in Chapter 3, Section 3.3.2.6 and Chapter 4, Section 4.4.2.2, 
respectively. 
 
5.3.2.15.2 Assessing stability of the formulation after reconstitution 
Assessing the stability of NLB suspensions post-reconstitution is critical to delineate pre-
administration storage conditions and the provision period that can be allowed between 
reconstitution of the formulation and administration to the patient. A Turbiscan™ LAB 
(Formulaction, L’Union, France) was employed to qualitatively analyze the behavioral 
characteristics of formulated NLB suspensions. The relevant NLB suspensions (20mL) 
were introduced into specialized vials and analyzed at pre-determined intervals over a 12 
hour period at 25°C.  
The Turbiscan™ LAB consists of a pulsed near infra-red light source which moves 
vertically along the sample acquiring data every 40µm, as well as 2 detectors. The 
transmission detector, positioned at 180°, detects light that is transmitted through the 
sample, whilst the backscattering detector, positioned at 45°, detects the light that is 
rebounded by the sample. Data obtained by the Turbiscan™ LAB is based on multiple 
light scattering whereby the photons are repeatedly scattered by the suspended material 
 108 
 
before detection. The Turbiscan™ LAB is very sensitive to detect changes in the 
formulation such as creaming, sedimentation, flocculation and changes in particle size 
which may be indicative of coalescence. Backscatter data was employed in the analysis of 
formulation stability in this study. The intensity of the light that is detected by the 
backscattering detector is influenced by: 
 
• The diameter of the suspended particulate matter. 
• The volume fraction of particles. 
• The respective refractive indices of the suspended and continuous phases.  
 
5.3.2.15.3 Determining the effect of long-term storage on physicochemical 
characteristics of formulated nano-lipobubbles  
The long-term stability of formulated NLB was determined as a function of change in 
average size, zeta potential, CPT content, and SB content over the analysis period of 3 
months. Lyophilized NLS were sealed in transparent vials with SF6 gas filled into the 
headspace and stored at 4°C and 25°C. At weekly intervals PBS was introduced into the 
vials and sonication in a bath-type sonicator was undertaken to form NLB, as outlined in 
Section 5.3.2.2. Drug content, zeta sizing, and zeta potential determinations were 
undertaken as outlined in Chapter 3, Sections 3.3.2.5, 3.3.2.6 and Chapter 4, Section 
4.4.2.2, respectively.  
 
5.4 Results and Discussion 
5.4.1 Size and surface charge characterization of candidate formulations  
The average size of CHO-NLS was 2.41% larger than predicted by statistical optimization 
which, given the nano-scale of the formulation, is quite satisfactory. In addition, the 
average size obtained was still adequately below the benchmark size of 160nm that was 
initially delineated for favorable passive targeting to tumour tissue, as indicated in Figure 
5.2A. The PDI (result not shown) was 0.151, indicating the narrow size distribution of NLS 
within the formulation. Conversion of NLS to NLB resulted in a slight decrease in average 
size, illustrated in the size profile in Figure 5.2B. This may be attributed to replacement of 
the aqueous core with a gaseous core which occupied a smaller volume. In addition, 
ultrasonication employed in creating the gaseous core may have caused a reduction in 
the average size of the CHO-NLB. 
 
The zeta potential obtained experimentally for the candidate CHO-NLS formulation was 
9.26% less negative than that predicted for this formulation by statistical optimization. 
There was a further unfavorable decrease in surface charge following conversion of the 
CHO-NLS to CHO-NLB. This may be attributed to slight destabilization of the lipid 
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membrane during the conversion process. However, the zeta potential of formulated 
CHO-NLB remained highly favorable, designating a stable formulation that is not inclined 
to aggregation.   
 
The average size and zeta potential of candidate NLS, as well as the average size and 
zeta potential following conversion of these NLS to NLB is outlined in Table 5.4. In 
addition, a comparison to the measured responses predicted by statistical optimization for 
each of the candidate NLS is highlighted through the percentage deviation value.  
 
Table 5.4 Experimentally determined average size and zeta potential of candidate CHO- and 
DSPE-NLS and NLB, as well as the percentage deviation from the values predicted for NLS by 
computational modelling. 
Formulation Average Size (d.nm) % Deviation Zeta Potential (mV) % Deviation 
CHO-NLS 132.4 2.41 -37.9 9.26 
CHO-NLB 125.6 - -28.1 - 
DSPE-NLS 83.41 2.18 -7.74 1.18 
DSPE-NLB 84.20 - -7.44 - 
 
The average size of candidate DSPE-NLS was 2.18% smaller than predicted for this 
formulation by statistical optimization, as illustrated in Figure 5.2C. Conversion to DSPE-
NLB demonstrated an insignificant increase in the average size of the formulation, 
depicted in Figure 5.2D. The exceptional size characteristics of DSPE-NLB greatly favors 
passive targeting of the DDS to tumour tissue by the Enhanced Permeability and 
Retention (EPR) effect and, hence, may tremendously improve the safety and efficacy of 
CPT delivered by this DDS in vivo.   
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Figure 5.4 Size-Intensity profiles of A) candidate CHO-NLS, B) CHO-NLB, C) candidate DSPE-
NLS and D) DSPE-NLB (in all cases n=3 and SD<0.02).   
 
The zeta potential achieved experimentally for the candidate DSPE-NLS was very closely 
correlated with the zeta potential predicted for this DDS by statistical optimization, 
deviating by only 1.19%. Conversion of the DSPE-NLS to DSPE-NLB resulted in a 
marginal decrease in surface charge, analogous to that observed for CHO-NLB. Despite 
the stabilizing effect of PEG in the formulation, the zeta potential of DSPE-NLS was not 
adequately negative to be pharmaceutically acceptable. Hence, manipulation of DSPE-
NLB to enhance the surface charge and the stability of the formulation was considered 
critical. 
 
5.4.2 Determination of the effect of lyophilization on formulated nano-lipobubbles  
The clinical merits of NLS, precursors to the formation of NLB, has been widely described 
and further validated by the NLS formulations that have gained the approval of regulatory 
bodies for clinical use (Chen et al., 2010 (b); Chaudhury et al., 2012). However, long term 
storage stability has presented a constant challenge, leading to a growing interest in 
stabilization mechanisms for liposome storage (Chaudhury et al., 2012). This 
consideration was also relevant in the present study, whereby the storage form of the 
proposed DDS was envisaged to be NLS in the presence of SF6, which would form the 
gaseous core upon conversion to NLB. Hence, lyophilization was investigated as a means 
of creating a formulation that demonstrates long-term storage viability.  
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The effect of lyophilization on the formulated CHO- and DSPE-NLB was determined as a 
function of changes in the average size, zeta potential, and DIE of formulations pre- and 
post-lyophilization and in the absence and presence of a lyoprotectant. Under all 
conditions, lyophilization appeared to have a destabilizing effect on formulated CHO-NLB. 
This was more distinctly evident in the resultant zeta potential of formulations following 
lyophilization, which was markedly less favorable, as highlighted in Table 5.5. The 
decrease in surface charge allowed aggregation and coalescence of the NLB, which was 
evident in the fluctuating average size over the analysis period. Moreover, the ~9% 
decrease in DIE observed with CHO-NLB post-lyophilization attested to the instability of 
the formulation. The structural integrity of the lipid membrane was compromised during 
the freezing and lyophilization processes, as outlined in Figure 5.3, leading to reduced 
incorporation of the lipophilic drug molecule into the NLB-DDS. The addition of suitable 
lyoprotectants had an immensely favorable effect on the average size of CHO-NLB 
determined post-lyophilization. The zeta potential of lyophilized and reconstituted products 
was comparable to that of pre-lyophilized formulations. The presence of lactose enhanced 
the DIE of CHO-NLB, demonstrating an insignificant (<2%) decrease relative to that of the 
DIE achieved prior to lyophilization.  
 
Table 5.5 Tabulation of the physical characteristics of CHO- and DSPE-NLB formulations 
highlighting the effect of lyophilization and lyoprotectant incorporation on the resultant NLB 
properties.  
 Average Size (d.nm) Zeta Potential (mV) DIE (%) 
Pre-lyophilization 
CHO-NLB 125.60 -28.10 80.10 
DSPE-NLB 84.20 -7.44 59.21 
Post-lyophilization (no lyoprotectant) 
CHO-NLB 278.21 -22.70 71.31 
DSPE-NLB 91.62 -7.32 57.17 
Post-lyophilization (with lactose) 
CHO-NLB 129.40 -27.90 78.65 
DSPE-NLB 85.17 -8.20 57.20 
 
By contrast, the effect of lyophilization on DSPE-NLB was distinctly less unfavorable 
relative to that on CHO-NLB, even in the absence of a lyoprotectant. The presence of the 
PEG molecule conjugated to DSPE was credited for the stability of this formulation to 
lyophilization. PEG exhibits cryoprotectant as well as lyoprotectant properties, which 
facilitated stability of the formulation under freezing and lyophilization conditions. The 
addition of a lyoprotectant demonstrated comparable size and a marginal improvement in 
the resultant surface charge characteristics of DSPE-formulations.   
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The water replacement hypothesis suggests the mechanism of lyoprotection of sugars 
involves interactions between sugars and the head groups of phospholipids, resulting in 
maintenance of the spacing of the phospholipid head groups (Chen et al., 2010 (b)). 
Moreover, the sugars also act to reduce the van der Waals forces between the acyl chains 
of phospholipids, collectively maintaining the structural integrity if the lipid bi-layer 
membrane. Figure 5.3 schematically illustrates the underpinnings of the water 
replacement hypothesis. Briefly, Figure 5.3A represents the aqueous NLS suspension. 
Freezing and lyophilization in the absence of a lyoprotectant sugar would follow the path 
from 5.3A-D. Figures 5.3B and 5.3C illustrate the slight disorganization that will occur with 
the phospholipid bilayers and water molecules during the freezing and drying processes, 
respectively. Reconstitution of the formulation shows a disruption of the structural integrity 
of the lipid bi-layer membrane, the effect of which may be demonstrated through alteration 
of the size distribution and zeta potential of the formulation as well as increased leakage 
of encapsulated drug compound out of the NLS. In comparison, lyophilization employing a 
sugar as a lyoprotectant would follow the pathway from 5.3A directly to 5.3E and 5.3F. 
The lyoprotectant sugar molecules gradually replace the water molecules, thereby 
maintaining the space between the polar head groups of the phospholipids in the lipid bi-
layer, whilst also reducing the interactions between the non-polar chains of the 
phospholipids. Upon reconstitution, the structural integrity of the lipid membrane is 
restored, resulting in maintenance of the pre-lyophilization size and surface charge 
properties of the formulation as well as the drug loading capacity.     
 
 
Figure 5.3 Schematic representation of the mechanism of lyoprotection afforded by sugar 
molecules in the lyophilization of liposomes. (Recreated from Chen et al., 2010 (b)) 
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5.4.3 Determination of lyoprotectant efficacy on formulated nano-liposomes and 
nano-lipobubbles  
As previously explicated, the process of lyophilization is undertaken to enhance the 
storage stability of formulations, particularly with regards to NLS. Thorough removal of 
moisture from the formulation reduces the propensity for hydrolytic degradation and other 
chemical reactions associated with the presence of water. The maximal water content of 
lyophilized products deemed acceptable is 3%w/w (Chaudhury et al., 2012).  
 
In the absence of a lyoprotectant the lyophilized products of CHO-NLS tended to 
aggregate, requiring slight agitation for loosening. In addition, formulations appeared to be 
more hygroscopic, showing greater moisture absorption after 48 hours, as was evidenced 
by the macroscopically observed clumping of the lyophilized powder. Two sugars, fructose 
and lactose, were investigated for their efficiency as lyoprotectants in the formulations. 
The presence of fructose in the formulations resulted in a post-lyophilization product that 
tended to aggregate with a somewhat spongy appearance and texture, particularly in 
CHO-NLS, as illustrated in Figure 5.4. Alteration of the concentration of fructose had no 
significant effect on the texture of the lyophilized product. However, the addition of lactose 
as a lyoprotectant to CHO-NLS resulted in a more freely flowing powder post-
lyophilization. DSPE-NLS showed only very slight aggregation of the lyophilized powder, 
due to the cryoprotectant and lyoprotectant properties of the PEG molecule. Macroscopic 
observation of lyophilized DSPE-NLS containing fructose or lactose as lyoprotectants 
revealed similar, though less pronounced, effects to that observed with CHO-NLS. KF 
titration corroborated these macroscopic findings, with formulations containing fructose 
exhibiting approximately 2-4% higher water content on a 10mg sample size. Lactose-
containing NLS samples displayed acceptable water content (<3%w/w), hence lactose was 
employed as the lyoprotectant in all ensuing formulations.   
 
 
Figure 5.4 Digital images of the post lyophilization products of CHO-NLS A) in the absence of a 
lyoprotectant, B) with fructose and C) with lactose. 
 
A) B) C)
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5.4.4 Generation of a standard curve for the photospectroscopic quantification of 
silibinin 
A wavescan was undertaken between 250-600nm to determine the optimum analytical 
wavelength at which SB is detected at physiologic and tumoural pH. The wavescans 
depicted in Figures 5.5A and B represents the absorption spectra of SB over the 
aforementioned wavelength range at pH 7.4 and pH 6.0, respectively. The optimal 
wavelength for the detection of SB at physiologic pH was deemed to be 334nm. The 
absorption spectrum of SB at pH 6.0 displayed a double peak, however the intensity was 
greatest and the peak sharpest at 290nm. Hence, UV-photospectroscopic analysis of SB 
at pH 6.0 was undertaken at 290nm. 
 
The standard curves generated for the photospectroscopic quantification of SB in 
DMSO:PBS (pH 7.4 and 6.0; 37°C) (1:1) as well as the regression co-efficients and y-
values are depicted in Figures 5.6A and B, respectively. Moreover, the 95% prediction 
and confidence bands are depicted. The standard deviation between absorbance data on 
day 1 and day 2 were <0.025, highlighting the precision of the instrument, accuracy of 
analysis and reproducibility of results. 
 
 
Figure 5.5 Three dimensional absorption spectrum of SB in A) DMSO:PBS (pH 7.4; 37°C) (1:1) 
and B) DMSO:PBS (pH 6.0; 37°C) (1:1). 
 
A) B)
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Figure 5.6 Standard curves of the absorbance of SB in A) DMSO:PBS (pH 7.4; 37°C) (1:1)  and B) 
DMSO:PBS (pH 6.0; 37°C) (1:1), as well as the 95% confidence and prediction bands for the 
respective curves (in all cases n=3 and SD<0.02). 
 
5.4.5 Silibinin incorporation and the effect thereof on the physical characteristics 
of formulated nano-lipobubbles 
The incorporation of SB in the formulated NLB-DDS was undertaken to enhance the 
cytotoxic activity of the formulations and provide a means of effective delivery of this 
poorly soluble phytochemical. However, the maintenance of the nano-scale of the 
formulation was the focal point of the study and could not be compromised by the addition 
of a second antineoplastic compound. Moreover, this modification preceded the intended 
polymeric coating of the NLB. Hence, only size increments up to 20 nm could be 
accommodated for CHO-NLB and that of ~50 nm could be allowed for DSPE-NLB.  
 
The initial incorporation of 100-200mg of SB resulted in large average sizes and erratic 
changes in size over time for CHO-NLB. The size distribution was also very broad with 
PdI>0.6. The size profiles of CHO-NLB obtained following the addition of 15-50mg SB 
were notably more favorable. The disparity in the physical characteristics and DIE of 
CHO-NLB upon the addition of 15mg and 30mg SB was marginal. Increasing the quantity 
of SB to 50mg resulted in ~22 nm increase in average of the CHO-NLB, which in turn 
would not allow for adequate polymeric coating whilst remaining below the 200 nm 
benchmark size. Furthermore, the concurrent decrease in surface charge and efficiency of 
SB incorporation proved unfavorable. The tremendously favorable size profile obtained for 
DSPE-NLB allowed the DDS to remain within a suitable size range following the addition 
of 15-200mg SB. However, the already unfavorable surface charge was further diminished 
as the quantity of SB was increased within the defined range, as was the efficiency of SB 
incorporation. DIE of SB above 50% was identified following the addition of 15mg and 
30mg SB only. The disparity in average size of DSPE-NLB to which 15mg and 30mg SB 
had been added was insignificant, whilst the zeta potential of the formulations was 
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marginally more favorable following the addition of 30mg SB. Hence, 30mg of SB was 
delineated for incorporation into both CHO- and DSPE-NLB. Table 5.6 summarizes the 
resultant average size and zeta potential of CHO- and DSPE-NLB resulting from the 
addition of a range of SB quantities, as well as the respective efficiency of SB 
incorporation.  
 
Table 5.6 Physical characteristics of formulated NLB-DDS and efficiency of SB incorporation 
relative to quantity of SB added to the formulation. 
 CHO-NLB DSPE-NLB 
SB 
Added 
(mg) 
Average 
Size 
(d.nm) 
Zeta 
Potential 
(mV) 
SB 
Incorporation 
(%) 
Average 
Size 
(d.nm) 
Zeta 
Potential 
(mV) 
SB 
Incorporation 
(%) 
15 137.32 -27.26 66.89 91.57 -8.13 54.63 
30 137.56 -27.58 65.59 93.65 -8.24 52.75 
50 159.30 -21.23 61.72 93.09 -7.02 43.03 
100 246.30 -18.70 50.28 99.84 -6.10 36.21 
150 249.73 -18.90 46.77 132.14 -6.46 30.14 
200 267.80 -16.30 43.00 143.10 -6.29 24.28 
 
5.4.6 Investigating the feasibility of polymeric coating of nano-lipobubbles: 
Macroscopic and microscopic evaluation 
The application of successful polymeric coating was assessed through inversion of the 
zeta potential through positive and negative values following the introduction of an 
oppositely charged polymer. Despite the simplicity of achieving successful polymer 
coating by this method, as described in the literature, this proved particularly challenging 
in this study. Coating of CHO- and DSPE-NLS with PLL was discontinued following 
coating with concentrations up to 3%w/v, as well as increasing the volume ratio of polymer 
to NLS suspension. The zeta potentials obtained after coating with PLL for CHO-NLS 
ranged between -7mV and -3.6mV and that obtained for DSPE-NLS ranged between -
2.1mV and +0.003mV following coating for 24 hours. Hence, an adequate cationic surface 
to enable the electrostatic attraction and deposition of an anionic polymer was not 
achieved.   
 
The deposition of gelatin onto the anionic CHO- and DSPE-NLS surfaces appeared to be 
incomplete after 18 hours, as evidence by the lack of a positive zeta potential. The zeta 
potentials acquired were close to neutral, despite varying the concentration of the cationic 
polymer. The indication of instability and lack of a positively charged surface did not augur 
well for the deposition of an anionic polymeric layer by electrostatic attraction.  
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Following coating with the various polymers and combinations of polymers employed, the 
lyophilized products exhibited varied macroscopic appearances, most of which were 
incongruent with the uniform powder that was expected. Coating of NLS with alternating 
layers of PEI and pectin or carrageenan produced a fine network structure (depicted in 
Figure 5.7A), reconstitution of which required prolonged stirring times (~3 hours) at 
elevated temperatures of approximately 40°C. PEI, when used alone and in combination 
with alginate, produced uniformly spongy products with a micro-spindle appearance, as 
displayed in Figure 5.7B. Reconstitution of the sponges also necessitated extended 
stirring periods and was incomplete after continuous agitation for 4 hours at physiologic 
temperature. This is unsuitable to clinical application and will result in release of drug from 
the DDS prior to administration. 
 
Coating with CHT and carrageenan proved unsuccessful with separation into 2 distinct 
layers being observed following the addition of carrageenan. Variation in the concentration 
of each of these polymers did not prove to have an adequately favorable effect. Coating of 
formulated CHO- and DSPE NLS alternately with CHT and pectin produced spongy 
products (highlighted in Figure 5.7C), the reconstitution of which was incomplete after 
stirring for 8 hours at ~37°C.  
 
 
Figure 5.7 Digital images of typical post-lyophilization products of CHO-NLS coated with A) PEI 
and pectin, B) PEI and alginate, C) CHT and pectin, D) CHT and PAA.   
 
A) B)
C) D)
PEI and Alginate
CHT and Pectin CHT and PAA
C) D)
PEI and Pectin
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The sequential layering of CHO- and DSPE-NLS with CHT and PAA proved extremely 
beneficial, displaying adequate inversion of zeta potential following the adsorption of each 
layer, as illustrated in Figure 5.8. This change in zeta potential manifested over a shorter 
period with CHO-NLS. This was attributed to the initially more highly charged nature of the 
formulated NLS, which resulted in swifter and more complete adsorption of the oppositely 
charged polymeric layer. Increasing the concentration of PAA from 0.5%w/v to 2%w/v 
resulted in an overall strongly anionic surface with no significant polymer precipitation in 
the suspension. Similarly, decreasing the concentration of CHT from 0.5%w/v to 0.1%w/v 
facilitated the establishment of the desired overall anionic zeta potential. Lyophilization of 
the NLS following the successful application of four polymeric layers, in the presence of 
lactose, resulted in a somewhat flaky powder (as illustrated in Figure 5.7D), which could 
be rapidly and easily re-dispersed under ambient conditions. Moreover, the average size 
of resultant polymer coated-NLB following reconstitution and the introduction of a gaseous 
core, remained well below 200 nm (CHO-NLB=189.81 nm; DSPE-NLB=141.62 nm), which 
was the benchmark size delineated for the stabilized nanosystem. The resultant surface 
charge of polymer-coated CHO-NLB following the application of four polymeric layers was 
-32.47mV and that of DSPE-NLB was -24.27mV. The institution of polymeric coating had 
a more pronounced favorable effect on the surface charge of DSPE-NLB than on CHO-
NLB. The strongly anionic surface achieved for both formulations had propitious 
consequences on the stability of NLB formulations. Moreover, anionic surfaces have been 
reported to have advantageous implications with regard to haemocompatibility and cellular 
internalization, as expounded in Chapter 3, Section 3.2.1.3.2.   
  
 
Figure 5.8 Effect of the sequential deposition of alternating layers of CHT and PAA on the zeta 
potential of CHO- and DSPE-NLB. 
 
Qualitative assessment of the morphological characteristics of lyophilized polymer coated 
CHO- and DSPE-NLS, employing scanning electron microscopy, provided a deeper 
understanding of the macroscopic appearance and behavior of the formulations. The 
network structure observed macroscopically following coating of CHO-NLS with PEI and 
Unc
oat
ed N
LB
Lay
er 
1 (C
HT)
Lay
er 
2 (PA
A)
Lay
er 
3 (C
HT)
Lay
er 
4 (PA
A)
Ze
ta
 
Po
te
n
tia
l (m
V)
-30
-20
-10
0
10
20
CHO-NLB
DSPE-NLB
 119 
 
pectin or carrageenan was identified as a polyelectrolyte complex (PEC) embedded with 
NLS as illustrated in Figures 5.9A and 5.9B. The NLS were well distributed through the 
PEC and there was a distinct absence of aggregation. However, the tight network 
structure may be responsible for the prolonged time required for complete solubilization of 
the product.  
 
The spongy macroscopic presentation of CHO-NLS coated with CHT and pectin was 
confirmed by the scanning electron micrograph in Figure 5.9C. The surface appears 
uneven with shallow contusions. CHO-NLS are fairly evenly scattered throughout the 
sponge, however, the concentration of NLS is distinctly lower than that observed with 
other formulations. This trend was consistent following assessment of representative 
sections from three samples. The reduced concentration was attributed to NLS being 
trapped in the shallow contusions of the sponge as well as partial aggregation of the NLS 
due to entrapment within the spongy environment. The micrograph in Figure 5.9D of 
DSPE-NLS coated sequentially with CHT and PAA revealed well defined NLS with the 
absence of a significant matrix. This substantiates the ease of reconstitution of the 
samples. The microscopic appearance of CHO-NLS coated with the same polymer 
combination exhibited comparable characteristics to that observed with coated DSPE-
NLS.  
   
 
Figure 5.9 Scanning electron micrographs of post-lyophilization products of CHO-NLS coated with 
A) PEI and pectin (4200x magnification); B) PEI and carrageenan (2800x magnification); C) CHT 
and pectin (3200x magnification) and D) CHT and PAA (4800x magnification). 
PEI and Pectin
CHT and PAA
PEI and Carrageenan
CHT and Pectin
A) B)
C) D)
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5.4.7 Confirmation of polymeric coating through chemical structural transition 
analyses 
The undertaking of FTIR analysis was intended, in conjunction with the results of zeta 
potential analysis, to confirm the adsorption of oppositely charged polymers to the surface 
of formulated CHO- and DSPE-NLS. The FTIR spectra of uncoated and optimized CHO- 
and DSPE-NLS as well as that of the native polymers (CHT and PAA) employed in 
polymeric coating of the NLS are depicted in Figures 5.10A and 5.10B. There is a distinct 
difference between the FTIR spectrum of uncoated and optimized NLS which is related to 
the adsorption CHT and PAA. The appearance of a prominent peak at 1702cm-1 in the 
spectrum of optimized CHO-NLS and at 1705cm-1 was the most outstanding difference 
relative to the spectra of uncoated CHO- and DSPE-NLS. These peaks corresponded to 
the carboxyl group of PAA, which manifested at 1695cm-1 in the spectrum of native PAA. 
There was a clear change in the appearance of minor peaks between uncoated and 
optimized CHO-NLS at the region of 1200-1660cm-1, due to CH2 bending and C=C bands 
in PAA. A broad band was observed from approximately 2800-3500cm-1 with optimized 
CHO- and DSPE-NLB, which was ascribed to the stretching hydroxyl band in PAA. The 
marked similarity in the spectra of optimized CHO- and DSPE-NLS to PAA is evident of 
successful and complete PAA adsorption. The high degree of PAA adsorption suggests a 
strong attraction to a cationic surface, which can be ascribed to successful CHT 
adsorption prior to the introduction of PAA, since the surface of uncoated NLS was of an 
anionic nature. These results corroborate the changes in zeta potential following the 
application of sequential polymeric layers and confirm the achievement of a robust 
polyelectrolyte coating of formulated NLS.      
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Figure 5.10 FTIR spectra highlighting the chemical structural transitions of optimized A) CHO-NLS 
and B) DSPE-NLS following polymeric coating, relative to uncoated CHO- and DSPE-NLS and the 
native polymers employed in the polyelectrolyte coating. 
 
5.4.8 Determining the restoration of nano-lipobubble structure employing 
fluorescence microscopy 
Fluorescence microscopy was employed to confirm the restoration of NLS structure and 
subsequent conversion to NLB, following reconstitution of the lyophilized powder. The 
fluorescence micrographs of CHO-NLB and DSPE-NLB displayed in Figures 5.11A and B, 
respectively, highlight the resilience of the bi-layer lipid membrane structure and the 
restoration of the spherical NLB structure. Moreover, there is a distinct absence of 
aggregation of the NLB.  
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Figure 5.11 Fluorescence micrographs of A) CHO-NLB and B) DSPE-NLB labelled with FITC dye 
confirming the restoration of NLB structure following lyophilization, reconstitution and SF6 gas 
introduction.   
 
5.4.9 Establishing the efficiency of camptothecin incorporation 
The efficiency of CPT incorporation for candidate CHO- and DSPE-NLS demonstrated 
exceptionally close correlation to those predicted by statistical optimization, as outlined in 
Table 5.7. Conversion of NLS to NLB did not result in significant change in DIE. However, 
lyophilization followed by reconstitution resulted in ~2% decrease in DIE for CHO-NLB 
and DSPE-NLB.  
 
Table 5.7 Experimentally derived and statistically predicted DIE of CPT for CHO- and DSPE-NLB. 
Formulation DIE 
 Experimental (%) Predicted (%) Variance (%) 
CHO-NLS 81.86 82.4128 0.007 
DSPE-NLS 59.11 59.1864 0.001 
 
The introduction of SB to the NLB formulations bore the potential to affect all physical and 
physicochemical characteristics of the formulations, not least of all being CPT 
incorporation. The considerations, with regards to drug incorporation, following this 
modification were two-fold. Firstly, the efficiency of SB incorporation was analyzed, since 
this directly influenced the synergistic antineoplastic effect desired from the introduction of 
this phytochemical. Secondly, the effect of SB incorporation on the efficiency of CPT 
incorporation was pertinent to the feasibility of this modification. CPT and SB are both 
lipophilic compounds and hence were expected to compete for incorporation within the 
NLB-DDS. The quantity of SB (30mg) determined to be the most feasible for incorporation 
into CHO- and DSPE-NLB displayed >65% incorporation into CHO-NLS with an 
insignificant decrease in CPT incorporation. DSPE-NLB exhibited a satisfactory 
incorporation efficiency of SB (~53%) following the addition of 30mg SB. However, this 
formulation repeatedly exhibited a concurrent increase in CPT incorporation of ~2.5%.   
The final modification undertaken on formulated CHO- and DSPE-NLB was the 
application of sequential layers of polymeric coating. The extended hours required for the 
A) B)
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complete adsorption of polymeric coats presented a concern with respect to the leakage 
of drugs from the NLB-DDS. Coating time was minimized by regular analysis of zeta 
potential to determine successful coating with the respective polymer in the shortest 
period. CPT and SB content were assessed before and after the application of polymeric 
coating.  
 
The robustness of CHO-containing bi-layer NLB membranes was again evident by the 
marginal decrease in CPT and SB content following complete polymeric coating. 
Moreover, the high surface charge of CHO-NLB perhaps contributed to swifter adsorption 
of polymers on to the surface, thereby further hindering drug leakage out of the NLB. 
DSPE-NLB, however, suffered higher drug leakage during the process of polymeric 
coating. Preliminary studies had displayed more rapid release of drug from DSPE-NLS as 
opposed to CHO-NLS hence this observation was not entirely unexpected. Nevertheless, 
CPT content of DSPE-NLB following polymeric coating was only ~4.5% lower and that of 
SB was ~2.7% lower than that achieved prior to the initiation of polymeric coating. Figure 
5.12 summarizes the final DIE of CPT and SB following polymeric coating, lyophilization 
and reconstitution in the presence of lactose.  
 
 
Figure 5.12 Graphical illustration of the post-modification DIE’s of CPT and SB in CHO-NLB and 
DSPE-NLB. 
 
5.4.10 Generation of a standard curve for the photospectroscopic quantification of 
CPT at tumoural pH 
The evaluation of CPT release characteristics at approximate tumoural pH of 6.0 (37°C) 
necessitated the development of a standard curve to quantify CPT release at the relevant 
time intervals. A wave-scan was fundamental in delineating the optimal wavelength at 
which CPT was detected and is illustrated in Figure 5.13. 
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Figure 5.13 Three dimensional absorption spectrum of CPT in DMSO:PBS (pH 6.0, 37°C) (1:1). 
 
A standard curve of CPT absorbance was subsequently prepared at 345nm based on 
serial dilutions of CPT in DMSO:PBS (pH 6.0; 37°C) (1:1). Figure 5.14 illustrates the 
standard reference curve of CPT in DMSO:PBS (pH 6.0; 37°C) (1:1) as well as the 
regression co-efficient, y-value, and 95% confidence and prediction bands. Absorbance 
values obtained on each of the two days the measurements were conducted exhibited a 
standard deviation of <0.02, validating the precision of the instrument and accurate 
reproducibility of data. 
 
 
Figure 5.14 Standard curve of the absorbance of CPT in DMSO:PBS (pH 6.0; 37°C) (1:1), as well 
as the 95% confidence and prediction bands (in all cases n=3 and SD<0.02). 
 
5.4.11 Establishment of drug release characteristics and the effects of 
modifications on candidate formulations  
The observed pattern of CPT release from candidate NLS was analogous to the general 
trend observed with formulations in each of the experimental designs. Candidate NLS and 
NLB displayed a somewhat bi-phasic CPT release pattern, which was most prominent for 
CHO-NLS, as illustrated in Figures 5.15A and 5.15B. The disparity between release of 
CPT from CHO-NLS and DSPE-NLS, depicted in Figure 5.15A, was once again a central 
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feature noted with the candidate NLS. The difference in CPT release may be directly 
attributed to the average size and surface charge characteristics of each of the candidate 
NLS. The lower average size of DSPE-NLS provides a greater surface area-to-volume 
ratio, thereby increasing the area of diffusivity for CPT out of the DDS. Moreover, the 
substantially more negative surface charge of CHO-NLS diminishes the tendency for 
agglomeration of the NLS, thus enhancing the stability of the formulation. CHO-NLS 
demonstrated a slightly more rapid CPT release than DSPE-NLS over the first 6 hours of 
analysis. Thereafter the rate of CPT release appeared to decrease. The bi-phasic pattern 
of DSPE-NLS exhibited faster CPT release for approximately the first 12 hours of the 
analytical period, followed by a slight decrease in CPT release. Hence the fractional 
release of CPT from DSPE-NLS exceeds that from CHO-NLS from 10 hours onwards. 
Complete release of CPT from DSPE-NLS was observed at 20 hours. CHO-NLS 
displayed only ~75% cumulative release of incorporated CPT over the 24 hour analysis 
period. The more acidic pH employed to represent the tumoural environment appeared to 
have only a marginal effect on CPT release, that varied over the analytical period, from 
each of the candidate NLS.    
  
 
Figure 5.15 Fractional drug release profiles of CPT from A) candidate CHO- and DSPE-NLS and 
B) candidate CHO- and DSPE-NLB, at tumoural and physiologic pH over 24 hours (in all cases n=3 
and SD<0.02). 
 
The introduction of a gaseous core in the conversion of candidate NLS to NLB resulted in 
a significantly more rapid release of CPT across all formulations, as illustrated in Figure 
5.15B. The first 6 hours of analysis demonstrated very similar CPT release from all of the 
formulations at physiological and tumoural pH, with the exception of DSPE-NLB at 
physiological pH. Beyond 8 hours, CPT exhibited a somewhat slower release pattern from 
CHO-NLB, achieving between 90-92% cumulative CPT release over the 24 hour 
analytical period under both pH conditions. The significant decrease in surface charge that 
followed the conversion of CHO-NLS to lyophilized and reconstituted CHO-NLB (-37.9mV 
to -27.9mV) was attributed with the increase in CPT release from the candidate CHO-
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NLB. A decrease in the intensity of a charged surface results in a less stable formulation 
that has a greater propensity for aggregation of the NLB. Notwithstanding the decrease in 
surface charge of CHO-NLB, the zeta potential achieved following conversion to NLB was 
highly satisfactory, accounting for the absence of a significant burst release from the NLB 
formulation as well as the controlled pattern of CPT release. Once again, analysis at the 
lower pH highlighted no significant consequence on the release of CPT from CHO-NLB.  
 
The release of CPT from DSPE-NLB, illustrated in Figure 5.15B, was notably higher than 
from DSPE-NLS, particularly at lower pH where complete CPT release was observed by 
16 hours. The swifter release of CPT from DSPE-NLB can be attributed somewhat to the 
low surface charge of the formulation. However, it is postulated that the average size of 
the formulation as well as permeability of the lipid membrane may further contribute to the 
pattern of CPT release since the zeta potential of post-lyophilization DSPE-NLB is 
marginally more favourable than that of DSPE-NLS. The considerably faster release of 
CPT from DSPE-NLB at pH 6.0 may suggest a higher permeability of the lipid membrane 
to the SF6 gas in the core of the NLB at lower pH, resulting in swifter release of the 
incorporated drug. 
 
The addition of a second active compound SB, constituted a need to assess the release 
characteristics of SB as well as determine the effect of SB release on the release profile of 
CPT. The release pattern of CPT from CHO-NLB containing SB (CHO-NLB+SB) 
demonstrated no outstanding differences to that of SB naïve formulations for the first 10 
hours, except for an evident burst release of CPT over the first hour (as illustrated in 
Figure 5.16A). A similar burst release of SB was observed over this period, displayed in 
Figure 5.16B, suggesting association of both compounds to a certain degree with the 
surface of the NLB. Furthermore, the presence of an additional compound may have 
altered the surface tension of the formulated CHO-NLB, leading to the initial burst release 
of both CPT and SB. From 10 hours the release of CPT from CHO-NLB+SB is 
approximately 7-9% higher than that observed for CHO-NLB without SB. An effect of the 
different pH of release medium (7.4 and 6.0) employed during analysis only became 
evident after 10 hours, when the release of CPT at pH 6.0 appeared to be slightly higher 
than that at pH 7.4. However, the effect of tumoural pH on the release characteristics of 
CPT from CHO-NLB+SB was still considered negligible following this study. A cumulative 
CPT release of 82-86% was achieved for CPT from CHO-NLB+SB over the 24 hour 
investigation.  
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The release pattern of CPT from DSPE-NLB containing SB (DSPE-NLB+SB) was slower 
relative to that for CHO-NLB+SB for the first 10 hours, thereafter exceeding that of CHO-
NLB+SB. The lack of significant burst release of CPT and SB suggests association of 
CPT and SB with the surface of the NLB was absent or to a far lesser extent than 
suspected for CHO-NLB+SB. The release of CPT from DSPE-NLB+SB was lower than 
that from SB naïve DSPE-NLB throughout the period under investigation. The difference 
in pH of the release medium had no demonstrable effect on the release behaviour of CPT 
from DSPE-NLS+SB. Complete release of CPT from DSPE-NLS+SB was determined by 
the completion of the 24 hour assessment period.    
 
 
Figure 5.16 Fractional drug release of A) CPT and B) SB, from CHO- and DSPE-NLB containing 
SB, at tumoural and physiologic pH over 24 hours (in all cases n=3 and SD<0.02). 
 
Following the aforementioned burst release of SB from formulated CHO-NLB during the 
first hour of analysis, the ensuing pattern, exhibited in Figure 5.16B, highlights a fairly 
constant release pattern that is considerably faster than that observed with CPT. SB is 
more aqueous soluble than CPT which may have contributed to retention of CPT within 
the lipid environment of the NLB to a greater extent than that of SB. SB appeared to 
release 3-8% faster at lower pH than at physiologic pH over the 24 hour period. Complete 
release of SB from CHO-NLB was denoted after 20 hours at both physiologic and 
tumoural pH. The pattern of SB release established from DSPE-NLS was remarkably 
constant, closely resembling first order release. The steeper gradient of the release profile 
substantiates the achievement of complete SB release from DSPE-NLB+SB in 16 hours. 
The pH of the release medium had a marginal influence on the release characteristics of 
SB. The release of SB from DSPE-NLB+SB was significantly more rapid than that of CPT 
from the same formulation, after the first hour.  
 
The challenge of delivering a poorly aqueous soluble compound that undergoes extensive 
metabolism has compromised the utilization of SB to its full clinical potential. This 
phytochemical has, however, demonstrated high permeability in vivo. Incorporation into 
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the NLB-DDS provides a mechanism of delivery to the tumour tissue where SB can enter 
tumour cells and exert its antineoplastic activity effectively.  
 
 
Figure 5.17 Fractional drug release of A) CPT and B) SB, from coated CHO- and DSPE-NLB, at 
tumoural and physiologic pH over 24 hours (in all cases n=3 and SD<0.02). 
 
The emphasis placed on delaying the onset and reducing the rate of CPT and SB release 
was established on the need to reduce the indiscriminate systemic activity of these 
compounds as well as increasing the concentration of CPT and SB at the tumour site. To 
achieve this, sufficient time was required to allow for passive accumulation of the 
formulated DDS at the tumour site before a significant proportion of the incorporated 
compounds were released. Moreover, extending the release of CPT would be particularly 
advantageous since the drug acts predominantly in the S-phase of the cell cycle. Hence, 
extended release facilitates the exposure of a greater quantity of tumour cells in the S-
phase to CPT, thereby enhancing the efficacy of CPT. The institution of layered polymeric 
coating on formulated NLB proved exceptionally advantageous at slowing the release of 
both CPT and SB from each of the candidate NLB-DDS.  
 
Whilst the application of polymeric coating significantly slowed the release of CPT from 
CHO-NLB at both physiologic and tumoural pH, the disparity in release characteristics 
was considerably more acute at pH 7.4. The bi-phasic release pattern observed with 
uncoated NLB was distinctly absent, with the release profile taking on a more constant 
linear shape, as demonstrated in Figure 5.17A. The cumulative release of CPT achieved 
at 24 hours was <50%. This is a considerable extension of the ≤1 hour half-life of CPT in 
aqueous medium as reported in the literature (Yang et al., 1999; Kang et al., 2002). In 
addition, less than 7% of CPT was released from the NLB-DDS in the first hour of 
analysis, highlighting the absence of burst release as well as indicating adequately low 
concentration of CPT released into the systemic circulation. The achievement of the 
aforementioned release characteristics of CPT from the formulated polymer coated CHO-
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NLB has the potential to address the toxicity profile of CPT which is one of the major 
drawbacks limiting the clinical application of this broad-spectrum antineoplastic agent.   
 
Evaluation of CPT release at a lower tumoural pH of 6.0, presented in Figure 5.17A, also 
revealed a favorable decrease in the release of CPT over the period of investigation. The 
release of CPT in the first hour of analysis was lower than that observed for uncoated 
CHO-NLB at pH 6.0 as well as for polymer coated CHO-NLB at physiologic pH. Moreover, 
the release profile of CPT from coated CHO-NLB had a notably more linear appearance 
than uncoated CHO-NLB, suggesting a more controlled manner of release. However, 
beyond the first hour the release of CPT from the polymer coated NLB-DDS was 
substantially more rapid than observed at physiological pH. A cumulative release of ~63% 
CPT was achieved over the 24 hour period, which was more than 14% higher than CPT 
release attained from coated CHO-NLB over the same period. This was attributed to the 
pH-responsive property of CHT which was incorporated in the polymeric layers coating 
the NLB. CHT is a linear polysaccharide that demonstrates aqueous solubility up to pH 
6.2, due to the protonation of glucosamine units at this lower pH (Pujana et al., 2012; 
Chatrabhuti and Chirachanchai, 2013). This alteration in the characteristics of CHT at 
lower pH facilitates use of this polymer for pH-responsive applications. While the 
formulated NLB-DDS cannot be considered strictly pH-responsive, increase in the release 
of CPT at the lower tumoural pH results in increased concentration of the antineoplastic 
drug within tumour tissue which has the potential to significantly enhance therapeutic 
efficacy of CPT. 
 
Evaluation of the release characteristics of CPT from coated DSPE-NLB bore a strong 
resemblance to that obtained from coated CHO-NLB in both a physiologic and tumoural 
pH release medium. A general trend observed with uncoated DSPE-NLB was more rapid 
release of active compounds relative to uncoated CHO-NLB. This observation was 
attributed to lower stability of the DSPE-NLB, due to the less anionic surface charge, as 
well as the higher permeability of DSPE-NLB lipid membrane. Following polymeric 
coating, the zeta potential of DSPE-NLB demonstrated a tremendously favorable 
enhancement of the anionic intensity of the surface charge, to a greater extent that the 
change observed with coated CHO-NLB. In addition, the polymeric coating considerably 
decreased permeability of the DDS to the SF6 gaseous core. The coated DSPE-NLB 
retained some of the bi-phasic release characteristics at pH 6.0 that was discerned from 
the uncoated formulations. Release of CPT from DSPE-NLB was faster over the first 8 
hours of evaluation. The cumulative release of CPT demonstrated from DSPE-NLB at 
physiological and tumoural pH approximated 50% and 58%, respectively. This favorable 
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release pattern combined with the smaller size of coated DSPE-NLB, relative to that of 
coated CHO-NLB may prove vastly advantageous to the passive targeting capacity of this 
DDS.  
 
As described for CPT, the release of SB from CHO- and DSPE-NLB was significantly 
reduced as a consequence of the polymeric coating, as depicted in Figure 5.17B. The 
burst release of SB from uncoated CHO-NLB was a particular concern. Polymeric coating 
successfully reduced the release of SB from CHO-NLB by ~19% during the first hour 
under both pH environments. The influence of pH was tangible, particularly after the first 2 
hours of analysis. The release of SB CHO-NLB was slightly faster than that derived for 
CPT. The cumulative release achieved for SB from CHO-NLB at pH 7.4 and 6.0 were 
57% and ~72%, respectively. Investigation of DSPE-NLB also highlighted considerably 
slower release of SB following polymeric coating of the DDS. There was a pronounced 
influence of pH on the release of SB from coated DSPE-NLB, with cumulative release at 
physiologic pH ~10% lower than that determined at tumoural pH. The reduced release of 
SB at physiologic pH indicates a lower concentration of SB will be subjected to 
metabolism in the systemic circulation and clearance prior to reaching the tumour tissue. 
The quicker release of SB from coated DSPE-NLB at tumoural pH will facilitate the 
achievement of higher concentrations of SB at the target site, resulting in superior SB 
efficacy as well as enhanced synergistic antineoplastic effect with CPT.        
 
5.4.12 Defining the stability characteristics of formulated nano-lipobubbles 
Stability of pharmaceutical formulations can significantly influence viability of the 
formulation from cost, production and clinical use standpoints. Formulations that cannot 
be stored for an acceptable period require production shortly before use which can result 
in an increase in production and transportation costs, delays in treatment due to 
unforeseen circumstances and ultimately complicate clinical use. Moreover, post-
reconstitution time-dependent stability of lyophilized products, suitable storage conditions, 
as well as post-administration stability is pivotal to the assessment of the overall feasibility 
of formulations. 
 
5.4.12.1 Determination of the stability of nano-lipobubbles in serum 
The intended intravenous delivery of the NLB formulations demands the establishment of 
stringent stability parameters, particularly with regards to the size characteristics of 
administered formulations. The adsorption of serum proteins, or the aggregation of NLB in 
the presence of serum proteins can significantly affect the feasibility of the formulation. 
Uncoated CHO-NLB exhibited a <10 nm increase in size in the presence of serum 
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proteins, over the analysis period, as well as a marginal decrease in surface charge. This 
was attributed to slight destabilization of the CHO-NLB in the presence of serum proteins 
which resulted in aggregation of the NLB. The increase in surface charge following 
polymer coating of the CHO-NLB afforded greater stability to the formulation. Hence the 
presence of serum proteins had only a marginal effect on the stability of the formulation. 
The <2 nm increase in size was not attributed to the presence of serum proteins, but 
rather to normal size variation of the nanosystem over time. Maintenance of the zeta 
potential was a further indication that aggregation of the CHO-NLB was absent.    
   
Table 5.8 Physical characteristics of uncoated and polymer coated CHO- and DSPE-NLB in the 
presence of FBS. 
CHO-NLB 
 Uncoated NLB Polymer-coated NLB 
Time 
(min) 
Average 
Size (d.nm) PdI 
Zeta 
Potential 
(mV) 
Average 
Size (d.nm) PdI 
Zeta 
Potential 
(mV) 
0 137.56 0.19 -27.58 189.81 0.21 -32.47 
15 140.02 0.23 -25.83 190.01 0.20 -32.41 
30 140.67 0.27 -24.02 190.72 0.23 -31.98 
45 143.91 0.24 -24.78 191.06 0.19 -32.42 
60 145.32 0.29 -23.35 191.39 0.21 -31.77 
DSPE-NLB 
 Uncoated NLB Polymer-coated NLB 
0 93.65 0.26 -8.24 141.62 0.21 -24.27 
15 93.91 0.22 -8.20 141.84 0.19 -24.21 
30 93.86 0.21 -7.94 141.91 0.20 -24.00 
45 94.27 0.24 -8.17 142.06 0.21 -23.84 
60 94.91 0.21 -8.21 142.24 0.21 -23.87 
 
There was a distinct absence of membrane destabilization for uncoated and polymer-
coated DSPE-NLB in the presence of serum proteins, as evidenced by the minute 
variations in size and zeta potential of formulations of the analysis period. The presence of 
PEG conjugated to DSPE in the membrane of the formulated DSPE-NLB conferred 
superior stability to the formulation against the effects of serum proteins. The strong 
anionic charge of polymer-coated DSPE-NLB was accredited for the stability of the 
formulation against aggregation and interaction with serum proteins.   
   
5.4.12.2 Characterizing the stability of reconstituted nano-lipobubbles 
The reconstitution of lyophilized powders or particulate formulations into suspensions is 
accompanied by a change in the stability of the formulation. Preparation and 
administration instructions by manufacturers of some cytotoxic preparations define a 
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period of just 4-6 hours between reconstitution of the product and complete intravenous 
infusion of the cytotoxic preparation. The stability of formulated NLB-DDS was assessed 
at ambient temperature employing a Turbiscan™ LAB (Formulaction, L’Union, France). 
Determination of the light backscattered by the coated and uncoated NLB preparations 
was employed to define stability characteristics of the formulations. The Turbiscan™ LAB 
is able to detect minute alterations in the behavior of suspended matter considerably 
earlier than macroscopic observation will allow. 
 
The backscatter plot of uncoated CHO-NLB (depicted in Figure 5.18A) highlights no 
localized changes in the behavior of the particulate matter, which would be indicative of 
sedimentation or creaming of the suspended NLB. However, the change in backscatter 
across the entire spectrum suggested a change in the size of the NLB. A decrease in size 
was observed over the first 6 hours post reconstitution, which may have been the result of 
gradual evaporation of the gaseous core out of the NLB. Thereafter a marginal increase 
(<2%) in size of the CHO-NLB was observed. The decrease in formulation stability that is 
associated with time after reconstitution resulted in aggregation, and possibly 
coalescence, of CHO-NLB thereby causing the increase in size detected by the increase 
in backscatter. The maximal variation in backscatter determined over the 12 hour period 
following reconstitution approximated 4%. The change in backscatter was quantified over 
the analytical period and is depicted in Figure 5.18C. The most distinct change in 
backscatter, as indicated by the steepest gradient, was observed from 0.5-4.5 hours with 
a 0.94%/hour change in backscatter.   
  
The backscatter profile for polymer coated CHO-NLB, depicted in Figure 5.18B represents 
an exemplary display of formulation stability. Similar to the uncoated CHO-NLB, there was 
no evidence of creaming or sedimentation. A marginal (<2%) variation in size of the CHO-
NLB was observed over the 12 hour period. However, unlike with uncoated CHO-NLB, 
only a uni-directional size variation was observed. The slight reduction in size of coated 
CHO-NLB was attributed to gradual permeation of SF6 gas out of the NLB. The enhanced 
stability of the formulated coated CHO-NLB underlies the absence of aggregation that was 
observed with the uncoated CHO-NLB from 6 hours post-reconstitution. Figure 5.18D 
quantifies the change in backscatter referenced to the initial measurement, over the 
analytical period. The gradient of the graph highlights the exceptional stability of the 
polymer coated CHO-NLB formulation with a 0.01% change in backscatter per hour.   
 
There is a definitive absence of migrational behavior of uncoated and coated DSPE-NLB, 
confirming stability of the formulation against sedimentation or creaming. The backscatter 
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plot of uncoated DSPE-NLB, presented in non-referenced mode in Figure 5.19A, 
highlights comparable characteristics to uncoated CHO-NLS with regards to a reduction in 
NLB size observed during the first half of the analysis period, followed by an increase in 
size of the suspended NLB. This phenomenon was again attributed to the evaporation of 
the gaseous core from the DSPE-NLB resulting in diminished size of the DDS followed by 
aggregation of the less stable DSPE-NLB during the latter stages of analysis. The 
maximal change in backscatter observed over the 12 hour period approximated 2.5%. 
Whilst DSPE-NLB were less stable than CHO-NLB, as concluded by the zeta potential 
displayed by each formulation, the change in backscatter was less than the 4% variation 
observed for CHO-NLB. The smaller initial size of uncoated DSPE-NLB contained a 
smaller volume of SF6 gas in the core of the formulation. Consequently, evaporation of the 
gaseous core out of the formulated DSPE-NLB caused a slighter size variation than that 
observed with larger CHO-NLB. The change in backscatter was quantified by means of 
the DeltaBS(t) plot depicted in Figure 5.19C.This plot  highlights the largest reduction in 
backscatter over the 0.5-4.5 hours, followed by alternating increase and decrease in 
backscatter which suggests insignificant size variation due to reversible aggregation of the 
suspended NLB in Brownian motion. The slope of the graph between 0.5-4.5 hours 
indicates a 0.3% change in backscatter per hour.  
 
The backscatter plot of polymer coated DSPE-NLB presented a significantly more 
favorable scenario with regards to stability characteristics of the DDS. This graph, 
presented in non-referenced mode in Figure 5.19B, highlighted an almost inconceivable 
change in backscatter over the 12 hour analysis period. This exceptional stability was 
confirmed by quantification of the change in backscatter with reference to the initial 
measurement at the start of the assessment, presented in Figure 5.19D. The virtually 
horizontal gradient of the graph concludes a 0% change in backscatter per hour over the 
entire 12 hour period. Hence, the stability profile of DSPE-NLB following reconstitution 
suggests a highly stable formulation that will allow sufficient time between reconstitution 
and administration to patients. 
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Figure 5.18 Backscatter profiles of A) uncoated CHO-NLB and B) polymer coated CHO-NLB in non-reference mode, up to 12 hours post reconstitution at ambient 
temperature. Change in backscatter as a function of time of C) uncoated CHO-NLB and D) polymer coated CHO-NLB, with reference to the initial measurement. 
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Figure 5.19 Backscatter profiles of A) uncoated DSPE-NLB and B) polymer coated DSPE-NLB in non-reference mode, up to 12 hours post reconstitution at ambient 
temperature. Change in backscatter as a function of time of C) uncoated DSPE-NLB and D) polymer coated DSPE-NLB, with reference to the initial measurement. 
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5.4.12.3 Evaluation of the storage stability of nano-lipobubbles 
The stability of formulated polymer coated CHO- and DSPE-NLB as a lyophilized product 
was assessed over a 3 month period under ambient and refrigeration temperatures. At 
weekly intervals the formulations were reconstituted, converted to NLB and the average 
size and zeta potential of the formulations as well as DIE of both CPT and SB were 
determined. The change in size of CHO-NLB was minimal over the first 8 weeks, following 
which refrigerated formulations maintained their size better than formulations stored at 
room temperature, as highlighted in Figure 5.20A. However, the difference between 
refrigerated and non-refrigerated formulations was <2 nm during the third month. At the 
conclusion of the 12 week study, the CHO-NLB formulations remained below 200 nm. 
DSPE-NLB displayed an insignificant variation in the average size of formulations stored 
at both temperatures over the entire study. In addition, the formulations exhibited only a 2-
3 nm increase in size by the end of the investigation. Long term storage, as well as the 
storage temperatures, appeared to have a greater impact on the surface charge of 
formulations, as illustrated in Figure 5.20B. CHO-NLB stored at ambient temperature 
demonstrated an unfavorable 7.24mV increase in zeta potential over the assessment 
period, whilst refrigerated samples bore a 4.17mV increase in zeta potential. The disparity 
in zeta potential between refrigerated and non-refrigerated samples increased as the 
study proceeded.   
 
The leakage of incorporated drugs from formulated liposomes and nanobubbles while 
stored as suspensions presents one of the fundamental stability challenges related to the 
feasibility of these DDS. Lyophilization has been previously explored and reported as a 
means of enhancing the storage stability of the aforementioned DDS. Hence, the final 
presentation of CHO- and DSPE-NLB formulated in this study was lyophilized products. 
The storage stability of both formulations with regards to the DIE of CPT over the 
analytical period, presented in Figure 5.20C, was outstanding. CHO-NLB displayed <3% 
decrease in the DIE of CPT, whilst the decrease was <4% for DSPE-NLB by the 
conclusion of the analysis. The influence of storage temperature on the incorporation of 
CPT in both DDS was insignificant. Storage temperature, as depicted in Figure 5.20D, 
appeared to have a negligible impact on the efficiency of SB incorporation in DSPE-NLB. 
However, storage time resulted in a gradual decrease in SB incorporation, culminating in 
a <3% lower DIE for SB at the end of the 3 month study. The storage stability of CHO-
NLB with respect to SB incorporation was slightly less favorable than observed with 
DSPE-NLB, with Figure 5.20D denoting ~4% decrease in SB DIE over the period of 
investigation. Between weeks 3-8, the influence of refrigeration on the incorporation of SB 
is evident. However, overall the influence of storage temperature on the incorporation 
stability of SB was negligible for CHO-NLB.     
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Figure 5.20 Defining the A) average size, B) zeta potential, C) CPT incorporation and D) SB 
incorporation of polymer coated CHO- and DSPE-NLB stored under ambient and refrigeration 
temperatures over a three month period (in all cases n=3 and SD<0.03). 
 
5.5 Concluding Remarks 
This chapter established a methodical characterization of the candidate nano-liposomal 
formulations defined by statistical optimization in Chapter 4. Evaluation of the 
experimentally derived results revealed close correlation to the predicted responses. 
Conversion to the intended NLB formulation highlighted superior stability, drug 
incorporation and drug release characteristics of CHO-NLB, whilst the size profile of 
DSPE-NLB was particularly favorable. The feasibility of lyophilization was investigated as 
a practical consideration to improve the long term stability of the formulation, thereby 
enhancing the industrial and clinical viability of the novel DDS. Fluorescence microscopy 
further confirmed the restoration of the morphological structure of NLB following 
lyophilization. 
    
Further modifications undertaken on the formulated NLB-DDS included the incorporation 
of a phytochemical with antineoplastic properties. Maintaining a favorable size profile to 
facilitate the passively targeted nature of the DDS was a central consideration in 
determining the optimal concentration of SB to be incorporated into the DDS. Interestingly, 
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the incorporation of SB into CHO-NLB had a marginal effect on the concurrent DIE of CPT 
and a slight increase in CPT incorporation into DSPE-NLB. The inclusion of SB into the 
DDS resulted in a burst release of both CPT and SB from CHO-NLB during the first hour, 
as well as more rapid release of CPT over the 24 hour assessment period. By contrast, 
the incorporation of SB into DSPE-NLB resulted in a slower release of CPT. The higher 
aqueous solubility of SB relative to CPT was attributed with the more rapid release of SB, 
with complete release of SB being achieved in 20 hours for CHO-NLB and 16 hours for 
DSPE-NLB.    
 
The application of sequentially layered polymeric coating of the formulated NLB proved 
challenging. SEM revealed the formation of PEC with the combination of PEI and pectin or 
carrageenan. The combination of CHT and PAA proved immensely favorable, with 
lyophilization producing a flaky powder that was easily reconstituted. In addition, the 
average size of both CHO- and DSPE-NLB remained below the benchmark 200 nm size 
initially outlined. The significant change in zeta potential observed following the application 
of the cationic (CHT) and anionic (PAA) polymers, as well as the chemical structural 
changes determined following polymeric coating confirm the successful application of a 
robust polymeric coating of formulated NLB. The bearing of polymeric coating had a 
particularly advantageous impact on the surface charge of DSPE-NLB, with a favorable 
~16mV decrease in zeta potential.  CHO-NLB displayed incorporation efficiencies of 
77.17% and 64.38% respectively for CPT and SB. DSPE-NLB displayed incorporation 
efficiencies of 55.17% and 50.10%, respectively, for CPT and SB. Moreover, the 
application of polymeric coating significantly enhanced the release characteristics of both 
drug compounds and introduced differential release characteristics at physiologic and 
tumoural pH, thereby improving the passive targeting capacity of the intended DDS.      
  
Stability of formulations is a pivotal consideration for pharmaceutical formulations. The 
assessment of stability of the formulated NLB-DDS further highlighted the impact of 
polymeric coating on the stability characteristics of CHO- and DSPE-NLB. Post-
reconstitution evaluation of polymer coated CHO- and DSPE-NLB denoted remarkable 
stability characteristics for the entire 12 hour assessment period, particularly for DSPE-
NLB. Marginal changes in size were observed, however, the study concluded adequate 
time could be allowed between reconstitution of the NLB-DDS and administration to the 
patient to facilitate ease of use. The evaluation of long term storage stability of the NLB-
DDS under ambient and refrigerated temperatures over a 3 month period highlighted 
excellent stability with regards to the incorporation of CPT and SB with insignificant 
influence of storage temperature. The increase in size of CHO-NLB was only evident after 
8 weeks whilst the non-refrigerated formulation underwent an unfavorable >7mV increase 
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in zeta potential. The size and zeta potential profiles of DSPE-NLB over the three month 
assessment period demonstrated superior stability.  
 
Lastly, the formulated polymer-coated CHO- and DSPE-NLB remained below the 
benchmark size initially outlined, displayed satisfactory incorporation of both CPT and SB 
and successfully enhanced the drug release characteristics of CPT and SB to facilitate 
more effective passive targeting and drug efficacy. The stability characteristics of the 
formulations further denote substantial industrial and clinical feasibility.       
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CHAPTER 6 
EX VIVO EVALUATION OF OPTIMIZED NANO-LIPOBUBBLE FORMULATIONS 
 
6.1 Introduction  
This study did not require clearance from the Human Ethics Research Committee of the 
University of the Witwatersrand (Waiver letter in Appendix D). 
      
The undertaking of in vitro analyses provides vital data on the physicochemical and 
physicomechanical characteristics of formulated drug delivery systems (DDS), thereby 
creating a basis on which to initially assess the feasibility of the formulation and 
substantiating further assessment. Subsequently, the undertaking of ex vivo investigations 
enables assessment of formulations under conditions that mimic the in vivo environment 
more closely and provides data under conditions that cannot be adequately simulated in 
vitro. The diverse array of ex vivo analyses undertaken on DDS is dictated by the intended 
application of the DDS, the route of administration of the DDS and the factors that can 
potentially affect the activity and fate of the DDS in vivo. Common ex vivo characterization 
studies include cell cytotoxicity determination on a relevant cell line, cellular uptake of the 
DDS, permeation studies employing animal tissue, hemolytic assessment and gene 
transfection efficiency. 
 
Following the feasibility of the optimized nano-lipobubble drug delivery systems (NLB-
DDS) determined in Chapter 5, comprehensive systematic characterization compelled 
pertinent ex vivo analyses of formulated cholesterol-containing NLB (CHO-NLB) and 
distearoylphosphatidylethanolamine-containing NLB (DSPE-NLB). The intended 
intravenous administration of the NLB-DDS necessitated assessment of the effect of the 
respective formulations on erythrocytes. This was determined through quantification of 
hemolysis following treatment with each of the formulations. The A2780 epithelial ovarian 
cancer cell line was employed for all cellular-based assays. This adherent cell line was 
originally isolated from the tumour tissue of an untreated patient. The strain employed in 
the analyses described herein was a non-resistant subtype. The intra-cellular target of the 
incorporated antineoplastic agent camptothecin (CPT) requires uptake of the DDS by the 
tumour cells in order for CPT to effectively exert its antineoplastic activity. Hence, 
qualitative analysis of cellular uptake was conducted. The achievement of enhanced 
cytotoxic efficiency against tumour cells was a central consideration in this study. Thus, 
cytotoxic characterization of the optimized DDS will be comprehensively described in this 
Chapter by deliberating the results achieved by 2 different methods of cytotoxicity 
determination as well as the merits thereof.  
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6.2 Materials and Methods 
6.2.1 Materials 
The materials employed in the formulation of optimized CHO-NLB and DSPE-NLB were 
unchanged from those described in Chapter 5, Section 5.3.1. In addition a human 
epithelial ovarian cancer cell line (A2780), from the European Collection of Cell Cultures, 
cryoprotective medium (15%v/v DMSO) and sulforhodamine B (SRB) dye was procured 
from Sigma Chemical Company (St Louis, MO, USA). RPMI-1640, foetal bovine serum 
(FBS), a penicillin-streptomycin antibiotic combination, L-glutamine and Trypsin-EDTA 
were purchased from Lonza Group Ltd (Basel, Switzerland). Trypan blue (0.4%v/v) and 
dual chamber cell counting slides were procured from BioRad Laboratories Inc. (Hercules, 
CA, USA). BD™ Falcon sterile round-bottom polystyrene test tubes (5cm), 7-amino-
actinomycin (7-AAD), fluorescein isothiocyanate (FITC), R-phycoerythrin (PE2), peridinin-
chlorophyll proteins (PerCP) and allophycocyanin (APC) stains were purchased from The 
Scientific Group (Randburg, Gauteng, South Africa). Specialized E-plates 16 were 
procured from ACEA Biosciences Inc. (San Diego, CA, USA). Sterile porvair cell culture 
flasks, sterile centrifuge tubes (15mL and 50mL), disposable 10mL pipettes, sterile micro-
pipette tips and all other equipment employed in the culturing and analyses of cells were 
procured from Whitehead Scientific (Pty) Ltd (Cape Town, Western Cape, South Africa). 
Culturing and treatment of cells were undertaken under a vertical laminar flow unit 
(Labotec, Midrand, Gauteng, South Africa). 
 
6.2.2 Methods 
6.2.2.1 Preparation of optimized and control nano-lipobubbles 
The preparation of placebo, uncoated and optimized CHO- and DSPE-NLB were 
undertaken as described in Chapter 5, Sections 5.3.2.2, and 5.3.2.7. Reconstitution of 
lyophilized products of the respective formulations and subsequent conversion to NLB 
was conducted immediately prior to treatment of erythrocytes or tumour cells, as 
applicable. All formulations were subjected to filtration sterilization employing 0.22µm 
millipore filters under aseptic conditions.   
  
6.2.2.2 Cell culturing and expansion of the A2780 ovarian cancer cell line 
A2780 ovarian cancer cells were cultured in RPMI-1640 medium supplemented with FBS 
(10%v/v), L-glutamine (0.2%v/v), and a penicillin-streptomycin antibiotic combination 
(0.2%v/v). Cells were incubated at 37°C in a humidified incubator with 95%O2 and 5%CO2 
(Afrox, Johannesburg, Gauteng, South Africa) and monitored daily through microscopic 
observation. Cells were sub-cultured at 80-90% confluence, under sterile conditions with 
aseptic technique being observed throughout the culturing and analyses of cells. Briefly, 
cell culture medium was removed from the culture flask and cells were thoroughly rinsed 
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with phosphate buffered saline (PBS) (pH 7.4; 37°C; 3-5mL) to remove remnants of 
serum. Trypsin-EDTA (~3mL) was added to the cell culture flask and cells were incubated 
for 3 minutes in the humidified incubator to facilitate detachment of the cells. Fresh cell 
culture medium (~3mL) was introduced into the cell culture flask to re-suspend the cells 
and the entire volume was transferred to a sterile test tube. The suspension was 
subsequently centrifuged at 800rpm for 3 minutes, the supernatant discarded and the 
pellet of cells was re-suspended in fresh cell culture medium. The cell suspension was 
subsequently split into 3 cell culture flasks and allowed to attach and proliferate in the 
humidified incubator. Following adequate expansion of the cell line, cells were suspended 
in a combination of cell culture medium and cryoprotectant medium (1:1) and frozen at -
70°C until further analysis.  
 
6.2.2.3 Determination of cell concentration and viability 
Previously frozen cells were thawed and pipetted into sterile test tubes containing cell 
culture medium. The total volume was centrifuged at 800rpm for 3 minutes and the 
supernatant discarded. The cell sediment was re-suspended in cell culture medium (3-
5mL). Cell counting was undertaken by the trypan blue assay, according to the 
manufacturer’s specifications. Briefly, the cell suspension (10µL) was added to trypan blue 
(20µL) and the combination was introduced into the chamber of a specialized cell counting 
slide. The concentration of cells was determined employing an automated cell counter 
(TC10™ Automated cell counter, BioRad Laboratories Inc., Hercules, CA, USA). For each 
analytical experiment cells of the same passage number were employed and analyses 
were undertaken in triplicate. Moreover, only cells demonstrating ≥95% viability after 
freezing were used for analyses.  
 
6.2.2.4 Delineating experimental controls 
Control samples are essential in ex vivo studies, to confirm the integrity of the study. 
Untreated cells and plain cell culture medium incubated without further treatment were 
employed as positive controls, to confirm the viability of the cell line and the sterility of the 
medium, respectively. Cells treated with CPT or silibinin (SB) in DMSO, diluted with PBS, 
were utilized to determine the susceptibility of the cell line to the model drug and 
phytochemical, respectively, as well as to provide a basis for comparison of the efficacy of 
formulated DDS. Moreover, cell lines treated with DMSO+PBS or PBS were used to 
establish the effect of the solvents used for CPT, SB and the NLB-DDS on the cell line. 
Finally, treatment of the cell line with placebo NLB was utilized to establish the cytotoxic 
potential of the polymers and lipids employed in the formulation as well as the 
nanostructure itself. 
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6.2.2.5 Determination of hemolytic activity of nano-lipobubbles 
The intravenous nature of the proposed formulation demands an investigation of the effect 
of CHO- and DSPE-NLB on red blood cells (RBC) in order to establish hemocompatibility 
of the formulation. The method employed was analogous to that described by Shen and 
co-workers (2009), Elmowafy and co-workers (2013) and Sharma and co-workers (2013) 
(Shen et al., 2009; Elmowafy et al., 2013. Sharma et al., 2013). Sheep blood was 
employed for this investigation. Briefly, blood was collected into heparinized sterile test 
tubes and centrifuged at 2000xg for 5 minutes in order to separate the various blood 
components. The supernatant was discarded in order to isolate the RBC sediment. The 
RBC were re-dispersed in an anticoagulant preservative, Alserver’s buffer, followed by 
repeated washing and centrifugation, until a clear cell suspension was achieved. The RBC 
were subsequently divided into six test tubes for analysis. Two of the test tubes were used 
as controls to enable generation of a standard curve for the quantification of hemolytic 
activity. Hemolysis results in the disruption of the RBC membrane and subsequent 
release of hemoglobin, which can be detected by UV-spectroscopy. The RBC were 
treated as follows: 
 
Test tube 1: RBC incubated with PBS (pH 7.4; 37°C) for 30 minutes at 37°C. The 
suspension was centrifuged at 2000xg for 5 minutes and the supernatant analyzed by UV-
spectroscopy at 546nm. This control was also used as the blank sample and represented 
no hemolytic activity. 
Test tube 2: RBC incubated with excess ammonium chloride (NH4Cl) for 30 minutes at 
37°C, followed by centrifugation at 2000xg for 5minutes. The supernatant was analyzed 
by UV-spectroscopy as for test tube 1. This control represented complete hemolysis.  
Test tubes 3 and 4: RBC incubated with CHO-NLB (10mg/mL and 20mg/mL; 10mL) for 30 
minutes at 37°C, followed by centrifugation at 2000xg for 5 minutes. The supernatant was 
analyzed by UV-spectroscopy as for test tube 1.  
Test tubes 5 and 6: RBC incubated with DSPE-NLB (10mg/mL and 20mg/mL; 10mL) for 
30 minutes at 37°C, followed by centrifugation at 2000xg for 5 minutes. The supernatant 
was analyzed by UV-spectroscopy as for test tube 1.  
 
A wave-scan was performed from 250nm to 600nm on the sample from test tube 2 to 
establish the wavelength of maximal hemoglobin detection, which was determined to be 
546nm. A standard curve was subsequently generated from the UV absorbance values of 
samples in test tubes 1 and 2. Analysis was undertaken in triplicate. Test samples in test 
tubes 3 to 6 were used to establish the hemolytic activity of optimized CHO-NLB and 
DSPE-NLB. Hemolysis was quantified employing Equation 6.1. 
   Hemolysis (%) = (ANLB – APBS)/ANH4Cl x 100     Equation 6.1 
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6.2.2.6 Assessing cellular uptake of nano-lipobubbles through fluorescence 
microscopy 
Cells were seeded at a density of 1x105 cells/well in sterile, 6-well cell culture plates and 
incubated at 37°C in a humidified incubator with 95%O2 and 5%CO2. Fluorescently 
labeled CHO- and DSPE-NLB were prepared as previously described in Chapter 5, 
Section 5.3.2.7, with the addition of SRB during the emulsification process. Following 
attachment of the cells over a 24 hour period, cells were treated with SRB-labeled CHO- 
and DSPE-NLB as well as cell culture medium (1:1; 2mL), under sterile incubation 
conditions as described above. Following the incubation period, excess media and NLB 
suspension were removed and the cells were washed twice with PBS (pH 7.4; 37°C). PBS 
(pH 7.4; 37°C; 1mL) was added to each well to prevent dehydration of the cells during 
analysis. The fluorescent nature of SRB enabled qualitative determination of cellular 
uptake of the CHO- and DSPE-NLB through the application of fluorescence microscopy. 
Fluorescent images were super-imposed onto bright field contrast images to highlight the 
presence of fluorescently labeled CHO- and DSPE-NLB within the A2780 ovarian cancer 
cells.  
 
6.2.2.7 Characterizing the cytotoxicity of formulated nano-lipobubbles   
Cytotoxicity studies are employed to establish the degree of toxicity of the formulated 
NLB-DDS to the tumour cell line. In the present study toxicity of the formulation to the 
A2780 ovarian cancer cell was investigated, with the objective of maximizing toxicity and 
cell death. The cytotoxicity of formulations cannot be accurately defined without the use of 
experimental controls. Hence, in addition to the formulated coated and uncoated CHO- 
and DSPE-NLB, the cytotoxic activity of the controls outlined in Section 6.2.2.4 was 
investigated. The determination of cytotoxicity was assessed quantitatively employing flow 
cytometry, as well as analysis of real-time cell growth and cytotoxicity data employing the 
xCELLigence™ Real-Time Cell Analyzer (RTCA) (Roche Applied Science, Penzberg, 
Upper Bavaria, Germany and ACEA Biosciences Inc., San Diego, CA, USA). Moreover, 
counting of cells employing the automated cell counter as described in Section 6.2.2.3 
before and after treatment, in order to determine and adjust the concentration for specific 
analytical procedures, provided a solid indication of cell viability.   
 
6.2.2.7.1 Evaluating cytotoxicity employing flow cytometry 
Following the determination of post-freezing cell viability, as outlined in Section 6.2.2.3, 
cells were seeded at a density of 5 x 105 cells per well in sterile 6-well cell culture plates 
and incubated at 37°C in a humidified incubator with 95%O2 and 5%CO2. When regular 
microscopic evaluation revealed cells had reached ~80% confluence, treatment of cells 
was undertaken in triplicate as illustrated in Table 6.1 and maintained in the humidified 
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incubator as previously described. The saturation solubility of CPT in DMSO is 10mg/mL, 
which was subsequently diluted 25-fold in PBS and then 2-fold in cell culture medium to 
negate the toxic effect of DMSO on cells. The final concentration of CPT with which the 
cells were treated was thus 0.20mg/mL. Suspensions of uncoated and optimized CHO- 
and DSPE-NLB formulations were prepared with a CPT concentration of 0.4mg/mL. A 2-
fold dilution with cell culture medium thus produced preparations with CPT concentration 
of 0.20mg/mL. The concentration of SB in uncoated and optimized CHO-NLB was 
determined to be 1.02mg/mL and 0.99mg/mL, respectively. The concentration of SB in 
uncoated and optimized DSPE-NLB was determined to be 1.06mg/mL and 1.09mg/mL, 
respectively. Placebo suspensions were prepared at concentrations equal to the overall 
concentrations of optimized CHO- and DSPE-NLB. The maximum concentration of SB in 
DMSO that could be obtained was 15mg/mL, which was subsequently diluted 25-fold in 
PBS (pH 7.4; 37°C) and 2-fold in cell culture medium to create a final solution of 
0.3mg/mL.  
 
Table 6.1 Test and control preparations evaluated for their cytotoxic effect on A2780 ovarian 
cancer cells. 
Test Samples Control Samples 
Optimized CHO-NLB Untreated cells 
Optimized DSPE-NLB CPT 
Uncoated CHO-NLB SB 
Uncoated DSPE-NLB PBS 
 DMSO+PBS 
 Placebo CHO-NLB 
 Placebo DSPE-NLB 
 
The viability of cells following treatment with each preparation was assessed by flow 
cytometry 24, 48 and 72 hours post-treatment. The excess cell culture medium containing 
detached, no-viable cells was removed and added to sterile test tubes. Cells were rinsed 
with PBS (pH 7.4; 37°C) and trypsinized according to standard procedures outlined in 
Section 6.2.2.2. The cell suspensions were added to the respective sterile test tubes 
containing the previously removed non-viable cells. The total volumes were centrifuged at 
800rpm for 3 minutes and the supernatant discarded. The cell sediments were 
resuspended in 100µL cell culture medium each and transferred to round-bottom 
polystyrene test tubes. The 7-AAD stain (5µL) was added to each test sample and 
incubated at room temperature in darkness for 10 minutes, in accordance with the 
manufacturer’s guidelines. PBS (pH 7.4; 37°C; 500µL) was subsequently added to each 
test sample.  
Prior to cell analysis, quality control assessment was undertaken on the flow cytometer 
(FACS Calibur, BD Biosciences, Tullastrasse, Heidelberg, Germany). Unstained cell 
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counting beads as well as 4 stains, namely FITC, PE, PerCP and APC, were employed to 
ensure the quality of fluorescence detection by each of the 4 fluorescence detectors. The 
FL3 detector was of particular relevance in this study as the 7-AAD dye employed during 
analysis is detected by the FL3 detector. Following the successful outcome of the quality 
control test, the test parameters were determined. Evaluation of the forward scatter and 
side scatter plots of completely viable and completely non-viable cells enabled accurate 
distinction of the voltage threshold and region of interest. Test samples were subsequently 
analyzed at low and medium flow rates with buffer rinses between each sample to avoid 
results reflecting the effects of residue from previous samples. No less than 10000 cells 
were analyzed in each sample. Cell viability was analyzed employing BD CellQuest™ Pro 
version 5.1 software (BD Biosciences, Tullastrasse, Heidelberg, Germany).    
 
6.2.2.7.2 Real-time evaluation of formulation cytotoxicity    
Cell growth and cytotoxicity of the NLB-DDS and relevant controls were determined in 
real-time as a measure of electrical impedance employing the xCELLigence™ RTCA 
(Roche Applied Science, Penzberg, Upper Bavaria, Germany and ACEA Biosciences Inc., 
San Diego, CA, USA). A background scan of the cell culture medium (100µL/well) was 
performed prior to each analysis. A cell titration was initially performed in triplicate with cell 
densities ranging from 1250 to 10000 cells/well. The growth pattern of cells was observed 
over a 100 hour period and a density of 10000 cells/well was deemed suitable for 
analysis. This further identified the most suitable time period (22-34 hours post-seeding) 
to initiate drug treatment. All subsequent drug treatment was undertaken 24 hours post-
seeding.  
 
A titration of CPT was subsequently undertaken to establish sensitivity of the cells to CPT 
and to determine an effective concentration of CPT for the achievement of adequate 
cytotoxic activity. A saturated solution of CPT in DMSO (10mg/mL) was prepared with 
subsequent serial dilutions resulting in a concentration range of 2-10mg/mL. The CPT 
solutions were diluted 25-fold PBS (pH 7.4; 37°C) and then 2-fold in cell culture medium 
due to the toxicity of concentrated DMSO to cells, resulting in final CPT solutions of 0.04-
0.20mg/mL. Cells were seeded at 10000 cells/well and treated 24 hours later with serial 
dilutions of CPT and the response pattern of cells to the range of CPT concentrations was 
analyzed for 36 hours post-treatment. The final concentration of CPT determined to 
display the most appropriate response by the cells for the purposes of this study 
(0.20mg/mL following dilution in cell culture medium), coincided with the concentration 
employed for analysis by flow cytometry. Hence, all test and control samples were 
prepared in accordance with the description in Section 6.2.2.7.1.  
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6.3 Results and Discussion 
6.3.1 Hemolytic impact of formulated nano-lipobubble drug delivery systems 
For intravenous formulations, assessment of the hemolytic capacity of nanosystems is a 
pivotal determination and a foremost restriction to clinical application. Erythrocytes are 
negatively charged. The negative surface charge of optimized CHO- and DSPE-NLB was 
beneficial to intravenous application due to compatibility with the charge of erythrocytes. 
Formulations inducing <10% hemolysis are considered non-toxic, whilst those inducing 
>25% are considered to be of high risk (Elmowafy et al., 2013; Sharma et al., 2013). 
Optimized CHO- and DSPE-NLB demonstrated a concentration-dependent hemolysis. 
The hemolysis induced by CHO-NLB increased from 4.63% to 6.87% with an increase in 
concentration from 10mg/mL to 20mg/mL, as illustrated by the bar graph in Figure 6.1. A 
similar increase in concentration of DSPE-NLB resulted in a concomitant increase in 
hemolysis from 5.36% to 7.03%. However, NLB concentrations of 20mg/mL still 
demonstrated low hemolytic potential and were considerably below the hemolytic 
threshold delineating formulations that are considered safe for intravenous administration. 
     
 
Figure 6.1 Quantitative analysis of the hemolysis induced by optimized CHO- and DSPE-NLS. 
Despite the concentration-dependent hemolysis displayed, all formulations assessed displayed 
hemolysis that was below the toxic threshold.   
 
6.3.2 Cellular uptake of nano-lipobubbles 
The application of fluorescence microscopy provided conclusive evidence of cellular 
uptake of the formulated NLB-DDS by the ovarian cancer cell line under investigation. 
Bright-field contrast images denote the cellular morphology, whilst super-imposed 
fluorescence images highlight the presence of the NLB-DDS within the cells. Successful 
cellular uptake of the formulated NLB-DDS and the subsequent release of CPT and SB 
within the tumour cells are critical to the achievement of augmented antineoplastic activity 
relative to that of native CPT and SB. Formulated CHO- and DSPE-NLB demonstrated a 
time-dependent cellular uptake, which was more pronounced in CHO-NLB. The distinct 
increase in fluorescence intensity evident in the fluorescence micrographs in the upper 
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panel of Figure 6.2 highlights the increase in CHO-NLB uptake by the A2780 cells 30 
minutes post-treatment relative to that depicted 10 minutes post-treatment. Cellular 
uptake of DSPE-NLB was markedly higher and faster than observed for CHO-NLB, which 
was attributed to the smaller size of DSPE-NLB. Localization of both CHO- and DSPE-
NLB highlight the potential for released CPT to be transported to the cell nucleus, which is 
the target for antineoplastic activity.   
 
 
Figure 6.2 Qualitative evaluation of cellular uptake of SRB-labeled optimized CHO- and DSPE-
NLB 10 and 30 minutes post-treatment. 
 
6.3.3 Assessment of cytotoxicity by flow cytometry 
Flow cytometry is a laser-based technology with a diverse range of applications from cell 
counting, differentiation between cells with various properties, detection of biomarkers, 
immunophenotyping and protein engineering. Fluorescence-activated cell sorting (FACS) 
flow cytometry was employed in this study to quantify cell viability following treatment with 
test and control formulations. The flow cell in the flow cytometer contains sheath fluid and 
the fluidics system therein ensures cells pass through the sensors in single file. Light 
scattering at different angles generates forward and side scatter data, which are indicative 
of cell size and complexity, respectively. The application of specific fluorescent dyes 
produces optical fluorescence signals that are converted to electronic signals for 
computation by the software (Brown and Wittwer, 2000). 7-AAD is a fluorescent dye that 
is widely employed in cell viability analyses. This fluorescent marker has a strong affinity 
for DNA and is able to effectively intercalate with double stranded DNA. 7-AAD is unable 
to permeate uncompromised cell membranes, hence it is excluded by viable cells. 
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Quantification of 7-AAD may, therefore, be employed to quantify non-viable cells in a 
sample.  
 
Scatter plots and histograms depicted in Figures 6.3 and 6.4 provide graphical illustrations 
of the intensity of 7-AAD detected for each sample, which is directly related to the degree 
of cytotoxicity of the formulation under assessment. Evaluation of untreated cells provided 
an indication of natural cell death. As expected, the cell viability was >96% 24 hours post 
treatment and decreased over the next 2 days to 90.65% and 85.47%, respectively. 
Treatment of cells with PBS and DMSO+PBS did not demonstrate a significant increase in 
cell death. The high efficacy of CPT against A2780 tumour cells was readily highlighted, 
with 71.20% cytotoxicity recorded 24 hours post-treatment. However, there was a 
significant increase in cell viability 48-72 hours post-treatment. This increase in viability 
was attributed to the low stability of CPT and antineoplastic activity being restricted to 
cells in the S-phase of the cell cycle. CPT may have been readily internalized and had 
exerted high antineoplastic activity following initial treatment. However, rapid 
internalization may have also caused rapid saturation of cellular internalization 
mechanisms. CPT that was not initially internalized was converted to the inactive 
carboxylate form in the surrounding medium and was not able to exert any further 
antineoplastic effect. Surviving cells were able to recover and proliferate over the 
remaining analytical period leading to an increase in the ratio of viable cells:dead cells 
during analysis. On the contrary, SB displayed relatively low but increasing cytotoxic 
potential over the analysis period. SB is hypothesized to induce cell apoptosis, hence the 
effect is not restricted to a particular phase of the cell cycle. The cytotoxicity observed with 
cells treated with SB was 3.91%-8.41% higher than the natural cell death observed with 
untreated cells over the 72 hour analytical period.  
 
Evaluation of the cytotoxic effect of the materials employed in the fabrication of optimized 
NLB as well as of the nano-construct itself was determined through treatment of cells with 
placebo CHO- and DSPE-NLB. Both formulations demonstrated similar cytotoxic activity 
against the A2780 cell line, as well as minimal variation to the cytotoxicity displayed by 
untreated cells. This confirms the cytotoxicity demonstrated by optimized NLB 
formulations are attributed only to the location and manner in which the antineoplastic 
agents are released and cannot be ascribed to the other materials in the formulation.  
 
Treatment of A2780 cells with uncoated CHO- and DSPE-NLB was undertaken to provide 
insight on the effect of the release characteristics of these formulations on cells relative to 
those of the optimized polymer coated NLB formulations. The cytotoxicity observed 24 
hours post-treatment was substantially (10.46%) higher for uncoated DSPE-NLB than 
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uncoated CHO-NLB. The more rapid release of CPT and SB from uncoated DSPE-NLB 
was associated with the greater cytotoxic activity. Over the following 2 days the 
cytotoxicity of cells treated with CHO-NLB was greater than that treated with DSPE-NLB. 
At the conclusion of the experiment, cytotoxicity induced by uncoated CHO-NLB was 
12.58% greater than that induced by DSPE-NLB. The slower release of CPT and SB from 
uncoated CHO-NLB was attributed to the increased cytotoxic activity and provided an 
insight into the significant effect that drug release characteristics may have on the 
cytotoxic potential of formulated NLB. This was of particular significance given the 
consideration that CPT acts on a particular phase of the cell cycle, and displays instability 
in aqueous environments and at higher pH, which leads to loss of antineoplastic activity. 
The institution of polymeric coating considerably slowed the release of CPT and SB from 
CHO- and DSPE-NLB. The benefit of the slower release was distinctly evident in the 
consistent increase in cytotoxicity demonstrated by optimized CHO- and DSPE-NLB over 
the analytical period. The cytotoxicity of optimized CHO- and DSPE-NLB was 4.58% and 
8.46% lower than their uncoated counterparts 24 hours post-treatment. The lower 
cytotoxic activity was associated with lower concentration of CPT and SB due to slower 
release. However, the advantage of polymeric coating and the consequent slower, more 
constant pattern of drug release was readily evident over the following 2 days of 
treatment. The slower drug release translated into sustained cytotoxic activity evidenced 
by the increasing uptake of 7-AAD by the non-viable cells. Cytotoxicity induced by 
optimized CHO-NLB 48 and 72 hours post-treatment were 69.93% and 85.9%, 
respectively. Optimized DSPE-NLB induced cytotoxicity 48 and 72 hours post-treatment 
were 72.93% and 94.93%, respectively. Slower release of CPT enabled more cells in the 
S-phase of the cell cycle to be exposed to CPT, resulting in higher cell death. This 
cytotoxic effect may have been further intensified by the synergistic activity of SB. The 
cytotoxicity resulting from treatment of cells with CHO- and DSPE-NLB 72 hours post-
treatment was substantially higher than that observed with CPT and SB individually, or the 
sum thereof.     
 
Flow cytometry is a highly favored technique in cell-based studies due to the ability to 
rapidly obtain a high volume of data with regards to various cellular characteristics. The 
use of different fluorochromes with similar excitation wavelengths but different emission 
wavelengths enables multi-variate qualitative and quantitative analysis (Brown and 
Wittwer, 2000). Moreover single cell characterization, small sample size and simple 
sample preparation are added benefits of this technique. However, this is an end-point 
analysis and as such does not provide data on continuous physiological and kinetic 
changes undergone by cells during the course of the study. 
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6.3.4 Assessing cellular status through continuous real-time evaluation 
Continuous real-time evaluation of cellular cytotoxicity was undertaken through label-free 
quantitative assessment employing the xCELLigence™ RTCA system (Roche Applied 
Science, Penzberg, Upper Bavaria, Germany and ACEA Biosciences Inc., San Diego, CA, 
USA). The xCELLigence system comprises four main components, namely the RTCA 
analyzer, RTCA station, RTCA computer with integrated software, disposable E-plate 16. 
E-plates 16 are a single use, disposable device similar in structure to microtitre plates 
used in other cell-based studies. However the distinct feature of these plates is the 
presence of gold microelectrode cell sensors lining 80% of the bottom of each well, which 
enable the determination of electrical impedance (Urcan et al., 2010). The E-plate 16 is 
fitted into the RTCA station, which is further housed within a sterile cell culture incubator 
and connected externally to a computer with integrated software.  
 
The principle of this analytical technique is centered on the measurement of emerging 
electrical impedance of the cell population present in each well (Urcan et al., 2010). The 
measurement of electrical impedance enables the detection and characterization of 
physiological cellular changes. Electrical impedance is influenced by electrode geometry, 
the degree of cellular attachment to the electrode, and ion concentration within the well. 
Ion concentration in the bulk solution as well as at the electrode/solution interface will be 
the primary contributor to electrical impedance in the absence of cells (Urcan et al., 2010). 
The introduction of adherent cells and their subsequent attachment to the electrode 
sensors on the surface of the well has an insulating effect, thereby altering the local ion 
concentration at the electrode/solution interface. Changes in the ionic environment of the 
well are detected by the microelectrode sensors and can be related to the nature and 
intensity of cell attachment, the quantity of cells present and their morphology. The data is 
represented as cell index (CI), a unit-less parameter that relates the electrical impedance 
of the cell population in a well at a given time-point to the baseline electrical impedance 
determined at the initiation of the experiment (Urcan et al., 2010). Fundamentally, the 
healthier cells are and the greater their proliferation the greater their attachment and the 
higher the CI (Moodley et al., 2011). Morphological changes such as cytotoxicity reduce 
the attachment of cells and are thus indicated by a lower cell index.      
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Figure 6.3 Histograms (A; C; E) and scatter plots (B; D) indicating the intensity of 7-AAD detected as a measure of the cytotoxicity of test controls, CPT and SB 
formulations. Histograms in the first column provide an indication of the natural cell death that occurred in untreated cells over the analytical period, with an inset of 
the forward versus side scatter plot for each day, depicting the cell characteristics on each day. (M1 = R2 = cell cytotoxicity). 
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Figure 6.4 Histograms (A; C; E) and scatter plots (B; D; F) indicating the intensity of 7-AAD detected as a measure of cytotoxicity induced by placebo, uncoated and 
optimized CHO- and DSPE-NLB. (M1 = R2 = cell cytotoxicity). 
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A cell titration was initially performed in an attempt to firstly, determine the growth pattern 
of the A2780 ovarian cancer cell line and secondly, to identify an appropriate cell density 
that would demonstrate a rate of cell proliferation suitable to the purpose of the study. 
Measurements were taken at 15 minute intervals over a 100 hour period, however are 
represented graphically at 30 minute intervals. Each of the cell densities employed (1250-
10000 cells/well) demonstrated reproducible cell growth patterns, the average of which is 
represented in Figure 6.5. The cell indices observed over the initial 6-8 hours were 
attributed to attachment of the cells introduced into the wells, based on previously 
observed cell behavior, and were congruent with the variation in cell concentrations in 
accordance with the cell titration. Following this period, the significant difference in the cell 
indices of each cell concentration was attributed to proliferation of the cells. The 
proliferation of cells at lower densities (1250 and 2500 cells/well) was notably slower than 
that observed at higher cell densities (5000 and 10000 cells/well). This was attributed to 
sub-optimal cell signaling required for adequate cellular replication, as a result of sparser 
cell populations. Cells at the highest density (10000 cells/well) exhibited a rapid rise in cell 
index which was related to a high proliferation rate. The maximum cell index at this 
density was achieved at approximately 47 hours, followed by natural cell death. At a 
density of 5000 cells/well cellular proliferation proceeded notably slower, reaching 
maximum cell density at approximately 72 hours post-seeding. The earlier onset of cell 
death at 10000 cells/well relative to that at 5000 cells/well was hypothesized to result from 
nutrients being exhausted faster at the higher cell density as well as a lack of space for 
attachment of more cells. Cells at density of 1250 cells/well and 2500 cells/well did not 
demonstrate maximum cell indices during the analytical period. A density of 10000 
cells/well was delineated as the most appropriate for the purposes of this study, with a 
treatment period between 22-34 hours post-seeding.  
 
 
Figure 6.5 Growth profiles of A2780 cells at densities from 1250-10000 cells/well over a 100 hour 
period. (in all cases n=3 and SD<0.02) 
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A drug titration was subsequently performed with CPT to establish sensitivity of the cell 
line to the model drug, as depicted in Figure 6.6. Serial dilutions of CPT in DMSO were 
prepared, followed by dilution with PBS (pH 7.4; 37°C) to negate the toxic effects of 
DMSO on the cells. All samples were diluted with cell culture medium (1:1) prior to 
treatment of cells. Treatment of cells with DMSO+PBS was, therefore, assessed as a 
control. Cellular proliferation was noticeably reduced following treatment with the 
DMSO+PBS control relative to that of untreated cells. Whilst the DMSO+PBS solvent was 
not particularly toxic to the cells, their nutrient content is substantially lower than that of 
the cell culture medium environment in which the untreated cells grew. The rapid 
proliferation of this cell line is associated with high nutritional demands. Since the 
DMSO+PBS solvent is unable to cater adequately to these nutritional demands, the 
proliferation of cells will be compromised to a degree.  
 
Sensitivity of the cell line to CPT was apparent, even at the lowest concentration tested. 
There was an observable direct relationship between CPT concentration and cytotoxic 
effect on the cells over the initial 10 hours post-treatment. At a CPT concentration of 
0.20mg/mL there was a rapid and significant decline in cell index over the initial 10 hours 
post-treatment, succeeded by recovery of the cells as evidenced by the increase in cell 
index. Treatment with lower concentrations of CPT resulted in a similar response pattern, 
but with proportionally reduced intensity. Cellular internalization of CPT appears to have 
been highest during the first 10 hours resulting in cell death. However, conversion of CPT 
to the inactive carboxylate form over time led to reduced cytotoxicity. Moreover, the 
surviving cells were able to proliferate over time causing an increase in cell number. The 
rapidly diminished cell numbers following treatment with 0.20mg/mL CPT solution resulted 
in less nutrients being consumed and availability of sufficient nutrients for quicker recovery 
and proliferation of the surviving cells. Hence, the gradient of the portion of each curve 
associated with cell recovery and proliferation appears steeper with increasing 
concentration of CPT. Moreover, the swift recovery of cells treated with higher 
concentrations of CPT suggest some cells may have not been completely killed and 
detached. Rather, metabolic changes may have caused rounding of the cells, thereby 
covering a smaller surface and leading to lower cell index. Upon removal of the stress 
generated by the presence of active CPT, the cells were thus able to quickly recover. The 
considerable response of cells treated with 0.20mg/mL CPT was determined appropriate 
for analysis and comparison of the cytotoxic activity of optimized formulations.  
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Figure 6.6 Cell index curves highlighting cellular response to serial dilutions of CPT relative to the 
growth pattern of untreated cells and treatment with the PBS:DMSO solvent system. (in all cases 
n=3 and SD<0.02) 
 
Several controls were assessed in order to elucidate the potential of their effects on the 
overall cytotoxicity of the formulated nano-DDS’s. The response of A2780 ovarian cancer 
cells to test and control formulations are presented in Figures 6.7A and 6.7B. The ionic 
environment of plain cell culture media remained constant throughout the analytical period 
and displayed no electrical impedance. Untreated cells were employed as an indication of 
unhindered cellular growth and proliferation within the confines of this study, limited only 
by the availability of nutrients and space for attachment. The growth pattern for cells 
following treatment with PBS, the solvent for the formulated NLB’s, was analogous to that 
observed following treatment with the PBS:DMSO solvent combination. The slower growth 
pattern was attributed to the reduced availability of nutrients for cell replication, as 
previously discussed. Cells treated with placebo CHO-NLB demonstrated a growth pattern 
analogous to that following treatment with PBS, thus confirming the non-toxicity of the 
materials employed in nano-NLB, as well as the nano-construct itself. However, treatment 
with placebo DSPE-NLB resulted in a significantly lower cell index. Greater cellular 
internalization of the placebo DSPE-NLB relative to the larger placebo CHO-NLB is likely 
to have hindered cellular function to a slight degree, thereby reducing the proliferative 
capacity of the cells. However, this reduction in cell proliferation was not significant 
enough to have clinical relevance, particularly in such a rapidly proliferating cell line.  
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Figure 6.7 Graphical illustration of the growth and response of A2780 cells to various control 
preparations establishing the cytotoxic potential of each preparation. (in all cases n=3 and 
SD<0.02). 
 
The response of A2780 cells to treatment with native CPT has been previously 
expounded. The presence of native CPT may have led to saturation of cellular 
internalization of CPT, leading to rapid killing of cells in the S-phase of the cell cycle. 
However, the short duration of the cytotoxic stress presented by CPT had a marginal 
effect on cells in other phases of the cell cycle, resulting in expeditious recovery of the 
cells and subsequent proliferation. The cytotoxic activity of SB was notably less intense 
and of a shorter duration to that observed for CPT. The mechanisms of cell cytotoxicity 
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cell cycle and thus will have an indiscriminate cytotoxic effect on all cells. The initial 
decrease in cell index was attributed to this indirect effect. The solubility constraints of SB 
and the high dilution required due to the DMSO solvent resulted in a very low final 
concentration of SB for cell treatment and low cytotoxic activity. However, the analysis 
established a distinct sensitivity of A2780 cells to SB. Recovery and proliferation of cells 
was of a fairly swift nature with marginal differences in cell index relative to that of cells 
treated with PBS:DMSO from approximately 18 hours post-treatment.  
 
Treatment of cells with uncoated CHO- and DSPE-NLS demonstrated an immediate and 
considerable reduction in cell index due to the release characteristics of CPT and SB from 
these formulations. The degree of cytotoxic activity deduced from the cell indices 
highlighted greater cytotoxicity by DSPE-NLB over a shorter duration, with subsequent 
recovery of cells from approximately 16 hours post-treatment. This correlates with the 
release characteristics of CPT from DSPE-NLB observed during in vitro analysis. Rapid 
release of CPT and SB from the uncoated DSPE-NLB resulted in a high degree of cell 
cytotoxicity, augmented further by the differing mechanisms of action of the 2 compounds. 
However, the achievement of cellular uptake saturation was a swifter process and CPT 
and SB that did not have an impact initially, failed to achieve significant cytotoxicity later in 
the experiment. Whilst recovery of cells was apparent, the peak of the curve was at a 
conspicuously lower cell index than that of cells treated with PBS:DMSO. The release of 
CPT from uncoated CHO-NLB displayed a bi-phasic pattern, with slower release from 6-
24 hours relative to that of the initial 6 hours. Release of SB from this formulation was 
evidently more rapid. These characteristic proved beneficial in achieving a more sustained 
cytotoxic effect on A2780 cells than that observed with DSPE-NLB. The initial decrease in 
cell index may be attributed to synergistic activity of CPT and SB, whilst the prolonged 
activity may be a combination of continued CPT activity and the inability of cells to recover 
adequately. 
 
Treatment of cells with optimized CHO- and DSPE-NLB proved substantially favorable 
and to a large extent corroborated the drug release data expounded in Chapter 5, Section 
5.4.11. The slower release pattern of both CPT and SB following polymer coating 
translated into augmented and sustained cytotoxic activity of both optimized formulations. 
The achievement of superior cytotoxicity with DSPE-NLB was associated with enhanced 
cellular internalization due to the smaller size of this formulation. The enhanced 
cytotoxicity may also be attributed to a higher concentration of SB within the optimized 
formulations relative to that of native SB. The cell index curve of optimized DSPE-NLB 
treated cells displayed a steeper gradient over the initial 16 hours post-treatment, with a 
marginal decrease in cytotoxicity thereafter. The cell index profile of cells treated with 
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optimized CHO-NLB highlighted a fairly constant decrease in cell index, indicative of 
sustained cytotoxic activity. The slower release of CPT and SB from optimized CHO- and 
DSPE-NLB formulations prevented saturation of cell uptake of the compounds at an early 
stage resulting in constant exposure to the antineoplastic compounds. Moreover, 
prolonged release of CPT in particular allowed for more cells to be exposed to CPT whilst 
in the S-phase of the cell cycle, where CPT acts.     
 
The advantages of this technique include the ability to immediately gauge changes in 
cellular behavior. Continuous monitoring provides a more complete and accurate 
representation of changes in cellular morphology, cell numbers and viability (Urcan et al., 
2010). The technique provides high sensitivity and reproducibility due to the extent of 
microelectrode coverage on the base of the wells. A small sample size is required and the 
entire cell population in a well can be monitored. This is a label-free analytical process 
which often saves labor and reagents whilst providing substantial information content. 
Furthermore, real-time evaluation provides an indication of the optimal period for 
treatment, which is decidedly more accurate than that deduced solely from microscopic 
observation (Moodley et al., 2011). However, the specialized plates required for the 
experiment can prove costly.  
 
6.4 Conclusions 
The undertaking of ex vivo analyses was essential in the systematic characterization of 
formulated CHO- and DSPE-NLB, and the potential of these nano-DDS to enhance the 
cytotoxic activity of CPT and SB. The potential of formulated CHO-NLB to induce 
hemolysis was determined to be 4.36% and 6.87% for NLB concentrations of 10mg/mL 
and 20mg/mL, respectively. At equal concentrations, the hemolysis deduced for DSPE-
NLB was 5.36% and 7.03%. This concentration-dependent hemolysis was not completely 
unexpected and the safety observed even at the higher concentration was highly 
favorable. The optimized CHO- and DSPE-NLB can be considered hemocompatible. The 
intracellular target of CPT, in particular, requires adequate uptake of the formulated NLB 
by tumour cells. Successful cellular internalization was demonstrated for both CHO- and 
DSPE-NLB over a short period post-treatment. The size difference between DSPE-NLB 
and CHO-NLB resulted in higher cellular internalization of DSPE-NLB. A time-dependent 
uptake was also evident, which would be beneficial for the achievement of sustained 
antineoplastic activity.  
 
The evaluation of cell cytotoxicity was undertaken by flow cytometry, an end-point assay, 
and a continuous monitoring, real-time impedance-based study. The results of both 
studies demonstrated high correlation. The evaluation of control formulations highlighted 
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the inactivity of materials employed in the formulation of NLB, the structure of the nano-
system in the absence of antineoplastic compounds and the solvents employed in the 
assays. Cells displayed a marginally slower growth rate when treated with control 
formulations due to reduced availability of nutrients to meet the high demand of rapidly 
proliferating cells. The slower release pattern of CPT and SB from optimized CHO- and 
DSPE-NLB proved significantly beneficial to the overall antineoplastic activity of CPT and 
SB, as evidenced by the sustained and highly favorable cytotoxicity results obtained over 
the 72 hour assessment. Moreover, the high degree of cellular internalization of the NLB 
may have further contributed to the favorable antineoplastic characteristics demonstrated 
by the NLB formulations. Treatment of A2780 ovarian cancer cells with optimized CHO- 
and DSPE-NLB resulted in a cytotoxicity of 85.90% and 94.93%, respectively over the 72 
hour analysis, which was considerably higher than the cytotoxicity demonstrated by plain 
CPT and SB.  
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CHAPTER 7 
CONCLUSIONS AND RECOMMENDATIONS 
 
7.1 Conclusions 
Ovarian cancer is an aggressive pathology affecting several thousand women across all 
demographic barriers. Late clinical diagnosis, extensive metastasis and a high rate of 
recurrence collectively add to a very poor prognosis and low 5-year survival rate. The 
multivariate challenges associated with successful ovarian cancer therapy severely 
compromise the outcome of therapy and patient quality of life. Chemotherapy is an 
essential adjuvant to surgical resection due to the high likelihood of metastasis. 
Intravenous chemotherapy is associated with deleterious side-effects due to 
indiscriminate activity on rapidly dividing cells. However, this route of administration 
remains convenient, relatively cost effective, minimally invasive and acceptable to 
patients. The aim of this study was to formulate a novel antineoplastic nano-lipobubble 
drug delivery system (NLB-DDS) that would demonstrate passive targeting to tumour 
tissue through the Enhanced Permeability and Retention phenomenon, following 
intravenous administration.  
 
Camptothecin (CPT) was selected as the model drug due to the broad spectrum of 
antineoplastic activity as well as the formulation and physiologic stability challenges that 
hinder the clinical use of this compound. Nano-sizing was of paramount importance during 
this study with a maximum threshold size of 200 nm being delineated for the NLB in order 
to ensure passive targeting. Nano-liposomes (NLS) were formulated as a precursor to 
NLB and preliminary studies were undertaken on these NLS. The Reverse Phase Solvent 
Evaporation method was deemed the most appropriate method of formulation for the 
purposes of this study. Fixed formulation parameters defined during preliminary 
investigations included the lipid combinations employed, total lipid concentration, 
surfactant type, CPT concentration, ultrasonication and rotary evaporation parameters. 
The ratio of each lipid in the combination and surfactant concentration were identified as 
independent variables that needed to be optimized in order to achieve the desired zeta 
size, zeta potential, drug incorporation efficiency (DIE) and mean dissolution time.  
 
A Face-centered Central Composite design was employed to statistically optimize the 
independent variables for the desired outcomes. The concentration of dioctyl 
sulfosuccinate [DOS] had a statistically significant impact on the MDT achieved with 
cholesterol-containing NLS (CHO-NLS), whilst lipid ratio and [DOS] proved statistically 
significant on the average size and zeta potential, respectively of 
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distearoylphosphatidylethanolamine-containing NLS (DSPE-NLS). The optimal 
formulation constitution of CHO-NLS was determined to be Distearoylphosphatidylcholine 
(DSPC): CHO = 3:1 and [DOS] of 0.3%w/v. The optimal constitution of DSPE-NLS was 
DSPE:CHO = 1.33:2.67 and [DOS]  = 0.3%w/v. The composite desirability of both 
formulations exceeded 0.9.  
 
Statistically optimized CHO- and DSPE-NLS were converted to NLB through the 
introduction of sulfur hexafluoride gas into the core of the NLS. Formulated NLB were well 
below the size limit of 200 nm delineated for passive targeting and displayed high drug 
incorporation. The zeta potential of CHO-NLB was substantially more favorable than that 
of DSPE-NLB. Moreover, the release profile of CPT from CHO-NLB was slower and more 
favorable than that observed from DSPE-NLB. Formulations were successfully lyophilized 
in the presence of a cryoprotectant to produce flaky powders which were easily re-
dispersed and retained the NLB structure. Further modifications were undertaken to 
enhance the antineoplastic potential of the nano-DDS as well as minimize drug release in 
the systemic circulation. The incorporation of silibinin (SB) a phytochemical with well 
documented antineoplastic properties was intended to work synergistically with CPT. SB 
incorporation was satisfactory and had minimal effect of the properties of formulated NLB. 
Finally the application of sequential oppositely charged polymeric layers was instituted in 
order to enhance the stability profile of the formulation and delay release of CPT and SB 
from the NLB. Polymeric coating with CHT and PAA proved substantially beneficial on the 
surface charge of NLB, particularly DSPE-NLB whilst the average size of each formulation 
was successfully maintained below 200 nm. The release characteristics of CPT and SB 
were notably slower and the impact of this was highlighted in cytotoxicity evaluation.   
 
Ex vivo studies were undertaken on fresh blood samples and the A2780 epithelial ovarian 
cancer cell line. Optimized CHO- and DSPE-NLS demonstrated excellent 
haemocompatibility as well as rapid and efficient uptake by tumour cells. Cytotoxicity 
studies highlighted markedly sustained cytotoxicity with low recovery of cells, relative to 
that observed with uncoated NLB and native CPT and SB. This was a direct result of the 
slower release of CPT, in particular, which exhibits cell cycle phase-specific activity. 
 
In conclusion, formulated CHO- and DSPE-NLB were below the delineated size for 
passive targeting and demonstrated remarkable stability characteristics to substantiate 
feasibility of the formulation with regards to manufacturing, storage and clinical 
application. Materials employed were generally easily obtainable and cost-effective. The 
formulations demonstrated considerable safety and cytotoxicity against the ovarian cancer 
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cell line. The optimized CHO- and DSPE-NLB demonstrated significant potential for 
clinical application. 
 
7.2 Recommendations 
The passively targeted nature of this DDS lends applicability to other solid tumours since 
no targeting modalities that are specific to ovarian cancer have been employed. Hence, 
potential for use in other solid tumours should be investigated. To this end, the 
incorporation of other antineoplastic drugs that are currently employed in the treatment of 
other solid tumours such as colon, liver and lung cancer should be evaluated in this DDS. 
Moreover, ex vivo studies should extend to the respective cell lines that are applicable to 
other tumour subtypes.  
 
Drug resistance presents an increasing challenge to antineoplastic therapy. The potential 
of the formulated NLB-DDS to overcome or bypass established mechanisms of drug 
resistance should be assessed. It is recommended that antineoplastic drugs to which 
resistance has been identified be incorporated into the NLB-DDS and tested against 
resistant cell lines. Furthermore, the potential of phytochemical incorporation in 
overcoming drug resistance should be considered. Tailored release of the phytochemical 
and antineoplastic drug may result in sensitization of the cells to the drug or the 
phytochemical may act as a preferential substrate, thereby preventing deactivation of the 
antineoplastic drug. In addition, the antineoplastic activity of various combinations of 
phytochemicals with different mechanisms of antineoplastic activity should be evaluated 
against resistant and non-resistant tumour cells to effectively assess their potential and 
clinical applicability in tumour therapy.  
 
Uncoated CHO-NLB demonstrated immensely favourable characteristics during in vitro 
and ex vivo evaluation. The benefits of polymeric coating, although evident, were of lesser 
significance than that observed with DSPE-NLB. It is recommended that methods of 
delaying drug release from CHO-NLB, other than polymeric coating, be investigated. 
These methods should maintain the already favorable stability of the formulation and not 
significantly increase the size of the NLB. 
 
An outstanding characteristic of nano-DDS is the increased surface area which facilitates 
the attachment of targeting moieties. Targeted therapy will be especially beneficial for 
antineoplastic drugs since site-specific delivery enhances cytotoxicity at the desired site 
while maintaining the condition of healthy tissue. It is thus recommended that future 
research delves into the feasibility of adding targeting moieties to coated and uncoated 
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NLB and the benefits of widely applicable, passively targeted nano-DDS relative to a 
tumour specific nano-DDS.  
 
Nano-lipobubbles, as described in this dissertation, have theranostic potential and may be 
combined with ultrasound technology for tumour detection, imaging and monitoring the 
progress of therapy. In vivo studies are critical in assessing the clinical applicability of this 
DDS and will also shed valuable light on the imaging potential of this nano-structure. It is 
thus recommended that in vivo evaluation is undertaken in a suitable animal model, such 
as rats, to simultaneously assess the therapeutic and diagnostic potential of this nano-
DDS.  
 
The Reverse Phase Solvent Evaporation method employed in formulation of the optimized 
CHO- and DSPE-NLB was uncomplicated and did not require prolonged preparation 
times. This method can conveniently be adapted to industry-scale production, particularly 
through the employment of rotary evaporators similar to the one use in this study, that 
enable simultaneous solvent evaporation of numerous samples, without interference 
between samples. However, consistency in technique and timing was paramount to the 
achievement of consistently reproducible results and scientifically acceptable inter-
formulation variance in this study. Hence, industry-scale production may require 
automation of the processes that were undertaken manually during this study, such as 
intermittent addition of phosphate buffered saline and subsequent ultra-sonication, in 
order to minimize personnel involvement and formulation variance. The production of a 
lyophilized powder end-product provides a dosage form that is easily and readily usable in 
clinical practice.  
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Derusha Frank, Viness Pillay*, Yahya E. Choonara and Lisa C. du Toit 
University of the Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road, 
Parktown, 2193, Johannesburg, South Africa 
*Correspondence: viness.pillay@wits.ac.za 
Purpose: 
   The sophistication of current drug delivery systems (DDS’s) precludes the utilisation of advanced 
technology and innovative concepts to ensure progression in the field of drug delivery. Polymer 
blends offer the potential of exploiting the advantageous properties of individual polymers in the 
development of highly precise targeted DDS’s. This study investigated the effect of varying the 
composition of chitosan (CHT), a biodegradable and biocompatible polymer, and poly-
(caprolactone) (PCL), a pH-responsive polymer, on the resultant formulation and characterisation 
of these formulations. 
Method: 
   Solutions of (CHT) (1% and 2% w/v) in 1M acetic acid and (PCL) (2% and 5% w/v) in chloroform 
was prepared. Phosphatidylcholine (10mg) was incorporated into the PCL solution. All solutions 
were stirred overnight by means of a magnetic stirrer. The CHT solution was subsequently added to 
the PCL solution under the influence of a homogeniser. A surfactant, Tween 80 (2mL), was added 
drop wise to the emulsion during homogenisation. The resultant milky-white emulsion was 
subjected to rotary evaporation under vacuum by means of a rotary evaporator (30rpm; 90ºC) for 
12 hours. The final semi-transparent solution was allowed to evaporate under a fume hood for 48 
hours. The polymer composition of each formulation is as follows: 
   Formulation 1: Chitosan – 2% w/v; 100mL, Poly-(caprolactone – 5% w/v; 25mL. 
   Formulation 2: Chitosan – 1% w/v; 50mL, Poly-(caprolactone) – 2%w/v; 100mL 
Results: 
   Macroscopic analysis exhibited phase distinctions between the final products of each 
formulation. Formulation 1 produced porous macro-particles, whilst a semi-membranous structure 
with a microbead-like surface morphology resulted from Formulation 2. Microscopy studies 
revealed a more consistent size distribution in Formulation 2 (~100-200µm), as compared to 
Formulation 1. The formulations FT-IR spectra demonstrated minimal deviation from that of the 
spectra of individual polymers, signifying minor interaction between the polymers. This was 
further confirmed by DSC. Significant variation in the stability of these formulations was also 
highlighted by their zeta potential.  
Conclusion: 
   Individual polymer concentrations and their relative proportions in polymeric blends have a 
substantial influence on the resultant formulation. This principal can be manipulated to develop 
materials with precise properties for specific drug delivery functions. 
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Introduction: 
The gaping deficiency in current ovarian cancer therapy is substantiated by the elevated recurrence rate and 
appalling 5-year survival rate of ovarian cancer. Nano-enabled systems have been acutely successful in tumour 
imaging. The current research aims to extend this paradigm to targeted anti-tumour therapy with the formulation of 
a nano-liposomal (NL) drug delivery system that will be passively targeted to ovarian tumour tissue, via the EPR 
phenomenon, following intravenous administration. This system further aims to limit the solubility and toxicity to 
healthy tissue shortfalls that have hindered the clinical usefulness of the exceedingly potent anti-tumour drug 
Camptothecin (CPT).   
Methods: 
Preparation of CPT-loaded Nano-liposomes: Distearoylphosphatidyl choline (0.03%w/v) and cholesterol (0.01% 
w/v) were dissolved in chloroform:methanol (9:1). Dioctylsulfosuccinate (DOS) (0.01–0.03% w/v), CPT and PBS 
(pH7.4) were added to the organic phase under ultra-sonication (Amplitude=60%, Time=2 minutes). The resultant 
monophasic emulsion was subjected to rotary evaporation under vacuum at 60ºC for 2-3 hours, until complete 
evaporation of organic solvents was achieved. PBS (pH 7.4; 10mL) was added periodically during the evaporation 
process and ultra-sonication was undertaken at each addition as outlined above. This process culminated in the 
formation of CPT-loaded NL’s suspended in PBS (pH 7.4). 
Determination of Nano-liposomal Size and Size Distribution: NL suspensions were filtered through a 0.22µm filter 
and subjected to size and size distribution analysis employing a NanoZetasizer ZS. Analysis was conducted over a 
3 hour period whilst maintaining the formulations at physiological temperature. Size and morphology were further 
confirmed by Transmission Electron Microscopy (TEM). 
Evaluation of Drug Incorporation Efficiency (DIE): The solubility properties of CPT dictated that unincorporated 
drug would precipitate out in the suspending medium (PBS pH 7.4). Hence, the NL suspensions were double 
filtered through 0.22µm filters to remove free drug. The remaining suspensions were evaluated by UV 
spectroscopy at 366nm to quantify DIE.  
Elucidation of Drug Release Profiles: Following the removal of unincorporated CPT, the NL suspensions were 
contained in dialysis tubing (12000kDa) and suspended in PBS (pH 7.4; 200mL) in sealed receptacles, maintained 
at 37ºC in an orbital shaker bath (25rpm). At pre-determined intervals 5mL aliquots of the external phase were 
withdrawn and replaced with fresh PBS (pH 7.4). The samples were analyzed by UV spectroscopy.    
Nano-liposomal Life-time studies: NL’s were injected into a carrageenan hydrogel and observed employing a 
microultrasound imaging system.  
Quantification of Nano-liposomal surface charge: The surface charge of NL suspensions was quantified as Zeta 
Potential employing a NanoZetasizer ZS. Samples were filled into specialized cuvettes and analyzed over a 3 hour 
period while being maintained at physiological temperature.  
Results: 
All formulations successfully produced stable, regular CPT-NL’s, as evidenced by TEM images. Whilst all 
formulations fell into an acceptable size range (125nm-145nm) with narrow size distribution (PdI < 0.2) for 
successful extravasation through compromised tumour vasculature, DOS concentration appeared to have a 
significant effect on zeta potential. Increasing DOS concentration from 0.01% w/v to 0.03% w/v resulted in a ~14mV 
(-25.7 to -39.4mV) decrease in zeta potential. Zeta potential values for all formulations were significantly negative 
indicative of high stability and low propensity for aggregation. This could have significant impact on the stability 
(shelf-life and in-vivo) of the NL-DDS. In addition, increasing DOS concentrations resulted in an increase in DIE 
from ~61%-81%. The formulation with the highest DOS concentration was also more consistently reproducible. 
Drug release profiles revealed insignificant differences resulting from changes in DOS concentration. However, all 
3 formulations exhibited favourable drug release characteristics, achieving ~50% drug release after 4 hours, thus 
allowing sufficient time for the accumulation of NL’s within tumour tissue for targeted drug release. 
Microultrasound imaging displayed adequate diffusion of NL’s through the gel medium and an absence of 
aggregation.   
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Purpose: 
  This study aims to develop a camptothecin (CPT)-loaded nanolipobubble (NLB) intravenous formulation 
for the targeted treatment of ovarian cancer. This research is based on the pre-formulation studies undertaken 
to develop nanoliposomes (NL’s), as the precursor to NLB preparation, ranging in size between 100-150nm, 
to facilitate adequate extravasation through the leaky vasculature present in tumour tissue. Furthermore, drug 
release kinetics of the formulation was elucidated at physiological and tumour pH (pH 7.4 and 6.0, 
respectively), to determine the targeting potential of the formulation.   
Methods: 
  Preparation of CPT-loaded and placebo NL’s: Varying concentrations and ratios of distearolyphosphatidyl 
choline (0.1-0.3%w/v) and either distearolyphosphatidylethanolamine-m-PEG (DSPE-m-PEG) or cholesterol 
(CHO) (0.1-0.3%w/v) was dissolved in chloroform:methanol (9:1; 10mL). PBS (pH 7.4; 10mL) was 
subsequently added to the organic phase under ultra-sonication (60% amplitude for 90 seconds). Tween® 80, 
Span® 80 and polyvinylpyrrolidone (PVP) (0.1-0.3mL) were employed as surfactants. The resultant 
emulsion was subjected to evaporation under vacuum (65°C) for 3 hours, forming a NL suspension. In CPT-
loaded formulations, CPT was incorporated during ultrasonication.  
  Determination of NL size and size distribution: The NL suspension was analysed for size and size 
distribution profiles over a 3 hour period, whilst being maintained at 37°C. Effect of CPT loading on size of 
the NL’s was investigated. 
  Elucidation of drug release profiles: NL’s were centrifuged to remove unbound drug, and the sediment was 
re-suspended in PBS (pH 7.4 and 6.0; 100mL) and maintained in a shaker bath at 37°C at 25 rpm. Samples 
were withdrawn at pre-determined intervals and drug release was evaluated by UV spectroscopy.  
  Evaluating interactions of formulation components: Formulations were subjected to Fourier Transform 
Infra-Red (FTIR) analysis to determine the interactions of lipids and surfactants, and the effects of these 
interactions on the drug release kinetics and stability of the formulation. 
  Determination of NLB lifetime: Sulphurhexafluoride gas was incorporated into the NL, forming NLB’s. The 
NLB’s were injected into a hydrogel and observed using a microultrasound imaging system.  
Results: 
  Variation in the lipid component and surfactant proved to be a factor in size and stability of the NL’s. In 
general, the use of CHO instead of DSPE-m-PEG resulted in a 20-40nm increase in NL size and an 
unfavourable size distribution profile (PdI>0.2). Although more stable, PVP-containing formulations also 
displayed a dramatic increase in size (>200nm). Drug release was fairly rapid (100% in 15 minutes), thus 
polymer coating is being investigated as a means of retarding drug release. FTIR analysis highlighted only a 
physical interaction between lipids and surfactants, which had no significant influence on stability or drug 
release kinetics. NLB lifetime studies are currently underway.  
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The gaping deficiency in current ovarian cancer therapy is substantiated by the elevated 
recurrence rate and appalling 5-year survival rate of ovarian cancer. Nano-enabled systems have 
been acutely successful in tumour imaging. The current research aims to extend this paradigm to 
targeted anti-tumour therapy with the formulation of a Camptothecin-Loaded Nano-Liposomal (NL) 
Drug Delivery System (DDS) that will be passively targeted to ovarian tumour tissue, via the EPR 
phenomenon, following intravenous administration. Extensive pre-formulation investigations 
culminated in the delineation of independent variables, namely phospholipid combination, 
phospholipid concentration and surfactant concentration. A Face-Centered Central Composite 
Design was employed to generate two sets of formulations based on the minima and maxima limits 
of the above-mentioned variables. Formulations were accurately prepared and analyzed in 
triplicate. Nano-sizing (<200nm) was highlighted as a vital measured outcome due to the 
intravenous nature of the formulation and the dependence of passive targeting on formulation size. 
Although all formulations were below 160nm, DSPC-containing formulations were ~20nm larger. 
Zeta potential was assessed as an indication of formulation stability. Increased surfactant 
concentration resulted in a more favourably negative zeta potential. Formulations from the DSPC-
containing design proved significantly more stable (25-40mV). The nano-scale size range poses a 
challenge to the quantity of drug incorporated into nano-enabled DDS’s. Hence, drug incorporation 
efficiency was determined by a novel method. The passively targeted nature of the DDS requires 
sufficient time for accumulation of the DDS within tumour tissue. Drug release profiles highlighted 
adequate time for extravasation before significant drug is released from the DDS, thereby 
favourably altering the biodistribution of camptothecin.   
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APPENDIX C 
 
Targeted Ovarian Cancer Therapy. Lisa C. du Toit, Derusha Frank, Viness Pillay, Yayha 
E. Choonara. SA Patent Application No: 2012/07435, 4 October 2012. 
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APPENDIX D 
 
Waiver letter confirming this study did not require clearance from the Human Research 
Ethics Committee of the University of the Witwatersrand.  
 
 
